answering questions matter annual report five questions five answers one mission question adapting business model one succeed current healthcare environment answer question consumer healthcare two business answer question share prices sector havent performed well three outlook gsk answer question research development pipeline four performing answer question improve healthcare five developing world answer website glaxosmithklines website wwwgskcom gives additional information group information made available website constitute part annual report notice regarding limitations director liability english law uk companies act safe harbour limits liability directors respect statements omissions report directors contained pages english law directors would liable company third party report directors contains errors result recklessness knowing misstatement dishonest concealment material fact would otherwise liable report directors pages inclusive consist report directors drawn presented accordance reliance upon english company law liabilities directors connection report shall subject limitations restrictions provided law cautionary statement regarding forwardlooking statements groups reports filed furnished us securities exchange commission sec including document written information released oral statements made public future behalf group may contain forwardlooking statements forwardlooking statements give groups current expectations forecasts future events investor identify statements fact relate strictly historical current facts use words anticipate estimate expect intend project plan believe words terms similar meaning connection discussion future operating financial performance particular include statements relating future actions prospective products product approvals future performance results current anticipated products sales efforts expenses outcome contingencies legal proceedings financial results group undertakes obligation update forwardlooking statements whether result new information future events otherwise forwardlooking statements involve inherent risks uncertainties group cautions investors number important factors including document could cause actual results differ materially contained forwardlooking statement factors include limited discussed risk factors pages annual reportchairman ceo summary mission five questions five answers global quest improve quality human life enabling people feel better live longer report directors business review spirit corporate governance undertake quest remuneration report enthusiasm entrepreneurs excited constant search innovation value performance achieved integrity attain success world class global leader every one people contributing passion unmatched sense urgency financial statements directors statements responsibility independent auditors report consolidated income statement consolidated balance sheet consolidated cash flow statement consolidated statement recognised income expense notes financial statements financial statements glaxosmithkline plc investor information financial record shareholder information taxation information shareholders glossary terms index inside back cover gsk annual report srotcerid eht fo troper stnemetats laicnanif noitamrofni rotsevni contentsannual report annual review history development company report annual report glaxosmithkline plc year glaxosmithkline plc public limited company incorporated ended st december prepared accordance united th december english law shares listed kingdom requirements approved board directors london stock exchange new york stock exchange th february published th february th december company acquired glaxo wellcome plc smithkline beecham plc english public limited companies summary report year annual review way scheme arrangem ent merger two prepared accordance united kingdom requirements companies glaxo wellcome smithkline beecham intended investor needing full detail annual major global healthcare businesses report produced separate document includes joint statement chairman chief executive officer gsk plc subsidiary associated undertakings constitute summary review operations summary financial statements major global healthcare group engaged creation discovery summary remuneration report annual review issued development manufacture marketing pharma ceutical shareholders annual report issued shareholders consumer healthrelated products elected receive documents available gsk corporate head office london also operational gsks website headquarters philadelphia research triangle park usa report glaxosmithkline group gsk means operations countries products sold glaxosmithkline plc subsidiary undertakings company countries principal research development rd facilities means glaxos mithkline plc glaxosmithkline share means uk usa belgium italy japan spain products ordinary share glaxosmithkline plc p american depositary currently manufactured countries share ads represents two glaxosmithkline shares major markets groups products usa france business performance japan uk italy germany spain business performance supplemental nonifrs measure business segments primary performance measure used management gsk operates principally two industry segments presented excluding costs relating new operational excellence programme commenced october pharmaceuticals prescription pharmaceuticals vaccines management believes exclusion items provides better c onsumer healthcare overthecounter medicines oral care reflection way business managed gives nutritional healthcare useful indication underlying performance group information provided addition total results brand names appearing italics throughout report prepared ifrs given assist shareholders gain clearer trademarks either owned andor licensed glaxosmithkline understanding underlying performance business associated companies exception baycol levitra increase comparability periods presented trademarks bayer bonivabonviva trademark roche citrucel trademark merrell pharmaceuticals entereg trademark exchange rates adolor corporation usa hepsera trademark gilead group operates many countries earns revenues incurs sciences countries including usa humaxcd costs many currencies results group reported trademark genmab integrilin trademark millennium sterling affected movements exchange rates pharmaceuticals lymphostat b trademark human genome sterling currencies average exchange rates prevailing sciences nicoderm trademark sanofiaventis pfizer canada period used translate results cash flows elan novartis merrell glaxosmithkline vesicare trademark overseas subsidiaries associates joint ventures sterling astellas pharmaceuticals many countries yamanouchi period end rates used translate net assets entities pharmaceuticals certain countries used certain currencies influence translations us countries licence group dollar euro japanese yen order illustrate underlying performance groups practice discuss results terms constant exchange rate cer growth represents growth calculated exchange rates used determine results overseas companies sterling remained unchanged used previous year cer represents growth constant exchange rates represents growth actual exchange rates commentaries report presented terms cer unless otherwise stated gsk annual report review chairman ceo summary natural stakeholders want know facing seeing results investment rd challenges fastchanging healthcare environment last year gsk received record product approvals filed plan convert strategic direction profitable results product applications new products launched return value shareholders tykerb breast cancer veramystavamys allergic rhinitis altabaxaltargo treatment skin infections cervarix annual report aims answer questions vaccine prevention cervical cancer demonstrate strategic focus research development delivering improved pipeline productivity enhance currently new product opportunities filed returns shareholders longterm success regulators commenced nine new phase iii clinical development consumer healthcare business strong performance many programmes present key assets phase key pharmaceutical vaccine products current portfolio iii registration stages also providing strong contributions growth helped us leading way deliver business performance earnings per share eps growth although future remains challenging gsk determined constant exchange rates cer results remain industry leader across many fronts high end guidance pipeline progress also efficiency initiatives also continue balance needs shareholders fulfilling responsibilities communities worldwide commitment improve healthcare communities across world october announced significant new billion operational feel right thing thing excellence programme improve operational efficiency financial performance outlook productivity expect deliver annual pretax savings total sales billion business performance eps million p board declared dividend global community investment contributions year p p continued deliver positive influence lives people pharmaceutical turnover level billion impacted worldwide proud play part full generic competition usa decrease avandia grateful dedicated people efforts passion sales globally among key products sales seretideadvair contributed much success also extend companys asthma copd rose billion lamictal thanks shareholders continuing support epilepsy bipolar disorder increased billion vaccines business grew billion consumer healthcare changes management team past generated strong sales growth almost billion months including departure david stout president pharmaceutical operations rupert bondy senior vice president also saw launch largest share buyback industry general counsel leaving gsk end march share repurchases billion made thank contribution gsk many programme billion expected expect years also welcomed professor sir roy anderson board repurchase billion shares programme mid nonexecutive director andrew witty chris viehbacher may article new england journal medicine executive directors suggested may cardiovascular risk associated overall confident gsks strength organisation avandia second largest product followed intense expertise deal changing environment media coverage despite efforts explain entirety data confirm risk sales avandia dropped face significantly second half thank support decline avandia sales together increased generic competition usa adversely impact earnings expect midsingle digit percentage decline business performance eps cer looking ahead remain confident gsks future fast growing vaccines business resurgence consumer healthcare division strong performance key pharmaceutical products providing contributions growth momentum latestage pipeline continues enhance business producing significant sir christopher gent jp garnier renewal product line chairman chief executive officer message sir christopher gent chairman agm sees retirement chief executive officer jp thank jp behalf board stakeholders gsk garnier served gsk great style distinction since andrew witty becomes new chief executive officer merger december jp brought wit wisdom hugely agm worked us since andrew experienced impressive business acumen role directly responsible enthusiastic wellrespected inside gsk beyond many innovations last seven years including doubt ensure gsk fulfils rich potential introduction centres excellence drug discovery look forward working alongside transformed way approach rd driving renewed focus energy behind vaccines business gsk annual report consult stakeholders many ways shareholders patients governments nongovernment organisations payers employees hear many different questions years annual report focused five key questions lie heart business q summary markets changing evolving rapidly reflect new environment wellpositioned relative peers broadbased geographicallydiverse well balanced business mproved pipeline productivity nnovative programmes reduce expenditure adapting work closely customers business model succeed positioned take advantage opportunities growing healthcare economies current healthcare environment reducing expenditure cost remains major issue customers demand diversity balance healthcare continues increase driven ageing populations operate fastchanging market regulatory rising expectations committed working governments payer perspective regulators becoming increasingly risk conscious reduce total healthcare costs lowering expenditure payers cost conscious imperative pharmaceutical operate efficiently profitably lower priced companies including gsk modernise evolve reflect environment enabling us continue investment rd market changes time adopting flexible creative move forward changing environment well approach product pricing alert opportunities share positioned relative peers broadbased risk customers means demonstrating great geographicallydiverse wellbalanced group encompassing belief medicines expect rewarded pharmaceuticals vaccines consumer healthcare medicines deliver anticipated benefits intellectual property system relatively short patent operational excellence programmes important part exclusivity traditional small molecule chemical pharmaceuticals strategy mean improving efficiency yearonyear however biological medicines vaccines consumer healthcare also working hard lower cost developing products products generally significantly longer product life cycle already outsourced areas business lowercost presence sectors continue grow enables us countries continue assess capture opportunities better balance risk sustain growth reduce costs growing pipeline seizing global opportunities recent years pipeline expanded flowed quickly globalisation increasingly important factor business ever seven years ago relatively products landscape past derived growth latestage pipeline today projects clinical development established economies usa europe japan countries nces new vaccines includes key assets brazil russia india china often known bric markets late stage development large populations increasingly able afford good quality healthcare opening significant new markets significant transformation driven largely changes important future growth areas gsk made research development rd hardware software radically changed rd infrastructure breaking investing people traditional big bureaucratic pharma model rd centres reach potential support talent excellence drug discovery cedds time highly motivated people ambition place great evolving adapting culture helping talented people people apply energy passion make difference improve quality science management world skills intellect key components successful implementation strategy continued invest continue ensure creating new medicines recruiting training best scientists professionals targeted unmet medical need focus developing medicines way allows regulators make clear assessment relative risks benefits gsk annual report q summary consumer healthcare business key part gsk profitable logical complement pharmaceutical operation powerful portfolio healthy pipeline utstanding performance double digit sales growth consumer e xcellent prospects particularly developing economies healthcare business pportunity share expertise resources across two businesses healthy performance consumer healthcare important business us steady longterm growth helps balance provide excellent balance pharmaceuticals operation pharmaceutical business also thriving business right delivering strong performance shareholders consumer healthcare shown significant acceleration top line sharing strengths performance sales growth powerful consumer healthcare pharmaceuticals businesses portfolio includes lucozade sensodyne panadol horlicks stand alone entities complementary synergistic aquafresh brand benefited investment number important areas backed science launch new brand extensions also saw successful endorsed strategies focus rd us launch alli first overthecounter otc weight loss aid approved food drug administration fda growing trend worldwide patients manage currently reviewed european regulatory authorities healthcare choosing otc products rather relying consumer healthcare business expertise prescription behaviour consumer healthcare sales marketing well placed partner choice professionals richly experienced able draw switch products bringing prescription skills knowledge pharmaceutical business share otc market costs resources also share expertise resources areas regulatory matters rd marketing distribution top five consumer healthcare products turnover procurement products turnover getting balance right pharmaceuticals business operates tough climate increased legislation cautious regulatory regimes pricing pressures lucozade among key challenges face pharmaceutical company aquafresh time patent framework pharmaceutical products sensodyne tends result relatively short life cycle even panadol successful treatments horlicks contrast consumer healthcare business offers longterm capitalising longterm potential steady cash flow broad portfolio pharmaceutical otc global healthcare markets state change example products help mitigate impact losses generics help increasing trend governments cut state healthcare costs smooth volatile nature pharmaceutical markets influencing switch prescription generic otc products looking ahead healthcare becoming consumercentred people expect able access medical knowledge influence treatments many otc products first destination everyday healthcare expect highest rates growth healthcare businesses driven developing emerging economies otc foundation healthcare countries china example otc accounts drug expenditure compared north america western europe gsk annual report q summary ensure remain industry leader addressing issues face pharmaceutical sector investment achieve industry leading rd productivity new billion operational excellence programme share prices sector increase dividend paid havent performed well shareholders largest share buyback programme outlook gsk industry sector challenges ttracting retaining best employees many years sustained value creation shareholders pharmaceutical sector suffered derating since beginning main factor behind derating rd productivity taking action create longterm value integral growth pharmaceutical industry board management continually review gsks business strategy declined share price valuations past also included value external environment view achieving growth longerterm potential rd pipelines currently case sustainable basis time level generic competition intensified industry longterm investment cycle driven primarily gsk able withstand pressure better many time takes develop new pharmaceutical product least peers broad nature product line flow new years decisions taken last seven years improved products pipeline greater protection experience rd productivity gsk still take time major impact vaccines consumer healthcare businesses revenues however investors become confident fact every year since merger end delivered strategy key pipeline products make market begin increased sales cer despite challenging market conditions factored share price financial terms period total returns shareholders time focused taking action enhance gsks peer group total return gsk returns shareholders accelerating efficiency programmes shareholders period performance returning cash shareholders dividends share buy peer group backs board approved increase dividend avandia factor july gsk announced largest share buyback programme gsks share price fell compared increase industry ftse index disappointing investors third quarter announced significant new billion significant number also employees operational excellence programme improve efficiency started strongly achieved several important milestones productivity operations expected deliver annual savings including launches tykerb fda approval alli million first quarter beat expectations delivered eps growth reducing costs mean cutting talent gsk respected market received positive news share price worldwide group best people best work outperformed peers may article continue attract retain reward brightest employees new england journal medicine nejm suggested may sales teams front line scientists cardiovascular risk associated avandia second largest forefront discovering new therapies product followed intense media coverage despite efforts explain entirety data confirm risk doctors reluctant prescribe avandia new patients without fda guidance sales avandia dropped significantly negative impact share price following clarification fda october new approved label move ahead clarity gsk annual report q summary good year rd team number important products potential products moved pipeline achieved several important objectives key assets phase iiiregistration hree new chemical entities approved one new vaccine research new product opportunities filed development pipeline regulators performing n ine new phase iii clinical development programmes commenced best year pharmaceutical rd since merger hree latestage development programmes saw gsks best year rd since group formed inlicensed undoubtedly made great strides last seven years remains achieve benefits look forward investment pipeline delivers october also received encouraging safety efficacy year three new chemical entities one new vaccine data vaccine protect malaria currently approved veramyst allergic rhinitis tykerb breast cancer phase ii development results given us confidence altabax skin infections cervarix prevent cervical cancer move large scale phase iii trials due begin progressed range products pipeline second half positioning us well future total nine new phase iii adapting changing environment programmes started large scale trials seek responding many ways challenges rd ascertain safety also prove unequivocally efficacy productivity faced companies pharmaceutical medicines submitting approval sector network cedds focus skills resources targeted initiative inlicense potential treatments continued disease areas cedds create spirit small rdled team brought three new latestage programmes gsk moved within large pharmaceutical organisation allow us four latestage development improving ability nimble therefore productive approach reload sustain pipeline need opened two new cedds immunoinflammation infectious diseases headed worldclass scientists nature rd carries inherent risk pleased year disappointments notable important element strategy access broad diversity termination odiparcil prevent blood clots number thinking one way partnering academic centres product line extensions delayed hoped would worldwide opened new clinical imaging centre gain final regulatory approval usa including lamictal xr hammersmith hospital london research concentrating requip xl cancer stroke neurological diseases second key strand make sure gsk wellrepresented wherever cutting promising progress vaccines edge science practised opened new fully integrated large promising vaccines pipeline projects research institute china clinical development including seven phase iii trials another five filed regulators gsk active external partnering strategy entered nine external product licensing collaborations together cervarix hpv vaccine prevent cervical cancer number partnerships develop utilise novel approved countries across world licensing science technologies pharmaceutical biological rd applications submitted countries including japan usa fda issued complete response letter cervarix continue review actively therapeutic area strategies december plan submit response letter examine areas presence prioritise second quarter continue discussions regarding demonstrate potential aim derive application fda pipeline biopharmaceuticals around present also increased investment neurosciences cervarix perhaps highprofile vaccine several vaccines oncology research vaccines made progress rotarix rotavirus disease causes severe childhood diarrhoea filed usa whilst remains tough challenge discover medicines vaccines june following approval countries worldwide also level understanding scientific advancement breakthrough filed synflorix vaccine prevent pneumococcal disease europe unprecedented believe gsk opportunity discover international markets end year meningitis new products greater ever vaccine menacwy innovative magea vaccine treatment non small cell lung cancer entered phase iii trials gsk annual report q summary gsk industry leader providing access medicines developing world preferential pricing ensures poorest still benefit treatments vaccines ur investment rd helping build rich pipeline reflects needs developing world innovative partnerships created breakthroughs improve healthcare treatments vaccines neglected diseases community investment activities help promote developing world education better healthcare getting balance right g sk also actively involved supporting commercial organisation like gsk balance patients developed world see struck return shareholders desire improve access products particularly patients preferential pricing developing world provided vaccines preferential prices developing hivaids worsened healthcare crisis subsaharan world years africa brought worldwide attention poverty means hivaids malaria treatments offered notforprofit many denied education die malnutrition lack prices public sector customers notforprofit organisations clean drinking water ability pharmaceutical company least developed countries subsaharan africa address healthcare problems developing world must including global fund eligible programmes notfor seen broader context profit prices available around countries offer antiretrovirals arvs antimalarials innovative partnerships notforprofit prices addition significant community products viable commercial market truly neglected investment activities corporate responsibility report tropical diseases work publicprivate partnerships provide details efforts improve access medicines rd technology manufacturing distribution expertise developing developed world information academic institutions provide research disease area knowledge community partnership programmes public sector partners governments organisations feel better live longer gates foundation help fund project assist getting hivaids tuberculosis malaria killing around people medicines people need funds usually every day believe playing part right thing channelled organisations tb alliance thing malaria vaccine initiative contribute action four areas preferential pricing programmes transformed rd neglected diseases arvs antimalarials vaccines investing rd example pipeline malaria treatments richest diseases developing world community investment activities world ever seen partnerships foster effective healthcare granted voluntary licenses allow generic manufacturers innovative partnerships produce versions key arvs hivaids sometimes healthcare crisis africa used pressure global capacity manufacture enough arvs meet groups attack industry intellectual property ip system worlds needs challenge get medicines people important understand rely ip generate need funds enabled us invest billion rd community investment continue stress would like see ip january saw th anniversary commitment environment weakened eliminate lymphatic filariasis lf also known elephantiasis date without investment rd see muchneeded new reached million people million children medicines vaccines requires delicate balance born areas lffree believe achieve benefit shareholders patients also currently support significant hivaids education world programmes africa india china mexico programme faces different challenges importance education among people marginalised society common community investment programmes include personal hygiene sanitation education phase focuses simple act washing hands prevent diarrhoeal disease save lives gsk annual report business review business review discusses gsks financial nonfinancial activities resources developments performance outlines trends factors likely affect future development performance overview financial trends ratios optimising performance marketed products delivering product pipeline patients best place best people best work improving access medicines corporate responsibility community investment global manufacturing supply regulatory environment world market products competition financial review financial position resources outlook risk factors financial review accounting presentation report prepared accordance international financial reporting standards ifrs adopted european union also ifrs issued international accounting standards board data market share market growth rates gsk estimates based recent data independent external sources appropriate valued sterling relevant exchange rates figures quoted product market share reflect sales gsk licensees business performance business performance supplemental nonifrs measure primary performance measure used management presented excluding costs relating new operational excellence programme commenced october management believes exclusion items provides better reflection way business managed gives useful indication underlying performance group information provided addition total results prepared ifrs given assist shareholders gain clearer understanding underlying performance business increase comparability periods presented exchange rates group operates many countries earns revenues incurs costs many currencies results group reported sterling affected movements exchange rates sterling currencies average exchange rates prevailing period used translate results cash flows overseas subsidiaries associates joint ventures sterling period end rates used translate net assets entities currencies influence translations us dollar euro japanese yen order illustrate underlying performance groups practice discuss results terms constant exchange rate cer growth represents growth calculated exchange rates used determine results overseas companies sterling remained unchanged used previous year cer represents growth constant exchange rates represents growth actual exchange rates commentaries report presented terms cer unless otherwise stated gsk annual report srotcerid eht fo troper weiver ssenisub performance overview gsks performance driven number important strategies key performance indicators turnover business performance earnings per share growth total shareholder return strategies turnover optimising performance marketed products bn cer growth pharmaceutical consumer healthcare businesses focus ways improve return groups intellectual property maximising sales key products gsks activities include achieving worldwide sales force excellence achieving pharmaceutical consumer healthcare marketing excellence maintaining highest ethical standards improving costeffectiveness operations business performance earnings per share pence cer growth delivering product pipeline patients gsk aims create best product pipeline industry benefit society includes developing focused strategy support pipeline manage full life cycle compounds launch prescription medicines potentially becoming overthecounter products total shareholder return gsk measures rd productivity number level innovation products creates ability address unmet patient needs best place best people best work gsk committed creating best place best people best work recruiting developing best people industry gsk total return index gsk pharma peers return index supporting culture high reward high performance ftse total return index ensuring good communication employee involvement maintaining diverse healthy workforce share price improving access medicines us gsk finding innovative ways bring medicines vaccines health education patients countries including suffering epidemics neglected diseases maximising total shareholder return tsr gsk continues work maximise tsr eps growth dividend increases share repurchases uk share price us adr price us february share price per adr calculation business performance supplemental nonifrs measure described note financial statements presentation financial statements gsk annual report srotcerid eht fo troper weivrevo ecnamrofrep key developments group turnover billion constant exchange rates compared top ten pharmaceutical products seretideadvair million imigranimitrex million vaccines products million flixotideflovent million avandia products million coreg million lamictal million seroxatpaxil million valtrex million augmentin million key pharmaceutical growth drivers arixtra avodart boniva requip delivered combined sales million top five consumer healthcare products lucozade million panadol million aquafresh million horlicks million sensodyne million launch alli usa june successful sales million achieved business performance operating margin improved percentage points turnover details february gsk pharmaceutical vaccine projects clinical development compared february major product opportunities phase iii development registration including elesclomol metastatic melanoma promacta thrombocytopenia entereg postoperative ileus rezonic chemotherapyinduced nausea vomiting hn pandemic flu vaccine synflorix pneumonia nontypeable haemophilus influenzae ofatumumab rheumatoid arthritis tykerb armala inflammatory breast cancer late stage projects terminated included odiparcil prevention blood clots details group carries global leadership survey managers every two years last survey showed strong commitment performance integrity management working since addressing areas improvement group committed encouraging diversity amongst employees global management population female details global community investment valued million total profit tax lymphatic filariasis elimination programme continued another million albendazole treatments donated making almost million treatments total gsk shipped million combivir tablets nearly million epivir tablets developing countries notforprofit prices approximately million tablets supplied generic manufacturers licensed gsk international humanitarian product donations totalled million details business performance eps p cer total eps p cer dividend declared p new share buyback programme billion two years announced july billion spent billion expected gsk annual report srotcerid eht fo troper weivrevo ecnamrofrep financial trends ratios total results growth growth cer cer turnover pharmaceuticals consumer healthcare total turnover cost sales selling general administration research development operating income operating profit profit taxation profit taxation year profit attributable minority interests profit attributable shareholders basic earnings per share pence p p p diluted earnings per share pence p p p business performance results turnover cost sales selling general administration research development operating income operating profit profit taxation profit taxation year profit attributable minority interests profit attributable shareholders basic earnings per share pence p p p diluted earnings per share pence p p p research development total pharmaceuticals consumer healthcare total net finance cost cover net finance costs cover times times times net finance cost cover profit tax plus net finance costs divided net finance costs tax rate total tax rate business performance borrowings net debt gearing gearing ratio calculated net debt percentage total equity cer represents growth constant exchange rates sterling represents growth actual exchange rates see calculation business performance supplemental nonifrs measure described note financial statements presentation financial statements gsk annual report srotcerid eht fo troper soitar dna sdnert laicnanifbusiness review optimising performance marketed products gsk annual report srotcerid eht fo troper stcudorp detekram fo ecnamrofrep eht gnisimitpo marketing codes gsk undertakes range activities gsk committed ethical responsible patientcentred maximise commercial potential marketing groups pharmaceutical marketing promotional intellectual property introducing activity policy governs marketing activities applies employees suppliers contractors agents policy requires innovative products accelerating marketing promotional activities based valid scientific process bringing many evidence comply applicable laws regulations markets possible increasing brand policy supported regional marketing practices codes recognition improving access europe gsks international region japan usa new medicines codes apply ethical standards reflect differences market structures national healthcare systems regulations incorporate principles industry codes practice worldwide pharmaceutical sales force excellence european federation pharmaceutical industries associations gsks sales force always ranked high surveys healthcare international federation pharmaceutical manufacturers associations professionals worldwide sales force excellence wsfe aims japan pharmaceutical manufacturers association pharmaceutical improve customer satisfaction even research manufacturers america marketing codes time available physicians learn new medicines next generation clinical studies precious wsfe initiative sales us pharmaceutical businesses created implemented representatives strengthen product knowledge learn deliver next generation operating model advertising agencies patientspecific treatment options efficiently design model aims improve creativity productivity effectively research shows sales visit highly effective achieve significant cost savings involved number key areas representative engages physician dialogue around patient result professional brand accounts consolidated types supports message visual aids illustrate single agency increased access best talent streamlined clinical results account management reduced rates team also instituted single global sales call model introduced focuses key changes agency reviews created financial parameters treating patient dialogue resource guides improve decision making processes gsk medicine appropriate effective health literacy administer safely field staff gsks key markets help patients understand basic information disease trained new approach entire sales organisation involved treatment options us pharma launched health literacy wsfe bring cultural change raises ethical standards programme employees agency staff gone helps build longterm trusting relationships healthcare training learn improve materials goal community addition dashboard key performance indicators helping patients learn disease manage product knowledge certification process effective leadership result obvious improvements patientdirected materials training programme established making easier read trimming content incorporating superior product knowledge essential serving needs userfriendly design including stepbystep instructions healthcare professionals physicians rely gsk keep abreast health behaviours health literacy gaining ground parts changes prescribing information new clinical studies involving gsk colleagues begin adopting concepts simpler clearer gsk medicines key goal wsfe gsk expanded annual patient communication certification program countries representatives consumer healthcare marketing excellence passed certification tests pathology prescribing information teams comprising marketing rd dedicated key messages leading products scores consistently seven global brands focused delivering pipelines around many representatives achieving perfect score global marketing programmes incountry commercial teams pharmaceutical marketing excellence execute efforts driving significant sales growth many large numbers patients suffering effects disease continue markets large brands one dominant market unable benefit innovative medicines treatments may available several territories dedicated team drives example within europe around patients suffering lead market brands dominant market chronic obstructive pulmonary disease copd diagnosed remaining assets termed enterprise brands locally managed receive regular maintenance drug therapy inmarket commercial teams retain entrepreneurial spirit local relevance gsks marketing initiative implements programmes overcome barriers proper diagnosis treatment providing accurate balanced information products allow many people possible benefit gsks medical advances programmes beginning show effects needs done societal costs disease decreasebusiness review delivering product pipeline patients metabolic research triangle park usa gsk spent billion rd ncology upper providence usa employs staff rd acrolide drug discovery zagreb croatia number major product opportunities n eurology harlow uk phase iii registration increased p sychiatry verona italy year since stands r espiratory stevenage uk cedd responsible identifying targets relevance therapeutic area building lead compounds transferred research development pharmaceuticals mdr produce potential medicine fundamental steps gsk rd developed one robust pipelines potential turning lead compound medicine optimising new medicines industry pharmaceutical rd potency efficacy safety defining biology animals actively managing projects human clinical trials across humans medicine tested effects right globe delivering pipeline patients safely efficiently patient groups number one goal candidate compound selected cedds responsible focus patient undertaking clinical studies necessary demonstrate beneficial one objective unites people work gsk effect sufficient declare proof concept first indication pharmaceutical rd staying focused patient patients new medicine works based programmes drives discover potential treatments disease profile safety efficacy decision made whether develop innovative medicines offer true benefit patients progress medicine latestage drug development reaching speaking patients families part gsks commitment towards pursuing best science understand impact disease lives work anywhere world centre excellence external drug community essential part gsk knows patients discovery ceedd established ceedd waiting focus patient driver deliver best objective cedds delivering medicines latestage every day development establishing managing longterm pharmaceutical rd gsk organised around discovery strategic collaborations biotech small mediumsized development medicines patients discovery conducted pharmaceutical companies ceedd exercised first gsks centres excellence drug discovery cedds option bring compound clinical development xl development gsks medicine development centres mdcs anticancer inhibitor exelixis along way many groups provide critical scientific input part strategic intent gsk established conduct important experiments aid managing rd dedicated rd centre shanghai rd china focus process groups described detail research neurodegeneration objective creating new discovering potential medicines medicines severe disorders multiple sclerosis parkinsons two components needed discovery new medicines disease alzheimers disease centre eventually direct identification important molecular targets global discovery development activities within therapeutic potential impact human disease discovery compounds area drugtarget identification latestage clinical studies modulate targets alleviate disease effective collaborating research institutions elsewhere china safe way countries establishing rd china reflects gsks commitment ally talented researchers wherever located molecular discovery research mdr produces lead compounds encourage within rd contest ideas needed create may interact targets form basis drug discovery new medicines efforts gsks cedds mdr progressed preclinical drug discovery programmes performed hundreds developing medicines patients assays per week provided cedds leads progression latestage development referred gsk medicines development consists optimising physical gsk rd designed cedds integrated groups product properties medicine chemical steps scientists clinicians organised work around specific formulation required manufacture deliver well disease areas intent produce nimble entrepreneurial large scale confirming studies efficacy safety former discovery units activity responsibility preclinical development latter gsks cedds based europe usa responsibility clinical development development operations teams combination results two biopharmaceuticals stevenage uk steps regulatory file submission regulatory agencies c ardiovascular urogenital upper merion usa approval patient use responsibility regulatory centre excellence external drug discovery team integration steps coherent project upper merion usa responsibility project teams grouped therapeutically mmunoinflammation stevenage uk medicine development centres roles described infectious disease upper merion research triangle detail follows park usa gsk annual report srotcerid eht fo troper stneitap rof enilepip tcudorp eht gnireviledbusiness review delivering product pipeline patients continued preclinical development pcd includes wide range activities safety data routinely collected throughout development throughout entire medicines development process addition programmes reported national regional regulatory function involved enhancement existing products agencies line applicable regulations devising convenient formulations early development gsks chief medical officer working global safety board process metabolism safety compounds evaluated ultimately accountable oversight major decisions regarding laboratory animals testing humans testing required patient safety gsk global safety board responsible internally animals highly regulated see animals research approving pivotal studies investigating issues related processes supporting analytical methods drug synthesis patient safety arising development programme product formulation delivery scaled meet increasing information gsk clinical trials widely easily available supply requirements leads technical transfer clinical trial register gsks website processes methods manufacturing new product supply inlicensing process partnership rd global manufacturing gsk continues identify compounds companies supply ensures robust product developed largescale would enhance portfolio create innovative collaborations commercial manufacturing launch ensure group regarded partner choice medicines development collection six therapeutically large small companies aligned mdcs mdc ultimate accountability developing subjects acquisitions inlicensing comarketingcopromotion experimental drugs regulatoryapproved medicines patients future options arrangements included mdcs responsible creating value execution full product development plans ensuring strong partnerships x enoport xp phase iii rls phase ii rest gsk particular cedds latestage neuropathic pain development groups epracor lunestalunivia excluding usa canada mexico japan gabaa agonist insomnia pending eu filing mdcs based major usa uk sites aligned ynta sta hsp upregulation melanoma sarcoma following therapeutic areas solid tumors phase iii c ardiovascularmetabolic olerx anticd mab autoimmune diseases phase ii nfectious diseases including diseases developing argacept tc phase ii acute postoperative pain world ddw novel leads central nervous system diseases musculoskeletalinflammationgastrointestinalurology nacor novel candidates viral bacterial diseases preclinical n euroscience psychiatryneurology ncomed cancer stem cell therapeutics preclinical ncology g alapagos novel antibacterials antivirals preclinical r espiratory antaris novel antiviral agents preclinical managing portfolio mdcs discharge responsibilities project teams medicine development project teams responsible key projects reaching significant milestones reviewed month maximising worldwide development opportunities product management board pmb responsible product within remit see information determining medicine met criteria passing next needed support registration safety programmes pricing phase development formulary negotiations available commercial input global progress portfolio communicated investors product strategy commercial operations ensures regional media regular intervals year details gsks product marketing needs integrated development plans development pipeline given pages early stage risk rd development operations drives operational excellence pharmaceutical rd nature inherently risky execution projects clinical studies done establishing venture time potential medicine discovered integrated planning ensure consistent predictable drug becomes approved medicine take years project plans supplying clinical operations capabilities one ten molecules starts human clinical trials ever reaches development operations managed clinical trials regulatory approval nine ten fail discontinued active patients handling everything patient recruitment data variety reasons insufficient safety thresholds lack management project planning efficacy manufacturing hurdles discontinuations office chief medical officer charged safety occur despite extensive predictive testing latestage projects patients involved clinical trials well proper filing terminated included ariflo copd odiparcil findings regulatory authorities clinical trials sponsored stroke prevention gsk irrespective take place conducted according international standards good clinical practice applicable laws regulations protocols reviewed external regulatory agencies relevant countries required protocols considered ethics review committee whose responsibilities cover sites studies take place gsk annual report srotcerid eht fo troper stneitap rof enilepip tcudorp eht gnireviledbusiness review delivering product pipeline patients continued research development vaccines diseases developing world gsks vaccine division activities include research clinical continued investment research diseases disproportionately development regulatory strategy commercial strategy scaling affect developing world essential longterm vaccine production packaging support functions improvement health people live regions discovery development new vaccine complex process part gsks response challenge operates drug discovery requiring longterm investment rd scientists unit based tres cantos spain primarily dedicated finding new devoted developing new vaccines costeffective medicines malaria tuberculosis additional research sites convenient combination vaccines prevent infections cause usa uk focused discovering new medicines serious medical problems worldwide gsks vaccine division also treat hivaids drug resistant bacteria vaccine research developing therapeutic immunotherapeutics aimed educating conducted rixensart belgium patients immune system identify attack cancer cells medicines vaccines enter clinical trials taken highly specific manner thanks use innovative technologies development regulatory processes dedicated groups based global business model gsk fastgrowing vaccine maker uk usa belgium rd efforts gsk delivering value contributing health wellbeing addressing prevention treatment three world people every generation around world health organizations priority infectious diseases recently vaccine discovery involves many collaborations academia gsk developed scoredtablets key antiretroviral products biotech industry identify new vaccine antigens simplify treatment children living hiv expressed yeast bacteria mammalian cells purified gsk currently clinical programmes relevance high level developing world seven aimed producing vaccines followed formulation clinical lots vaccine medicines diseases disproportionately affect developing may involve mixing antigens selected gsk novel proprietary countries adjuvant systems combinations selected adjuvants publicprivate partnerships ppps remain essential fund research designed enhance immune response first step commercially viable market potential product evaluate safety efficacy candidate vaccine gsk leader working ppps continues collaborate preclinical setting usually involving animal model candidate closely many governments academic centres united nations vaccine tested clinical trials healthy individuals evaluate agencies global funding bodies area maximise safety effectiveness inducing immune response protect expertise knowledge dual benefit encouraging body infection encountered later natural setting phase research development accelerating access medicines iii largescale field trials healthy individuals follow establish developing world safety efficacy cross section population phase iii animals research results obtained clinical trials data regarding ethical regulatory scientific reasons research using animals development quality largescale production process remains small vital part research development new facilities combined regulatory file submitted medicines vaccines gsk uses animals authorities countries vaccine alternative numbers required test group made available strives exceed regulatory standards care use launch post marketing studies considerable size set animals uses undergoes internal external review assure assess vaccination programmes monitor vaccine safety standards phase iv vast majority experimental methods use animals vaccine manufacturing particularly complex requires use gsk actively engaged research develop validate innovative technologies living microorganisms sophisticated tests either avoid use animals research reduce quality assurance quality control procedures place ensure numbers needed animals used research unnecessary quality safety vaccines commonly includes pain suffering scrupulously avoided animal use according health authorities requirements due gsk understands use animals research purposes biological nature individual health authorities may subject vaccines commands high level public interest glaxosmithkline public second control guarantee highest quality standards policy position care ethical use animals research gsk increasing capacity supply vaccines information reports available gsks website developing global manufacturing network see global secretariat manufacturing supply gsk annual report srotcerid eht fo troper stneitap rof enilepip tcudorp eht gnireviledbusiness review delivering product pipeline patients continued research development consumer healthcare products filed vodart alpha blocker coprescription focus rd identify develop novel products c ervarix usa japan benefit consumers overthecounter otc oral healthcare e ntereg poi nutritional healthcare markets achieve significant increase h n vaccine eu innovation internal external sources rd k inrix usa remodelled deliver valuable pipeline products l amictal xr usa change specific tasks performed lower cost outside l univia eu gsk transferred external development partners p romacta usa transfer along headcount reductions savings releases r equip xl usa substantial funds investment additional innovation projects r otarix usa remodelling builds consumer healthcare operating ynflorix eu international model whereby global brands rd mirrors commercial reximet structure branddedicated rd teams paired commercial v olibris eu brand teams located together innovation centres weybridge uk parsippany usa gsk expects sustained flow new products next two years details developments information gsks pipeline important launchesfilings see gsk outlook beginning february gsk nearly pharmaceutical content drug development portfolio change time vaccine projects development clinic new compounds progress discovery development comprising nces ples vaccines compared development market owing nature drug development process many compounds especially last months gsk commenced new phase iii clinical early stages investigation may terminated progress development programmes including vaccines development phase nces multiple indications key assets phase iiiregistration counted nces later phases counted indication competitive reasons new projects preclinical compounds phase iiiregistration development disclosed project types may identified gsks policy seek obtain patent protection protectable inventions discovered developed rd activities patent protection new active ingredients available significant markets protection also obtained example new pharmaceutical formulations manufacturing processes medical uses special devices administering products see intellectual property gsk maintained momentum delivering latestage pipeline receiving product approvals filing product applications currently new product opportunities filed regulators development programmes progressed phase iii b elimumab lymphostat b e lesclomol g sk xp agea therapeutic vaccine enacwy vaccine fatumumab ra p romacta hep c ykerb armala ibc ykerb head neck gsk annual report srotcerid eht fo troper stneitap rof enilepip tcudorp eht gnireviled business review delivering product pipeline patients continued key inlicense alliance relationship third party maa marketing authorisation application europe date first submission nda new drug application usa date first regulatory approval maa first eu phase evaluation clinical pharmacology usually conducted volunteers approval letter phase ii determination dose initial evaluation efficacy conducted al date approvable complete response letter received indicates small number patients ultimately approval given subject resolution phase iii large comparative study compound versus placebo andor established outstanding queries treatment patients establish clinical benefit safety bla biological license application estimated submission dates disclosed within months date chart date represents likely year submission considered reasonably high probability successfully meeting date assuming clinical data meets expected endpoints clinical trials estimated submission dates compound type indication phase maa nda cardiovascular metabolic cardiovascular projects high affinity nicotinic acid receptor dyslipidaemia hma agonist rilapladib lppla inhibitor atherosclerosis p kinase inhibitor atherosclerosis also chronic obstructive pulmonary ii disease copd neuropathic pain rheumatoid arthritis p kinase inhibitor atherosclerosis also copd depression rheumatoid ii arthritis darapladib lppla inhibitor atherosclerosis lliii coreg cr ace inhibitor beta blocker angiotensin converting hypertension fixed dose combination iii na enzyme inhibitor volibris endothelin antagonist pulmonary arterial hypertension submitted smar na arixtra synthetic factor xa inhibitor treatment acute coronary syndrome approved aaug alfeb sep metabolic projects remoglifozin etabonate sodium dependent glucose transport sglt obesity inhibitor ppar gamma partial agonist type diabetes bile acid receptor agonist type diabetes otelixizumab trx anticd monoclonal antibody type diabetes ii remoglifozin etabonate sglt inhibitor type diabetes ii syncria glucagonlike peptide agonist type diabetes ii avandamet xr ppar gamma agonist metformin type diabetes extended release iii na avandia ppar gamma agonist atherosclerosis type diabetes iii avandia simvastatin ppar gamma agonist statin type diabetes iii na avandia ppar gamma agonist prevention disease progression submitted sfeb infectious diseases ribosome inhibitor treatment bacterial infections topoisomerase inhibitor treatment bacterial infections hiv integrase inhibitor hiv infections farglitazar ppar gamma agonist hepatic fibrosis ii sitamaquine aminoquinoline treatment visceral leishmaniasis ii na tafenoquine aminoquinoline plasmodium vivax malaria ii gsk annual report srotcerid eht fo troper stneitap rof enilepip tcudorp eht gnireviledbusiness review delivering product pipeline patients continued estimated submission dates compound type indication phase maa nda musculoskeletal inflammation gastrointestinal urology monoclonal antibody rheumatoid arthritis parathyroid hormone agonist osteoporosis motilin receptor agonist delayed gastric emptying androgen modulator sarcopaenia interleukin antagonist rheumatoid arthritis belimumab antib lymphocyte stimulator monoclonal systemic lupus erythematosus antibody sc pazopanib multikinase angiogenesis inhibitor agerelated macular degeneration also cancer indications oxytocin antagonist threatened preterm labour ii gselective oestrogen receptor modulator treatment menopausal symptoms ii selective inos inhibitor rheumatoid arthritis ii p kinase inhibitor oral rheumatoid arthritis also atherosclerosis copd ii neuropathic pain p kinase inhibitor oral rheumatoid arthritis also atherosclerosis copd ii depression corticotrophin releasing factor crf antagonist irritable bowel syndrome also depression anxiety ii ronacaleret calcium antagonist osteoporosis fracture healing ii solabegron beta adrenergic agonist irritable bowel syndrome ii solabegron beta adrenergic agonist overactive bladder ii avodart alpha reductase inhibitor reduction risk prostate cancer iii avodart alpha blocker alpha reductase inhibitor alpha blocker benign prostatic hyperplasia fixed dose combination iii belimumab antib lymphocycte stimulator monoclonal systemic lupus erythematosus iii antibody iv bosatria mepolizumab antiil monoclonal antibody hypereosinophilic syndrome also severe asthma nasal iii polyposis entraregentereg peripheral muopioid antagonist opioidinduced bowel dysfunction iii ofatumumab anticd human monoclonal antibody rheumatoid arthritis also cancer indications iii entraregentereg peripheral muopioid antagonist post operative ileus approvable aljul alnov neurosciences ht antagonist depression anxiety histamine h antagonist dementia monoclonal antibody neuronal injury nk antagonistssri depression anxiety crf antagonist depression anxiety crf antagonist depression anxiety dopamine antagonist drug dependency dopamine antagonist drug dependency ampa receptor modulator schizophrenia monoclonal antibody alzheimers disease sodium channel inhibitor bipolar disorder type glycine transport inhibitor schizophrenia orvepitant nk antagonist depression anxiety histamine h antagonist narcolepsy ii triple htnoradrenalinedopamine reuptake depression ii inhibitor glycine antagonist smoking cessation ii orexin antagonist sleep disorders ii p kinase inhibitor neuropathic pain also atherosclerosis copd ii rheumatoid arthritis ht antagonist dementia ii mixed htdopaminergic antagonist schizophrenia ii noncannabinoid cb agonist inflammatory pain ii p kinase inhibitor depression also atherosclerosis copd rheumatoid ii arthritis crf antagonist depression anxiety also irritable bowel syndrome ii xp voltagegated calcium channel modulator migraine prophylaxis ii xp voltagegated calcium channel modulator neuropathic pain ii casopitant nk antagonist depression anxiety also zunrisarezonic chemo ii therapy induced postoperative nausea vomiting firategrast dual alpha integrin antagonist vla multiple sclerosis ii xp voltagegated calcium channel modulator restless legs syndrome iii lamictal xr sodium channel inhibitor epilepsy partial generalised tonicclonic seizures iii na oncedaily rosiglitazone xr ppar gamma agonist alzheimers disease iii lunivia nonbenzodiazepine gaba agonist insomnia submitted sjul na lamictal xr sodium channel inhibitor epilepsy partial seizures oncedaily approvable na alsep treximet ht agonist naproxen migraine fixed dose combination approvable na aljun aug requip modutabxl nonergot dopamine agonist parkinsons disease oncedaily controlled release approved amar aldec formulation gsk annual report srotcerid eht fo troper stneitap rof enilepip tcudorp eht gnireviledbusiness review delivering product pipeline patients continued estimated submission dates compound type indication phase maa nda oncology pololike kinase inhibitor cancer akt kinase inhibitor cancer centromereassociated protein e cenpe cancer inhibitor armala pazopanib multikinase angiogenesis inhibitor colorectal cancer iboctadekin rituximab immunomodulator anticd nonhodgkins lymphoma monoclonal antibody totrombopag thrombopoietin agonist thrombocytopaenia xl cmet kinase inhibitor papillary renal cell carcinoma gastric cancer head ii neck squamous cell carcinoma ofatumumab anticd human monoclonal antibody relapsed diffuse large b cell lymphoma ii armala pazopanib multikinase angiogenesis inhibitor nonsmall cell lung cancer ii armala pazopanib multikinase angiogenesis inhibitor ovarian cancer ii armala pazopanib multikinase angiogenesis inhibitor sarcoma ii armala pazopanib multikinase angiogenesis inhibitor erbb metastatic breast cancer ii tyverbtykerb epidermal growth factor receptor egfr dual kinase inhibitor armala pazopanib multikinase angiogenesis inhibitor erbb cancers ii tyverbtykerb egfr dual kinase inhibitor revoladepromacta thrombopoietin agonist chemotherapyinduced thrombocytopaenia ii tyverbtykerb erbb egfr dual kinase inhibitor head neck squamous cell carcinomas ii unresectable disease tyverbtykerb erbb egfr dual kinase inhibitor refractory inflammatory breast cancer ii armala pazopanib multikinase angiogenesis inhibitor renal cell cancer iii armala pazopanib multikinase angiogenesis inhibitor erbb inflammatory breast cancer iii tyverbtykerb egfr dual kinase inhibitor elesclomol sta oxidative stress inducer metastatic melanoma iii hycamtin topoisomerasei inhibitor ovarian cancer firstline therapy iii ofatumumab anticd human monoclonal antibody refractory chronic lymphocytic leukaemia iii also rheumatoid arthritis ofatumumab anticd human monoclonal antibody refractory follicular lymphoma also rheumatoid arthritis iii revoladepromacta thrombopoietin agonist hepatitis c iii revoladepromacta thrombopoietin agonist longterm idiopathic thrombocytopaenic purpura iii tyverbtykerb erbb egfr dual kinase inhibitor breast cancer adjuvant therapy iii tyverbtykerb erbb egfr dual kinase inhibitor breast cancer brain metastases iii tyverbtykerb erbb egfr dual kinase inhibitor breast cancer firstline therapy iii tyverbtykerb erbb egfr dual kinase inhibitor head neck squamous cell carcinomas resectable disease iii zunrisarezonic nk antagonist chemotherapy induced postoperative nausea iii vomiting also depression anxiety revoladepromacta thrombopoietin agonist shortterm idiopathic thrombocytopaenic purpura submitted sdec hycamtin topoisomerase inhibitor oral small cell lung cancer secondline therapy approved smay aoct tyverbtykerb erbb egfr dual kinase inhibitor refractory breast cancer approved soct amar respiratory interleukin antagonist cystic fibrosis histamine hh dual antagonist oral allergic rhinitis histamine hh dual antagonist intranasal allergic rhinitis lipoxygenase activating protein flap inhibitor respiratory diseases longacting beta agonist copd also copd asthma combination ii glucocorticoid agonist longacting beta agonist copd also copd asthma combination ii glucocorticoid agonist pde iv inhibitor inhaled copd ii pde iv inhibitor inhaled asthma ii pde iv inhibitor intranasal allergic rhinitis ii muscarinic acetylcholine antagonist copd ii longacting beta agonist copd also copd asthma combination ii glucocorticoid agonist monoclonal antibody severe asthma ii p kinase inhibitor oral copd also atherosclerosis neuropathic pain ii rheumatoid arthritis glucocorticoid agonist asthma also copd asthma combination ii longacting beta agonist also avamysveramyst allergic rhinitis p kinase inhibitor oral copd also atherosclerosis depression rheumatoid ii arthritis novel glucocorticoid agonist asthma ii muscarinic antagonist beta agonist copd ii darotropium muscarinic acetylcholine antagonist copd ii mepolizumab antiil monoclonal antibody severe asthma nasal polyposis also hypereosinophilic ii syndrome avamysveramyst glucocorticoid agonist allergic rhinitis approved ajan aapr gsk annual report srotcerid eht fo troper stneitap rof enilepip tcudorp eht gnireviledbusiness review delivering product pipeline patients continued estimated submission dates vaccine type indication phase maa bla paediatric vaccines hibmencytt conjugated neisseria meningitis groups c disease iii haemophilus influenzae type b disease prophylaxis menacwytt conjugated neisseria meningitis groups c w disease iii prophylaxis infanrixipvkinrix subunit inactivated diptheria tetanus pertussis poliomyelitis prophylaxis submitted sapr boosterth dose synflorix conjugated streptococcus pneumoniae disease nontypeable submitted sdec haemophilus influenzae prophylaxis children rotarix live attenuated oral rotavirusinduced gastroenteritis prophylaxis approved afeb sjun vaccines cytomegalovirus recombinant cytomegalovirus infection prophylaxis hiv recombinant hiv infection prophylaxis pneumoniae adult recombinant conjugated streptococcus pneumoniae disease prophylaxis l dengue fever attenuated tetravalent vaccine dengue fever prophylaxis epsteinbarr virus recombinant ebv infection prophylaxis hepatitis e virus recombinant hepatitis e prophylaxis mosquirix recombinant malaria prophylaxis tuberculosis recombinant tuberculosis prophylaxis ii varicella zoster virus recombinant varicella zoster prevention ii flu pandemic hn inactivated split monovalent pandemic influenza prophylaxis iii quebec flu prepandemic hn inactivated split monovalent pandemic influenza prophylaxis iii quebec new generation flu inactivated split trivalent seasonal influenza prophylaxis elderly iii vaccine simplirix recombinant genital herpes prophylaxis lll boostrix subunit adult booster diphtheria tetanus pertussis submitted sfeb flu pandemic hn inactivated split monovalent pandemic influenza prophylaxis submitted sfeb dresden flu prepandemic hn inactivated split monovalent pandemic influenza prophylaxis submitted sjan dresden cervarix recombinant human papilloma virus infection prophylaxis approved asep aldec antigen specific cancer immunotherapeutic asci magea asci recombinant treatment melanoma ii magea asci recombinant treatment nonsmall cell lung cancer iii gsk annual report srotcerid eht fo troper stneitap rof enilepip tcudorp eht gnireviledbusiness review best place best people best work gsk annual report srotcerid eht fo troper krow tseb rieht od ot elpoep tseb eht rof ecalp tseb eht gnieb business ethics reputation gsk employs people gsk expects employees meet high ethical standards aspects countries business conducting activities honesty integrity committed creating best place adhering corporate responsibility principles complying applicable laws regulations gls showed best people best work believed people department showed commitment performance integrity agreed report recruitment talent management leadership development unethical practices without fear reprisal halfday workshop attracting recruiting best people critical enhancing ethical decisionmaking extended three sustaining gsks performance recruiters across gsk focused elearning modules implemented across gsk actively targeting best talent assessing fit commitment gsk code conduct reinforced senior organisation many key roles gsk seeks recruit people management certification programme year highest level integrity interview questions specific ethical managers certify complied performance integrity components developed inclusion integrity principles gsk audits operations regularly ensure standard interview questionnaire relevant standards marketing practices reached annual performance development planning pdp exceeded process ensures employees set businessaligned objectives diversity behavioural goals pdps reviewed throughout year diversity inclusion initiatives focus improving performance culminating end year review factored fifth year annual multicultural marketing diversity compensation decisions annual talent management cycle awards award winning projects repeatedly demonstrated identifies highest performing people business key business value understanding diverse perspectives leveraging talent developed tailored management leadership differences make positive difference workplace programmes exposure top management programmes customers communities served chief executive forum stretch assignments pool global management population male female potential successors identified vicepresident position details diversity measures see groups corporate critical roles throughout group responsibility report performance reward group committed employment policies free reward systems designed support culture high performance discrimination existing potential staff grounds attract retain best people performance based pay age race ethnic national origin gender sexual orientation faith bonuses share awards share options align employee interests disability gsk committed offering people disabilities meeting business targets access full range recruitment career opportunities communication employee involvement every effort made retain support employees become group conducts global leadership survey gls every two disabled working group years recent survey conducted among healthy high performance managers gauge opinions critical issues healthy energised engaged employees together healthy culture confidence groups future scores morale sustainable ways working contribute performance engagement steadily increased since compare group global policies employee health supported favourably global benchmarks topranked companies mandatory standards integrate employee health survey managers proud part gsk safety environmental requirements commitment flexible would gladly refer friend family member work working flexitime teleconferencing remote working gsk business develops action plans address areas flexible work schedules recognises employees work improvement based results gls surveys best environment helps integrate work group also consults employees changes affect personal lives discusses developments business european employee groups employee health management function actively consultation forum similar bodies countries delivering implementing team personal resilience national practice programmes available languages employee numbers region partnership groups leadership development function energy performance training introduced order improve potential employees usa europe asia pacific japan middle east africa latin america canada business review improving access medicines gsk annual report srotcerid eht fo troper senicidem ot ssecca gnivorpmi looking ahead gsk committed contributing gsk continue build product pricing partnership health improvements sustainable commitments help improve healthcare developing world manner developing world however significant increase funding global community still needed also important maintain incentives rd includes notforprofit pricing protection intellectual property community investment programmes much achieved sustainable progress occur innovative solutions significant barriers stand way better access developed world focus patient healthcare tackled shared responsibility sectors global assistance programmes society governments international agencies charities academic institutions pharmaceutical industry others access healthcare developing world access medicines developed world access healthcare developing countries remains major programmes usa challenge global community problem rooted gsk working provide access medicines people limited poverty demands significant mobilisation political additional financial resources without prescription drug insurance resources true spirit partnership gsk continues play marked launch gsks newest patient assistance vital role commitment rd diseases particularly programme gsk access eligible patients enrolled medicare prevalent developing world programme notfor part prescription drug plans enrolment new programme profit prices antiretrovirals arvs antimalarials vaccines encouraged multimillion dollar national advertising community investment programmes see campaign major magazines newspapers willingness seek innovative solutions voluntary licensing arrangements uninsured americans qualify medicare medicaid gsk pharmaceutical companies created together rx preferential pricing programme access programme qualified individuals offering reductions gsk offered vaccines key organisations vaccination pharmacy cost medicines programmes developing countries preferential prices together rx access cardholders saved million years group also sets single notforprofit price arvs antimalarials wide range customers gsk also participates partnership prescription assistance ppa least developed countries un definition subsaharan africa national service helps match people need prescription well country coordinating mechanismprojects fully funded medicine access programmes date ppa provided patients global fund fight aids tb malaria us presidents usa information assistance obtain necessary medicines emergency plan aids relief pepfar launched tykerb help access medicine tykerb gsk committed contributing health improvements cares single point contact physicians patients tykerb sustainable manner prices arvs antimalarials cares provides reimbursement support adherence support therefore set levels profit made direct costs services like pretherapy counselling trained oncology nurse covered allowing supply sustained long required patient advocacy gsk shipped developing countries million tablets patient advocacy initiative demonstrated significant progress notforprofitpriced combivir million tablets notfor since inception initially launched us programme profitpriced epivir gsks licensees supplying key critical initiative throughout gsk patient advocacy teams markets significant way usa europe share best practices established processes offer notforprofit prices requires sustainable framework optimise interaction patient groups typically relationships combining gsks commitment preferential pricing commitments provide mutual opportunities learn patient needs governments developed world avoid price referencing priorities patient groups develop understanding drug preferentially priced medicines governments help development challenges prevent product diversion gsk taken steps minimise threat gsk continued work patient groups educate diversion registration specific access packs access tablets issues mutual concern advocate access medicines differentiated red tablet opposed traditional white key treatment improve reputation governments arvs gsk remains group registered arvs media efforts promote transparency gsk considered european unions antidiversion regulation trustworthy partner patient groups developed innovative solutions guidelines procedures working patient groups gsk shown industry leadership granting voluntary licences imitated throughout industry eight generic companies manufacture supply arvs programmes countries public private sectors subsaharan africa gsk also group also introduced orange cards providing discounts leader collaborating publicprivate partnerships enable new certain gsk prescription medicines eligible patients number drug discovery development take place effectively countries nature discounts varies countries way healthcare system operatesbusiness review corporate responsibility community investment gsk annual report srotcerid eht fo troper tnemtsevni ytinummoc dna ytilibisnopser etaroproc gsks cash giving targeted primarily health education gsk made product cash initiatives follows donations valued million support community programmes around world health education arts culture commitment corporate responsibility environment gsk committed connecting business decisions ethical social environmental concerns thus corporate responsibility integral embedded part way gsk business uk gsk contributed million continuing gsk published set corporate responsibility principles programme charitable activities supporting organisations provide guidance standards group committed health medical research science education arts sets approach areas standards ethical environment conduct research innovation products customers access programmes north america focused improving public medicines employment practices human rights community education access better healthcare children seniors investment caring environment leadership advocacy nationally locally funding million national engagement stakeholders group reports annually philanthropy day usa gsk received excellence progress upholding principles corporate responsibility corporate philanthropy award committee encouraging report available gsks website corporate philanthropy cecp partnership success gsk operate single charitable foundation gsk works partner underserved communities developed community investment programmes number country developing world supports programmes innovative based foundations grants made foundations sustainable bring real benefits communities included investment total group engages numerous external stakeholders funds community led initiatives around world donates medicines global health programmes support humanitarian efforts community based healthcare eliminating lymphatic filariasis groups effort eliminate disabling disease lymphatic community investment filariasis lf world continued close partnership governments countries disease endemic gsks global community investment activities valued partner organisations gsk committed donate million equivalent group total profit tax much antiparasitic drug albendazole required treat comprised product donations million cash giving one billion people risk countries million million inkind donations million plus costs million albendazole treatments worth million wholesale acquisition manage deliver community programmes countries cost donated countries since global elimination product donations follows programme started cumulative total almost million albendazole treatments donated positive action hivaids patient assistance programs positive action gsks pioneering global programme working million communities affected aids started supports albendazole lf communitybased organisations deliver effective hiv aids million education prevention healthcare services humanitarian product donations positive action worked partners support programmes million countries positive actions larger programmes operate mexico kenya india china cambodia vietnam product donations valued wholesale acquisition cost wac glaxosmithkline african malaria partnership gsks malaria advocacy programme mobilising malaria launched country coalitions malaria uk belgium france ethiopia cameroon increase awareness malaria mobilise resources innovation grants malaria advocacy awarded four organisations africa working nigeria congo senegal uganda benefits gsks three previous behavioural development programmes targeting malaria eight african countries continue seenbusiness review corporate responsibility community investment continued gsk annual report srotcerid eht fo troper tnemtsevni ytinummoc dna ytilibisnopser etaroproc phase education initiatives phase programme personal hygiene sanitation education gsk continued support institute initiated gsk providing education thousands competitive workforce business coalition staffed business school children kenya uganda zambia nicaragua peru mexico civic leadership center us chamber commerce tajikistan bangladesh improve health hygiene aimed improving education creating skilled workforce fight infectious diseases group committed three year future funding million extend programme indonesia gsk also supports range local initiatives usa example bolivia partnership save children usa also science summer free librarybased science education includes funding introduce phase millennium village programme philadelphia area teaching basic scientific concepts project employs sciencebased interventions meet continued receive support grant nearly gsk millennium development goals also major sponsor university north carolinas humanitarian product donations travelling science laboratory destiny since inception gsk donated essential products antibiotics destiny serves approximately underserved secondary schools nonprofit partners including americares direct relief reaches students per year international map international project hope support gsk helped launch crest star investigators education humanitarian relief efforts community healthcare total initiative programme developed partnership value groups international humanitarian product donations british association advancement science provide million excludes albendazole donated part science activities awards school clubs uk primary groups commitment lymphatic filariasis elimination schools schools children expected taking programme product donations valued wholesale acquisition part cost wholesale list price including discounts standard industry method valuation secondary school science teachers england chemistry specialists chemistry nonspecialists community initiatives developed royal society chemistry train teachers teach gsk dedicated strengthening fabric communities chemistry confidence flair enthusiasm gsk supporting providing health education initiatives support local civic programme donation three years cultural institutions improve quality life employee involvement gsks contribution improve healthcare includes grant almost gsk employees encouraged contribute local communities million three years childrens health fund expand employee volunteering schemes support includes employee referral management initiative rmi sites philadelphia time cash donations charities employees volunteer including delaware valley community health center rmi matching gift programmes ensures continuity specialist medical care highrisk children often homeless usa group matched employee retiree gifts value million group also matched marked tenth anniversary annual glaxosmithkline million employee donations gsks annual united impact awards recognise excellence work nonprofit way campaign gsks give program provided grants community health organisations across uk greater almost organisations us employees philadelphia area usa year charities receive volunteered unrestricted awards work dealing diverse difficult social issues domestic violence sexual health services gsks making difference programme uk provided grants young people community health support counselling services almost nearly nonprofit organisations registered charities based employee involvement medical research provided three uk medical charities primary immunodeficiency association research ageing wellchildbusiness review global manufacturing supply gsk annual report srotcerid eht fo troper ylppus dna gnirutcafunam labolg operational excellence gsks manufacturing operations comprise within gms operational excellence provides capability drive network sites countries improvements process robustness quality performance customer service operational excellence underpinned extensive employ people education culture continuous improvement vision factory gsk manufactures large portfolio products ranging tablets gsk introduced vision factory initiative work towards toothpaste inhalers complex capsules simpler efficient operating model within gms vision factory different pack sizes presentations enabling manufacturing operations accelerate improvement manufacture medicines starts development performance cost control therapeutic active ingredient bulk active selected formulation quality global manufacturing supply gms develops manufacturing quality organisation oversees product quality across supply processes full scale volume production active compounds chain suppliers third party manufacturers primary manufacturing sites secondary sites convert manufacturing supply operations deliver products active compounds finished medicines market quality organisation focuses improving quality year gms produces around tonnes bulk actives compliance increasing product quality understanding four billion packs sold countries harmonising quality approach across sites also supports new product line extension launches external suppliers every year gms spends billion annually many external suppliers adopting leading edge practices developing people purchasing active ingredients chemical intermediates packaging gms provides components partfinished finished products takes appropriate steps protect supply chains disruption secure source supply high quality products c ompliance regulatory requirements procurement customer expectations widely recognised industry analysts best practice leader best class cost procurement works collaboratively develop implement sourcing strategies ensures gsk receives best value organisation buying goods services gsk leverages procurement activities across group gms operates single global network sites countries sites grouped four supply divisions based common vaccines supply chain business drivers areas expertise commercial activities gsks global vaccine manufacturing network managed support vaccine divisions headquarters belgium present three major regions gsk aims ensure effective supply vaccines primary supply across globe primary supply sites six countries supplying high quality competitively priced bulk actives division focused n europe vaccine manufacturing located primarily rixensart improvements primary technologies processes wavre belgium three sites france germany hungary site extended new product global supply new product global supply sites seven countries north america gsk established vaccine production network sites work closely rds development team ensure three major acquisitions production site right technical competencies place support rapid hamilton montana manufacturing mpl key component gsks successful new product introduction sites also ensure secure novel proprietary adjuvant systems vaccine production site supply key brands sold across many markets division marietta pennsylvania flu vaccine manufacturing facilities focal point developing introducing new secondary laval ste foy quebec canada manufacturing technologies gms international region new vaccine production facilities regional pharma supply built india singapore china packaging regional pharma supply operates supply key products particular activities already performed shanghai regions markets tailor packaging meet specific local managing vaccine supply chain involves anticipating market requirements division focuses reducing costs allowing gsk needs using flexible approach able meet fluctuations compete effectively markets regional demand based forecasts different markets pharma supply sites countries firm orders health authorities mass vaccination campaigns consumer healthcare supply production bulk vaccines filling packaging activities consumer healthcare supply delivers highquality competitively carefully balanced planned storing vaccines helps manage priced products supports rapid new product introduction shortterm increases demand increases result disease highly innovative competitive business far shorter time outbreaks increased demand public prompted disease frames pharmaceuticals new technologies become awareness campaigns fundamental platform driving innovation lowering costs providing flexibility operations sites countriesbusiness review regulatory environment regulatory environment international region continues gsk operates highly regulated evolve gsk participating number regional regulatory environment encompassing product initiatives example china proposed changes regulatory framework provided gsk opportunity approval pricing restrictions work directly state food drug administration sfda gsk maintenance intellectual property continues include broader sets patient populations environmental health safety international region global development programmes order responsibilities increase global patient access new innovative medicines optimise regulatory approvals price controls regulation pharmaceuticals many countries prices pharmaceutical products gsk operates within highly regulated environment regional controlled law governments may also influence prices countryspecific laws regulations define data required show control national healthcare organisations may bear safety efficacy pharmaceutical products well govern large part cost supplying medicines consumers testing approval manufacturing labelling marketing drugs recent government healthcare reforms countries france regulatory requirements major factor determining spain germany may restrict pricing reimbursement whether marketable product may successfully developed amount time expense associated development usa recent legislative proposals healthcare reform cross border trade acceleration generics market comparative usa fda continues seek encourage innovation effectiveness increased focus pricing currently drug development via critical path initiative new tools government price controls private sector purchases processes pursued enhance development safe federal law requires pharmaceutical manufacturers pay effective drugs gsk others pharmaceutical industry prescribed rebates certain drugs eligible reimbursement collaborating fda national institutes health medicaid state federal healthcare programmes number areas including evaluation new biomarkers presidential elections healthcare one leading benefitrisk assessments domestic issues though prices part discussions increasingly drug safety remains primary focus fda congressional leading candidates proposing health reforms address oversight committees europe evaluation benefit chronic disease primary healthcare cost driver risk continues paramount consideration approval medicare new drug new legislation passed fda amendments us medicare program federally funded healthcare act renews user fee system drug reviews mandates insurance programme benefiting senior citizens certain disabled rigorous fda review safety approval post americans included coverage prescription medicines marketing phase product legislation also provides coverage voluntary includes brandname generic drugs fda new tools require sponsors complete postmarketing open million americans medicare coverage studies make labelling changes number competing private organisations provide benefit regulations requiring development prescription drugs premiums subsidised government benefits must satisfy biologics paediatric populations reauthorised us minimum standard outlined federal law law provides congress similarly europe new paediatrics regulation incentives manufacturers negotiate prices private health implemented gsk fully supports objective ensuring insurance plans provide government price controls development better medicines children government provides additional help million europe pharmaceutical companies government regulators people medicare limited incomes resources continue implement new medicines legislation introduced qualifying beneficiaries pay reduced premiums deductibles end involves significant changes low copayments prescriptions eu regulatory system including changes product approval benefit proved marked success competition procedures postmarketing requirements manufacturing controls reduced estimate total costs made congressional labelling requirements pharmacovigilance processes increased budget office billion ten year period recent polls transparency regulatory processes medicare beneficiaries enrolled new benefit show satisfaction eu regulators also engaged better regulation initiatives rates cut red tape overregulation pharmaceutical industry value money gsk welcomes recognition unnecessarily burdensome payers around world concerned cost healthcare regulatory requirements damage competitiveness may pricing medicines requirement satisfy healthcare negatively impact public health therefore active supporting purchasers value money becoming additional hurdle initiatives product acceptance regulatory tests safety efficacy quality gsk annual report srotcerid eht fo troper tnemnorivne yrotalugerbusiness review regulatory environment continued appropriate payers seek value money since term patent countries set period purchasing medicines often translates costcontainment filing date typically years effective term depends measures delay patient access new medicines make long product development launch leads difficult even significantly improved therapies achieve price variation patent term product product basis although reflects added value healthcare budgets could managed number markets including usa europe possible strategic longterm manner focus shift value certain circumstances obtain partial restoration patent term cost pricing reflect value value defined broadly compensate length development process matters whether medicine works responds medical patent position respect active ingredients significant patient needs rewarded appropriately products follows payers must also allocate resources efficiently provide advairseretide patent specific combination salmeterol best health outcomes attention focused three areas xinafoate fluticasone propionate due expire prevention innovation better management chronic diseases usa b europe us patent reissued part triple solution innovative medicines vaccines us patent trademark office usptoe litigation patents play key role preventing providing better treatments protecting product ongoing certain european marketse expensive diseases cervical cancer breast cancer asthma uk patent revoked uk courts patents alzheimers diabetes individual ingredients expired except patents salmeterol possible predict whether extent groups xinafoate usa august france december business affected future legislative regulatory developments italy relating specific pharmaceutical products price avandia avandamet avandaryl patent rosiglitazone due expire ac usa b europe patents regulation consumer healthcare commercial form active ingredient rosiglitazone maleate consumer healthcare industry subject national regulation due expire usa b europe litigation testing approval manufacturing labelling marketing challenging validity patents protecting products products many countries high standards technical appraisal usae settled terms allowing generic entry late involve lengthy approval process new product launched first quarter e national regulatory authorisation also required approve switch avodart patent dutasteride due expire products prescription otc requirements include long usa b europe litigation challenging validity term experience quality safety efficacy product patent protecting product usa ongoinge wide patient population data confirm relevant avamysveramyst patent fluticasone furoate due condition selflimiting easily diagnosed consumer expire usa europe boniva gsk copromotion rights patent intellectual property ibandronate due expire usa b intellectual property key business asset gsk effective legal europe litigation challenging validity patent protecting protection intellectual property critical ensuring reasonable product ongoing usae return investment rd intellectual property protected combivir patent specific combination lamivudine patents trademarks registered designs copyrights domain zidovudine due expire usa b name registrations europe litigation challenging validity patent protecting certain markets including usa eu canada also combination ongoing usae provide period regulatory data exclusivity qualifying drugs coreg gsk exclusive licensee us patent carvedilol new chemical entities new formulations expired ac coreg cr protected formulation uses marketed drugs manufacturers generic drugs may patent due expire usa patent following period data exclusivity launch attempt launch active form carvedilol phosphate due expire generic versions patented drugs prior normal patent expiry litigation challenging validity patent active arguing relevant patents invalid andor form ongoing usae infringed product significant litigation concerning challenges summarised note financial statements epivir patent lamivudine due expire ac legal proceedings usa b europe patents imigranimitrex patent sumatriptan due expire gsks policy seek obtain patent protection protectable c usa expired europe except italy december inventions discovered developed rd activities patent litigation challenging validity patent protecting protection new active ingredients available significant product usa settled allowing generic entry markets protection also obtained example new fourth quarter pharmaceutical formulations manufacturing processes medical uses lamictal patent lamotrigine due expire ac special devices administering products patents protecting usa litigation challenging validity patent usa new active ingredients generally applied early settled terms allowing generic entry tablet forms development process mid europe corresponding patent expired generic competition exists gsk annual report srotcerid eht fo troper tnemnorivne yrotalugerbusiness review regulatory environment continued levitrad gsk copromotion rights us patent vardenafil due expire lexivatelzir gsk exclusive licensee patent fosamprenavir due expire usa b europe lovaza formulation omega acid ethyl esters protected patent expires usa paxilseroxat patent commercial form paroxetine expired generic competition exists paxil instant release ir forms usa europe markets litigation relating patents protecting product ongoing usae paxil cr protected patent issued june relating delayed controlled release formulation paroxetine hydrochloride litigation relating patent settled terms allowing generic entry strengths paxil cr later fourth quarter e requip patent ropinirole expired usa due expire november b europe patent relating use ropinirole parkinsons disease due expire may usa b europe litigation challenging validity parkinsons use patent usa dismissed court generic entry expected expiry patent may e serevent patent salmeterol xinafoate expires august usa europe patent expired except france december b italy b trizivir patent method treatment using combination lamivudine zidovudine abacavir expire usa europe tykerbtyverb patent lapatinib due expire usa b europe valtrex patent valaciclovir due expire usa b europe except greece spain august litigation challenging validity patent usa settled terms allowing generic entry late e wellbutrin sr wellbutrin xl zyban patent active ingredient expired generic competition sustained release sr instant release ir mg dosage form wellbutrin xl usa litigation usa relating formulation patents covering wellbutrin xl settled terms allowing generic entry mg form europe regulatory data exclusivity provides protection markets ziagen patent abacavir due expire ac usa b europe zofran patent ondansetron expired usa europe except italy november b patent use treating emesis also expired generic competition exists usa europe markets including granted pending patent term restoration hatchwaxman act b including granted pending extension term national european supplementary protection certificates c including granted pending extension term paediatric exclusivity registered trademark bayer ag e see note financial statements legal proceedings gsk annual report srotcerid eht fo troper tnemnorivne yrotaluger trademarks gsks pharmaceutical products protected registered trademarks major markets may local variations example usa trademark paxil used instead seroxat advair used instead seretide trademark protection may generally extended long trademark used renewing necessary gsks trademarks pharmaceutical products important maintaining brand identity product upon expiration patent consumer healthcare trademarks particularly important business brand oriented many products patent protection responsibility environment health safety environment health safety ehs key element corporate responsibility group high priority responsibility ehs highest level corporate department reporting general counsel overall responsibility providing governance leadership ehs issues head department makes regular reports corporate executive team cet audit corporate responsibility committees board within businesses executives managers responsible ehs supported sitebased ehs occupational medical staff ehs strategy plan gsk year strategic plan ehs extends annual action plans plan aligned gsk business drivers includes management objectives performance measures targets gsks progress evaluated targets set focus ehs stewardship building sustainable business involves caring present thinking future making decisions supports three aspirations plan embedding ehs business environmental sustainability open transparent stakeholder relations accomplishments c limate change comprehensive strategy climate change energy efficiency approved available gsks website climate change energy reduction team formed manage special fund used support climate change projects team identified projects reduce energy consumption increase gsks use renewable energy anufacturing efficiency ongoing effort improve efficiency manufacturing processes therefore significantly decrease purchase raw materials production waste gsk selected best candidate medicines improvement mass efficiency processes development continues improve progress made achieve target double mass efficiency thereby halve waste per unit product manufacturing processes phase iii compounds late stage products evaluated since efficiency improvement average certain marketed products known market potential also selected improvement efficiency manufacturing processesbusiness review regulatory environment continued workplace chemical exposure occupational hygiene measures selected similar reported measurements completed gsk tasks companies recommended global reporting initiative involving exposure potent materials results longterm multistakeholder international undertaking develop show exposures adequately controlled respiratory disseminate globally applicable sustainability reporting guidelines protective equipment worn verified respirator free targets set eliminate chlorofluorocarbons cfcs meaning respiratory protection necessary immediate action uses year reduce nonhazardous waste disposed taken control exposures instances levels reduce water use volatile organic compound voc found higher predicted manufacturing sites releases air reduce pollution wastewater measured target respirator free end chemical oxygen demand reduce energy usage process safety gsks process safety management system related greenhouse gas emissions year enhanced new engineering standards training programmes target set reduce energy usage greenhouse gas emissions development standards used design new targets normalised process plant upgrade existing plants needed sales based constant exchange rate training programmes increase process safety awareness gsk remained track eliminate use cfcs competencies engineers chemists managers meet targets energy use related external stakeholders addition ongoing uk stakeholder greenhouse gas emissions progress towards energy group meeting march panel us stakeholders met october related greenhouse gas emissions target expected accelerate provide input ehs issues us perspective benchmark beyond annual targets met reduction assessment environmental programmes carried uk water use wastewater pollution gsk meet targets charity business environment gsk ranked top nonhazardous waste disposal voc releases air case companies gsk also included ftse good index nonhazardous waste disposal dow jones sustainability index increase solid waste disposal vaccines business due expansion programme development launch ehs audits new vaccines case voc releases due part governance responsibility gsk conducts ehs audits product mix changes solvent recovery equipment sites operating entities key suppliers assessing management manufacturing sites inadequate completely capture key risks impacts performance gsks global ehs recycle certain solvents used manufacturing process standards includes providing audited sites quantitative performance information well highlighting areas risk reduction final ehs performance data explanations improvement operating entities audited trends published corporate responsibility report achieved audit scores better reflects long gsks website term goal sites score site scored less sustainability seven critical findings raised working towards sustainability gsk addressing economic corrected ensure continuous improvement progress monitored environmental social issues research manufacturing sales corrective preventive action plans arising audits distribution medicines consumer healthcare nutritionals part commitment corporate responsibility products sustainability starts healthcare solutions found proactive management gsk manufacturing supply base rd continues innovations improve efficiency current potential suppliers also assessed process manufacturing processes new products reduces resource evaluated management key ehs risks impacts including use turn lowers waste cost lower cost fire explosion risks aspects process safety loss prevention products available wider population around world control exposure hazardous substances environmental future ehs plan excellence proposes investigating protection well core human rights issues based groups use renewable resources manufacturing requirements suppliers recommendations made group seeks dialogue external stakeholders considers improvements needed potential suppliers views developing approaches sustainable development failed achieve gsks recommendations gsk plans partner information ehs programmes performance may successful candidates improve overall environment found gsks website health safety loss prevention performance ehs targets part ehs plan targets set every five years baseline year targets gsk selected measures performance improvement based potential adverse impact people environment business continuity business reputation gsk annual report srotcerid eht fo troper tnemnorivne yrotalugerbusiness review world market world economy world market pharmaceuticals global economy continued broadly positive global pharmaceutical sales billion compared buoyed growth developing markets china although billion mortgagerelated issues usa adverse effect several countries world gross domestic product gdp growth eased world market value growth geographic region bn total international monetary fund forecasts global gdp growth usa europe equity markets struggled backdrop record france breaking oil prices continued concerns situations germany iraq afghanistan oil prices averaged per barrel uk throughout year rose later year inflation italy oecd countries expected increase japan asia pacific us economy weakened significantly led slump new latin america housing starts exacerbated subprime lending crisis gdp middle east africa growth slowed many canada analysts expect fall mark dow total jones industrial index gained period interest rates dropped significant cut january us market decreased still represents took us dollar continued global prescription pharmaceutical market compared decline euro sterling fallen throughout decade ago year us dollar worth less p november lowest point since th september gsk held second position world pharmaceutical market market share behind pfizer chinese economy continued make sound progress growing market share gsk four worlds top growth forecast dip slightly pharmaceutical products avandia lamictal seretideadvair particularly problems usa may impact demand valtrex chinese exports japan gdp nikkei fell year marking first annual decline five world market value growth years indian brazilian economies achieved doubledigit top six therapeutic classes bn total growth central nervous system eurozone gdp growth slowed cardiovascular expected fall france expanded alimentary tract metabolic germany uk spain antineoplasticimmunomodulatory european central bank interest rates closed year antiinfectives bacterial end uk rates started year rose three viral fungal excluding steps fell back yearend vaccines ftse index gained weakest annual performance respiratory since note data based months th september exchange currencies influence groups results us dollar euro japanese yen us dollar fell sterling yearend yearend rates euro strengthened japanese yen sterling gsk annual report srotcerid eht fo troper tekram dlrowbusiness review products competition requip specific dopamine dd receptor agonist indicated prescription pharmaceutical treatment parkinsons disease restless legs syndrome rls consumer healthcare industries antivirals highly competitive despite combivir combination retrovir epivir consolidated second largest pharmaceutical company position two reverse transcriptase inhibitors world gsk share cornerstone many multiple antihiv product regimens physician acceptance clearly demonstrated value placed minimising world market pill burden faced patients ziagen reverse transcriptase inhibitor products potency pharmaceutical products ease use resistance profile allow play significant role glaxosmithklines principal pharmaceutical products currently directed variety highly active well tolerated simplified hiv eight main therapeutic areas analysis sales therapeutic area treatment regimens description principal products set trizivir combination combivir ziagen combining three antihiv therapies one tablet twicedaily administration turnover therapeutic area epzicomkivexa approved use usa europe respiratory combination epivir ziagen taken one tablet central nervous system oncedaily dosing hivaids combination least one antivirals antihiv drug metabolic vaccines lexivatelzir protease inhibitor treatment hiv well cardiovascular urogenital tolerated convenient agenerase supersedes antibacterialsantimalarials lexiva may taken twicedaily oncedaily boosted oncology emesis ritonavir zeffix approved marketing usa europe china markets treatment chronic hepatitis b products formulations may approved valtrex treatment episodic genital herpes well long indications markets available term suppression reduction transmission genital herpes zoster shingles cold sores chicken pox valtrex supersedes respiratory zovirax also used treat herpes infections seretideadvair combination serevent flixotide offers longacting bronchodilator antiinflammatory single metabolic inhaler approved treatment asthma copd avandia potent insulin sensitising agent acts underlying pathophysiology type diabetes flixotideflovent becotidebeclovent inhaled steroids treatment inflammation associated asthma copd avandamet combination avandia metformin hci targets insulin resistance decreases glucose production one serevent longacting bronchodilator used treat asthma convenient pill copd ventolin selective shortacting bronchodilator used treat bronchospasm avandarylavaglim combination avandia amaryl sanofi aventis product avandarylavaglym targets insulin resistance veramystavamys flixonaseflonase beconase steroid intra stimulates pancreatic insulin production nasal preparations treatment perennial seasonal rhinitis bonvivaboniva longacting bisphosphonate available central nervous system cns monthly oral quarterly injection forms treatment seroxatpaxil selective serotonin reuptake inhibitor ssri osteoporosis copromoted roche treatment major depressive disorder panic obsessive compulsive disorder post traumatic stress disorder social anxiety disorder vaccines generalised anxiety disorder controlled release formulation paxil gsk markets vaccines worldwide half cr available usa combination vaccines protect children adolescents andor adults six diseases time wellbutrin antidepressant available usa many european international markets normal sustainedrelease sr infanrix gsks range paediatric vaccine combinations infanrix oncedaily xl formulations provides protection diphtheria tetanus pertussis whooping cough infanrix penta europepediarix usa canada provides additional imigranimitrex ht receptor agonist used treatment protection hepatitis b polio infanrix hexa adds protection severe frequent migraine cluster headache become haemophilus influenzae type b cause meningitis reference product sector naramigamerge also ht boostrix available add protection pertussis whopping cough receptor agonist indicated treatment migraine routine tetanusdiptheria booster administered teenagers lamictal well established treatment epilepsy also indicated gsks hepatitis vaccines range havrix protects hepatitis bipolar disorder engerixb hepatitis b gsk annual report srotcerid eht fo troper noititepmoc dna stcudorpbusiness review products competition continued twinrix available combined hepatitis b vaccine fraxiparine lowmolecular weight heparin indicated prophylaxis protecting diseases one vaccine available thromboembolic disorders particularly deep vein thrombosis adult paediatric strengths europe fendrix vaccine pulmonary embolism general surgery orthopedic surgery prevent hepatitis b patients renal insufficiency including high treatment deep vein thrombosis prevention clotting risk groups prehaemodialysis haemodialysis patients haemodialysis available years age onwards integrilin gp iibiiia inhibitor approved eu prevention gsk added fluviral portfolio products acquired early myocardial infarction patients unstable angina canadian vaccine manufacturer id biomedical corporation nonqwave mi december fluviral marketed canada following fda antibacterials antimalarials approval usa approved active immunisation augmentin broadspectrum antibiotic suitable treatment adults years older influenza disease wide range common bacterial infections particularly brand flulaval fluviral flulaval add fluarix gsks seasonal flu effective respiratory tract infections augmentin es vaccine distributed countries including usa extra strength suspension specifically designed treat children gsk also markets priorix measles mumps rubella vaccine recurrent persistent middle ear infections augmentin xr typherix vaccine protection typhoid fever varilrix extended release formulation treatment patients vaccine varicella chicken pox priorixtetra gsks new community acquired pneumonia acute bacterial sinusitis combination vaccine prevent measles mumps rubella altabaxaltargo approved topical treatment varicella mmrv first launched germany august certain bacterial skin infections represents first new class addition group markets range vaccines prevent topical antibiotics approved fda nearly two decades meningitis umbrella name mencevax gsks new hib menc vaccine menitorix available uk gsks meningitis ceftinzinnat oral antibiotic used primarily community vaccine portfolio complemented new meningitis conjugate acquired infections lower respiratory tract vaccines near future malarone oral antimalarial used treatment part paediatric franchise gsk continued roll prophylaxis malaria caused plasmodium falciparum launch vaccine rotavirus induced gastroenteritis oncology emesis rotarix launched countries worldwide rotavirus tykerb oral treatment patients advanced metastatic vaccination included national vaccination calendar breast cancer whose tumours overexpress five latin american countries rotarix available received prior therapy including anthracycline taxane free public health clinics part governmental paediatric trastuzumab tykerb approved usa immunisation programmes submitted european approval cardiovascular urogenital hycamtin second line treatment ovarian cervical small coreg alphabeta blocker proven effective cell lung cancer treating patients mild moderate severe heart failure heart attack hypertension gsk sole marketing rights bexxar treatment patients cd follicular non usa canada controlled release formulation coreg cr also hodgkins lymphoma without transformation whose available usa generic versions coreg available disease refractory rituximab relapsed usa canada following chemotherapy levitra pde inhibitor indicated male erectile dysfunction arranon nelarabine treatment patients tcell acute gsk copromotion rights usa lymphoblastic leukaemia tcell lymphoblastic lymphoma markets zofran used prevent nausea vomiting associated avodart ari inhibitor currently indicated benign prostatic chemotherapy radiotherapy cancer available hyperplasia large clinical study underway examining efficacy oral injectable forms also approved use prevention reducing risk prostate cancer treatment postoperative nausea vomiting vesicare antimuscarinic indicated overactive bladder gsk copromotion rights astellas usa major competitors category includes betnovate higher potency dermovate detrol la ditropan xlgeneric oxybutynin enablex newer cutivate topical antiinflammatory steroid products used treat skin diseases eczema psoriasis arixtra selective factor xa inhibitor indicated treatment relafen nonsteroidal antiinflammatory drug treatment deep vein thrombosis dvt pulmonary embolism pe arthritis zantac treatment peptic ulcer disease prevention dvt pe patients undergoing major orthopaedic range gastric acid related disorders surgery abdominal surgery acutely ill medical patients eu also eu arixtra indicated treatment patients acute coronary unstable angina nstemi stemi gsk annual report srotcerid eht fo troper noititepmoc dna stcudorpbusiness review products competition continued pharmaceuticals competition antivirals gsk pioneer hiv market launching azt retrovir pharmaceutical industry highly competitive gsks principal epivir today available combivir single competitors range small large pharmaceutical companies tablet cornerstone hiv combination therapy launches often substantial resources companies ziagen agenerase trizivir lexiva epzicom broadened major products mentioned groups portfolio hiv products major competitors hiv pharmaceuticals may subject competition products market include gilead bristol myers squibb abbott roche period patent protection patent boehringer ingelheim generic versions manufacturers generic products typically valtrex strengthened groups position antiherpes bear significant research development education area gsks valtrex zovirax compete novartis famvir marketing development costs consequently able offer valtrex market leader whilst zovirax faces competition products considerably lower prices branded competitors generic acyclovir hepatitis b market gsks zeffix first research development based pharmaceutical company antiviral market gileads hepsera second group normally seek achieve sufficiently high profit margin sales secured marketing rights hepsera key markets volume period patent protection repay original investment generally substantial fund research metabolic future competition generic products generally occurs major competitor avandia takeda chemicals actos patents major markets expire increasingly patent challenges whose copromotion eli lilly usa ended takeda made prior patent expiry claiming innovator patent also market actoplusmetcompetact combination metformin valid andor infringed generic product following hci actos usa eu markets duetact loss patent protection generic products rapidly capture large combination glimepiride actos usa share market particularly usa monthly bonivabonviva competes mercks weekly fosamax gsk believes remaining competitive dependent upon proctor gamblesanofiaventis twicemonthly actonel discovery development new products together effective novartis reclastaclasta dosed annual infusion marketing existing products within pharmaceutical industry generic fosamax alendronate available many markets introduction new products processes competitors including usa uk germany canada may affect pricing levels result changing patterns product vaccines use assurance products become vaccine market dominated five key players gsks major outmoded notwithstanding patent trademark protection competitors sanofi pasteur sp merck novartis wyeth addition increased government pressures physicians within paediatric vaccine field infanrixs main competitor sps patients use generic pharmaceuticals rather brand range dtpabased combination vaccines although infanrix hexa name medicines may increase competition products combination available hexavalent paediatric combination longer protected patent europe merck joint venture merck sp europe respiratory market two new vaccines rotavirus induced infection hpv gsks respiratory franchise driven growth seretideadvair respectively compete rotarix cervarix major respiratory competitors singulair merck especially cardiovascular urogenital usa symbicort astrazeneca spiriva pfizer gsk markets coreg usa major competitors toprol xl boehringer ingelheim generic betablockers avodart competes directly mercks proscar cns disorders within bph enlarged prostate market group copromotion major competitors usa paxil generic forms well rights usa levitra faces competition pfizers viagra generic fluoxetine generic form eli lillys prozac generic lillys cialis major competitor arixtra low molecular sertraline generic form pfizers zoloft cymbalta eli lilly weight heparin enoxaparin product marketed sanofiaventis forest laboratories celexa lexapro effexor xr wyeth antibacterials antimalarials principal competitors usa wellbutrin generic forms generic versions augmentin ceftinzinnat available bupropion generic forms ssris lexapro effexor xr usa augmentin also faces generic competition various cymbalta generic competition seroxatpaxil also occurred european countries augmentin xr augmentin es compete number markets broad range branded generic antibiotics major competitors lamictal epilepsy jjs dilantin malarones safety profile convenient dosing regimen generic phenytoin novartis egretoltegretol xr generic helped put product strong position versus mefloquine carbamazepine ucbs keppra abbots depakotedepakote malaria prophylaxis er bipolar major competitors generic lithium altabaxaltargo competes topical antibiotic market antiepileptics including abbotts depakotedepakote er number generic competitors including generic mupirocin atypical antipsychotics including astrazenecas seroquel major fusidic acid altabaxaltargos offers less frequent shorter duration competitors imitreximigran astrazenecas zomig mercks therapy lack cross resistance established classes maxalt pfizers relpax antibacterials gsk annual report srotcerid eht fo troper noititepmoc dna stcudorpbusiness review products competition continued oncology emesis overthecounter medicines major competitors diverse therapeutic market include roche leading products panadol widely available paracetamol genentech novartis sanofiaventis bristol myers squibb acetaminophen analgesic nicorette gum usa nicoderm gsks therapeutic portfolio led recently approved tykerb niquitin cq nicabate range smoking control products tums hycamtin currently holds relatively small market position zofran calciumbased antacid citrucel laxative contac treatment provided gsk leadership position antiemetic market colds abtei natural medicines vitamin range zovirax competitor companies include roche mgi merck abreva treatment cold sores recent additions generic competitors became available late portfolio include breathe right nasal strips gently lift open nasal passages provide better breathing fiberchoice daily fibre consumer healthcare products supplements acquisition cns inc switch orlistat prescriptiononly status united states glaxosmithklines principal consumer healthcare products three overthecounter marketed weight control product alli major areas analysis sales areas set oral care leading oral care products toothpastes mouthwashes aquafresh odol sensodyne macleans brand names otc medicines range toothbrushes sold aquafresh dr best oral care names addition denture care products available principally nutritional healthcare polident poligrip corega brand names nutritional healthcare leading products category lucozade energy sports major products necessarily sold markets drinks ribena blackcurrant juicebased drink horlicks range category product milkbased malted food chocolate drinks overthecounter medicines consumer healthcare competition analgesics panadol dermatologicals zovirax gsk holds leading global positions key consumer product abreva areas worldwide third largest oral care otc external nasal dilators breathe right medicines nutritional healthcare holds leading position gastrointestinal tums uk india ireland citrucel environment consumer healthcare business respiratory tract contac operates become ever challenging beechams smoking control commit consumers demanding better quality better value nicorette improved performance nicoderm cq r etailers consolidated globalised strengthened niquitin cq negotiation power nicabate cq manufacturers consolidating leading aggressive natural wellness support abtei competition across elements marketing mix fiberchoice weight control alli c ycle times innovation reduced oral healthcare aquafresh main competitors include major international companies dr best colgatepalmolive johnson johnson procter gamble unilever macleans wyeth addition many companies odol compete gsk certain markets polident major competitor products otc medicines poligrip usa metamucil laxative pepcid indigestion private sensodyne label smoking control products nutritional healthcare lucozade n uk lemsip cold remedy nurofen anadin analgesics ribena nicorette nicotinell smoking control treatments horlicks oral care major competitors colgatepalmolives colgate procter gambles crest nutritional healthcare major competitors horlicks ovaltine milo malted food chocolate drinks competitors ribena primarily local fruit juice products lucozade competes energy drinks gsk annual report srotcerid eht fo troper noititepmoc dna stcudorp gsk annual report srotcerid eht fo troper weiver laicnanif business review financial review cns gsk turnover grew cns sales decreased billion sales decreased business performance eps grew usa europe reflecting generic competition seroxatpaxil p dividend raised p regions international sales grew included growth paxil japan total seroxatpaxil sales declined share repurchases billion million total wellbutrin sales declined million billion expected owing us generic competition wellbutrin srir wellbutrin xl mg tablet pharmaceutical turnover sales lamictal treatment epilepsy bipolar disorder growth rates included review turnover constant grew billion driven sales usa exchange rates cer unless otherwise stated sterling growth rates may million benefiting new indication lamictal found tables pharmaceutical turnover therapeutic area also medicine longterm clinical data demonstrates geographic region total pharmaceutical delay onset depressive episodes bipolar disorder turnover million compared million gsk expects respond us fdas approvable letter lamictal line turnover cer sterling terms total xr middle pharmaceutical turnover decreased four percentage points less sales requip parkinsons disease restless legs syndrome cer principally due strength sterling us dollar rls grew million requip xl new oncedaily formulation parkinsons disease approved pharmaceutical turnover therapeutic area european countries launched seven markets european gsks turnover line highvalue growth approvals anticipated usa gsk expects products offset lower avandia sales us generic response fda application requip xl competition coreg ir flonase wellbutrin xl zofran first half highvalue growth products included seretideadvair vaccines antivirals lamictal valtrex requip avodart boniva total sales hiv products billion competition respiratory older products combivir million epivir gsk continues global leader respiratory pharmaceuticals million largely offset strong sales growth sales three key products seretideadvair flixotideflovent new products epzicomkivexa grew million serevent amounting billion total sales lexivaagenerase million seretideadvair asthma copd rose billion sales valtrex herpes rose million us sales usa sales grew billion europe sales grew million driven increased use product billion international markets sales grew prevention disease transmission sales europe grew million enhanced launch japan june million international grew million sales market share value antiasthma copd therapy class relenza antiviral treatment flu million europe usa million driven primarily oneoff government orders stockpiling possible flu pandemic market share value seretideadvair metabolic sales avandia product group type diabetes declined billion usa sales fell million fourth quarter sales million following publication article new england journal medicine article suggested may cardiovascular risk associated avandia despite gsks efforts doctors became reluctant start new patients avandia without guidance fda following clarification fda october new approved label avandia outside usa sales europe grew year million europe usa international markets sales declined million september september gsk recorded turnover million share copromotion gsk continues see increased use seretideadvair treatment income bonivabonviva oncemonthly oral bisphosphonate copd ongoing discussions fda expand treatment postmenopausal osteoporosis indication use patient group including assessment data supporting claim reduction exacerbations vaccines vaccine sales increased billion good performances regions us sales rose million european sales grew million sales international million sales hepatitis vaccines grew million driven us growth business review financial review continued gsk annual report srotcerid eht fo troper weiver laicnanif pharmaceutical turnover therapeutic area total usa europe international therapeutic area growth growth growth growth major products total cer cer cer cer respiratory seretideadvair flixotideflovent serevent flixonaseflonase central nervous system seroxatpaxil paxil ir paxil cr wellbutrin wellbutrin ir sr wellbutrin xl imigranimitrex lamictal requip antivirals hiv combivir trizivir epivir ziagen agenerase lexiva epzicomkivexa herpes valtrex zovirax zeffix relenza metabolic avandia avandamet avandaryl bonvivaboniva vaccines hepatitis influenza infanrix pediarix boostrix rotarix cervarix cardiovascular urogenital coreg levitra avodart arixtra fraxiparine vesicare antibacterials augmentin oncology emesis zofran hycamtin tykerb zantac cer represents growth constant exchange rates represents growth actual exchange rates turnover quarter given financial record pages business review financial review continued infanrixpediarix grew million driven us growth sales constant exchange rate growth region sales new twodose vaccine rotarix prevent rotavirus gastroenteritis doubled million strong growth europe international sales cervarix gsks vaccine prevent cervical cancer million approved countries licensing applications submitted countries including japan gsks prepandemic influenza vaccine cer achieved sales million discussions regarding orders growth continue number governments cer cardiovascular urogenital growth sales coreg heart disease fell million following cer introduction us generic competition coreg ir september sales decline coreg cr launched march million avodart benign prostatic hyperplasia enlarged prostate continued perform strongly sales million positive data combat study assessing use avodart alpha blocker tamsulosin combination therapy recently published usa europe international journal urology gsk filed coprescription indication usa europe international markets response individual governments determine pricing medicines expected fda second quarter countries within europe result wide price variations antibacterials product parallel trade occurs third parties exploit antibacterial sales declined million reflecting generic price differential purchasing products markets low prices competition regions enforced selling governments purchasers markets higher prices agreed parallel trade oncology emesis permitted single market rules european union gsk tykerb achieved sales million first year million derive benefit profit resale higher price arose usa following launch march sales zofran declined million reflecting generic competition usa europe result management believes within european region international sales declined respectively turnover market invoiced basis presented properly represent consumption products within therapeutic areas market gsk employees based market instrumental sales zantac fell million declines regions promotion groups products within market thereby regional analysis creating product sale final consumption market pharmaceutical turnover geographic region following table gives adjustments made order restate invoiced basis turnover markets within europe turnover created basis turnover reported table represents sales invoiced pharmaceutical turnover europe region gsks local entity customers local market plus co turnover created basis promotion income within market region growth region invoiced adjustment created invoiced adjustment created major markets total cer major markets usa europe france europe uk france italy uk germany italy spain germany europe spain europe adjustments gsks estimates based recent international data independent external sources valued sterling relevant asia pacific exchange rates management believes turnover created japan basis reporting turnover market provides better reflection middle east africa performance businesses market within europe latin america total turnover europe region unaffected canada restatement parallel trade occurs occasionally elsewhere world sufficiently material affect significantly turnover data c er represents growth constant exchange rates represents growth actual exchange rates market presented invoiced basis gsk annual report srotcerid eht fo troper weiver laicnanif business review financial review continued pharmaceutical turnover geographic region europe turnover created basis discussion individual market performance europe region turnover market within europe adjusted effects turnover created basis parallel trade show turnover basis country sales europe contributed pharmaceutical turnover product finally consumed product sold gsk grew billion strong sales seretide region growth vaccines offsetting impact generic competition number major markets total cer products continued price cuts resulting government usa healthcare reforms europe major markets recorded growth exception italy france adversely impacted pricing restrictions generic uk competition major growth drivers seretide gsks largest italy selling product europe growth vaccines germany franchise spain generic competition adversely impacted sales seroxat europe lamictal zofran imigran international sales antibacterials decreased due combination asia pacific weaker flu season generic competition japan sales avandiaavandamet grew middle east africa latin america international canada international region reported year year turnover growth faster growing markets included japan china middle eastafrica modest cer represents growth constant exchange rates represents growth sales growth canada australia latin actual exchange rates turnover quarter given financial record pages america canadian sales performance reflected lower sales avandia generic competition zofran whilst australian usa business adversely impacted government pricing lower sales usa declined billion reflecting generic government orders relenza competition wellbutrin zofran flonase coreg ir good performance japan driven launch year declined respectively decline adoair strong demand relenza partially offset sales avandia products partly offset growth sales declines older products zantac zovirax advair antivirals vaccines lamictal requip across remaining markets international key products sales avandia product group declined following driving growth seretide grew record sales publication article new england journal medicine may million valtrex grew million vaccines suggested may cardiovascular risk associated franchise recorded growth achieved sales avandia following clarification fda october million hiv products grew million new approved label avandia avandia range products declined million advair sales grew million owing increased use declines canada korea partly offset growth australia treatment copd sales antivirals therapeutic area grew million consumer healthcare sales herpes products hiv products within hiv analysis consumer healthcare sales set competition older products combivir epivir following table partly offset growth new products epzicomkivexa growth lexiva valtrex herpes grew million cer driven patients switching suppression therapy sales relenza otc medicines antiviral treatment flu million primarily driven oneoff analgesics government orders stockpiling possible flu pandemic dermatological vaccines grew million reflecting good performance gastrointestinal hepatitis family products pediarix fluarixflulaval respiratory tract launch boostrix smoking control natural wellness support sales lamictal treatment epilepsy bipolar disorder weight management grew million benefiting new indication treat one serious forms epilepsy primary generalised oral care tonicclonic seizures nutritional healthcare sales requip parkinsons disease restless legs syndrome rls grew million following launch rls indication gsk annual report srotcerid eht fo troper weiver laicnanifbusiness review financial review continued otc medicines research development overthecounter medicine sales grew billion rd expenditure declined included charges related new panadol million alli sales million since operational excellence programme million nil launch usa june smoking control products declined benefit arose lower impairment charges windingdown million due strong competition us market breathe previous restructuring activities excluding items rd expenditure right fiberchoice added portfolio acquisition declined last year pharmaceutical rd expenditure represented cns december achieved combined sales million pharmaceutical turnover oral care operating income oral care sales grew billion sales aquafresh operating income includes royalty income equity investment million helped success new aquafresh disposals impairments product disposals fair value white trays sensodyne also grew strongly year adjustments financial instruments operating income million driven successful launch sensodyne pronamel million million increase primarily due higher royalty income million compared nutritional healthcare million favourable fair value movements financial nutritional healthcare product sales grew million instruments million compared million lucozade grew million horlicks grew roche litigation settlement relating carvedilol million ribena sales million partially offset lower asset disposal profits operating profit total results operating profit overall operating profit margin decreased percentage points total results include restructuring costs related new operational operating profit decreased sterling terms million excellence programme commenced october operating profit increased constant exchange rates growth cer margin increased percentage points reflecting flat sga cer expenditure higher operating income partially offset turnover increase cost sales cost sales year gains asset disposals million million selling general costs legal matters million million administration fair value movements financial instruments resulted research income million income million charges development related old restructuring activity million million operating charges related new operational excellence income programme million nil total operating profit impact items million charge operating profit million charge cost sales profit taxation total results cost sales percentage turnover increased percentage points constant exchange rates cost sales percentage net finance costs turnover increased percentage points reflecting charges related new operational excellence programme finance income million nil unfavourable product regional mixes interest finance income compared fair value adjustments hedges selling general administration selling general administration sga costs percentage turnover reduced percentage points constant exchange rates finance costs decrease percentage points reflecting flat expenditure interest costs compared prior year turnover growth sga unwinding discount liabilities costs included charges related new operational excellence fair value adjustments hedges programme million nil advertising promotion increased selling distribution increased general administration expenditure declined finance costs increased owing increased levels debt finance share buyback programme gsk annual report srotcerid eht fo troper weiver laicnanifbusiness review financial review continued share tax profits associates joint ventures selling general administration share profits associates arises principally groups selling general administration sga costs percentage holding quest diagnostics inc turnover reduced percentage points constant exchange rates decrease percentage points reflecting decline profit taxation total results expenditure compared prior year turnover growth taking account net finance costs contribution sga costs due lower selling general associates total profit taxation million compared administration expenditure partly offset higher advertising million increase constant exchange promotion advertising promotion increased accounted rates sterling decline less increase total sga selling distribution declined general administration expenditure declined collectively operational excellence items accounted decline total sga one october gsk announced significant new billion percentage point due lower charges related legal matters operational excellence programme improve effectiveness research development productivity operations rd expenditure decreased partly result lower impairment new programme expected deliver annual pretax savings charges windingdown previous restructuring activities million gsk expects realise majority excluding items rd expenditure flat pharmaceutical rd annual savings within first two years programme expenditure represented pharmaceutical approximately million expected million turnover savings partly mitigate expected impact operating income earnings generic competition lower avandia sales operating income includes royalty income equity investment associated adverse impact gsks gross margin oneoff charges disposals impairments product disposals fair value million tax relating programme recorded adjustments financial instruments operating income q significant acquisitionrelated restructuring million million increase primarily costs incurred due higher royalty income million compared significance new programme columnar million favourable fair value movements financial presentation adopted income statement order instruments million compared million illustrate gsks underlying performance analysis roche litigation settlement relating carvedilol operating profit subsequent discussion excludes restructuring partially offset lower asset disposal profits costs related new operational excellence programme operating profit commenced october management believes exclusion overall operating profit margin increased percentage points items provides useful reflection way operating profit increased sterling terms million business managed accordingly supplemental information operating profit increased constant exchange rates provided addition contained consolidated income margin increased percentage points reflecting declines sga statement prepared accordance ifrs rd expenditure turnover growth higher operating income operating profit business performance year gains asset disposals million growth million costs legal matters million cer million fair value movements financial instruments resulted turnover income million million charges related cost sales old restructuring activity million million selling general operating profit impact items million charge administration million research development profit taxation business performance operating net finance costs income operating profit finance income interest income cost sales fair value adjustments hedges cost sales percentage turnover increased percentage points constant exchange rates cost sales percentage turnover increased percentage points reflecting unfavourable finance costs product regional mix interest costs unwinding discount liabilities fair value adjustments hedges gsk annual report srotcerid eht fo troper weiver laicnanifbusiness review financial review continued share tax profits associates joint ventures gsk uses best advice determining transfer pricing share profits associates arises principally groups methodology seeking manage transfer pricing holding quest diagnostics inc taxation issues satisfactory conclusion basis external professional advice continues believe made profit taxation business performance adequate provision liabilities likely arise open taking account net finance costs contribution assessments ultimate liability matters may vary associates business performance profit taxation amounts provided dependent upon outcome litigation million compared million increase proceedings negotiations relevant tax authorities cer flat sterling terms profit year taxation growth cer total profit taxation uk corporation tax year overseas taxation total profit attributable current taxation shareholders deferred taxation basic earnings per share pence p p basic earnings per ads us charge taxation total profit amounting million business performance profit represents effective tax rate charge taxation year taxation business performance profit amounting business performance profit million represents effective tax rate attributable shareholders group balance sheet st december included tax payable adjusted earnings per share pence p p liability million tax recoverable asset million adjusted earnings per ads us weighted average number groups main open tax issues uk usa canada shares millions japan diluted total earnings per share pence p p gsk continues dispute hm revenue customs diluted total earnings per ads us hmrc primarily respect transfer pricing controlled weighted average number foreign companies cfc matters years date hmrc shares millions yet formalised claims respect matters gsk seeking resolve discussions hmrc continues total results including restructuring costs related new however wide difference group hmrc operational excellence programme produced basic eps p positions may ultimately settled litigation compared p increase cer terms following audit period us internal revenue compared decline sterling terms service irs notices proposed adjustment challenged business performance profit year million increase deductions arising intercompany financing arrangements sterling terms profit attributable minority interests years gsk disagrees vigorously million profit attributable shareholders contest gsk estimates irs claim tax interest st million increase sterling terms interest cost december net federal tax relief years share buyback programme adversely impacts groups profits million gsk believes supported external professional advice benefits eps business performance eps increased reflecting claim merit adjustment warranted higher profits also reduction weighted average number contrary gsks view irs prevailed argument shares resulting groups share buyback programme court gsk would expect additional liability four actual rates exchange earnings per share increased year unaudited period proportionate liability unfavourable currency impact eps six percentage points reflected three year audited period event gsk strengthening sterling us dollar compared able resolve issue irs court decision would four percentage point unfavourable currency impact turnover expected dividend lower courts japan upheld claims tax authorities board declared fourth interim dividend pence per share yen billion million relating japanese cfc legislation gsk resulting dividend year pence five pence increase paid fully provided full tax pursuing claim dividend pence per share equivalent refund japanese supreme court canada court hearing fourth interim dividend receivable adr holders cents respect transfer pricing early completed july per ads based exchange rate exdividend gsk still awaiting courts judgement date th february record date th february payment date th april gsk annual report srotcerid eht fo troper weiver laicnanifbusiness review financial review continued critical accounting policies w historical experience customer returns gsk records accrual estimated sales returns applying historical consolidated financial statements prepared accordance experience customer returns amounts invoiced together ifrs adopted use european union also market related information stock levels wholesalers ifrs issued iasb following accounting policies approved anticipated price increases competitor activity board described note financial statements accounting policies management required make estimates reconciliation gross turnover net turnover us assumptions affect amounts assets liabilities revenue pharmaceuticals business follows expenses reported financial statements actual amounts results could differ estimates critical accounting policies adopted relate following areas gross turnover urnover chargebacks axation managed care gpo l egal disputes rebates medicare mpairment property plant equipment part ntangible assets us government p ensions postemployment benefits state programmes cash discounts information judgements estimates made areas customer returns given note financial statements key accounting prior year adjustments judgements estimates items respect turnover accounting policy groups largest total deductions business us pharmaceuticals us market net turnover complex arrangements rebates discounts allowances following briefly describes nature arrangements chargebacks increased result significant sales existence groups us pharmaceuticals business product us government stockpiles customer rebates fallen compared result products traditionally gsk arrangements certain indirect customers whereby higher rebate percentages becoming subject generic competition customer able buy products wholesalers reduced prices replaced sales newer products lower rebate chargeback represents difference invoice price percentages wholesaler indirect customers contractual discounted price accruals estimating chargebacks calculated based terms total accruals rebates discounts allowances returns agreement historical experience product growth rates us pharmaceuticals business follows customer rebates offered key managed care group st st purchasing organisations gpo direct indirect december december customers arrangements require customer achieve certain performance targets relating value product purchased chargebacks formulary status predetermined market shares relative managed care gpo competitors rebates given medicare part included medicare part rebates category medicare part programme introduced us government state programmes replaced government medicaid subsidies cash discounts individuals subsidised coverage provided private customer returns prescription plans accrual rebates estimated based specific terms agreement historical experience product growth rates total us medicaid programme stateadministered programme monthly process operated monitor inventory levels providing assistance certain poor vulnerable patients wholesalers abnormal movements process uses gross medicaid drug rebate program established sales volumes prescription volumes based third party data sources reduce state federal expenditure prescription drugs gsk information received key wholesalers aim participates providing rebates states accruals medicaid maintain inventories consistent level year year based rebates calculated based specific terms individual pattern consumption basis us pharmaceutical state agreements using combination historical experience inventory levels wholesalers distribution channels product population growth anticipated price increases st december estimated amount approximately impact contracting strategies one month turnover calculation uses third party information accuracy totally verified believed cash discounts offered customers encourage prompt sufficiently reliable purpose payment accrued time invoicing adjusted subsequently reflect actual experience gsk annual report srotcerid eht fo troper weiver laicnanifbusiness review financial position resources financial position property plant equipment gsks business sciencebased technologyintensive highly regulated governmental authorities group allocates significant financial resources renewal maintenance assets property plant equipment minimise risks interruption noncurrent assets production achieve compliance regulatory standards property plant equipment number processes use chemicals hazardous materials goodwill total cost groups property plant equipment st intangible assets december million net book value investments associates joint ventures million land buildings represented million plant investments equipment million assets construction deferred tax assets million gsk invested million new renewal derivative financial instruments property plant equipment mainly related large noncurrent assets number projects renewal improvement expansion total noncurrent assets facilities various worldwide sites property mainly held freehold new investment financed group liquid resources st current assets december gsk capital contractual commitments future inventories expenditure million operating lease commitments current tax recoverable million gsk believes facilities adequate trade receivables current needs derivative financial instruments liquid investments group observes stringent procedures uses specialist skills cash cash equivalents manage environmental risks activities environmental assets held sale issues sometimes dating operations modified discontinued reported responsibility environment total current assets health safety note financial total assets statements legal proceedings liabilities goodwill current liabilities goodwill increased year million st shortterm borrowings december million increase reflects goodwill trade payables arising acquisition reliant pharmaceuticals million domantis million well strengthening derivative financial instruments overseas currencies translation existing foreign currency current tax payable goodwill balances shortterm provisions intangible assets total current liabilities intangible assets include cost intangibles acquired noncurrent liabilities third parties computer software net book value longterm borrowings intangible assets st december million deferred tax provision million increase reflects additions pensions post million currency movements partly offset employment benefits amortisation impairment existing intangibles largest provisions element additions million relating acquisition derivative financial instruments reliant pharmaceuticals inc added range speciality noncurrent liabilities medicines combating heart disease gsk portfolio including us marketing rights lovaza total noncurrent liabilities investments total liabilities gsk held investments including associates joint ventures net assets carrying value st december million million market value st december equity million million largest investments share capital associate quest diagnostics inc book value share premium account st december million million retained earnings investments include equity stakes companies group reserves research collaborations provide access biotechnology shareholders equity developments potential interest interests companies arise business divestments minority interests total equity gsk annual report srotcerid eht fo troper secruoser dna noitisop laicnanifbusiness review derivative financial instruments assets total equity gsk held noncurrent current derivative financial summary movements equity set instruments held fair value million million increase primarily reflects fluctuations far forward valuations foreign exchange contracts hedging intercompany loans total equity beginning year deposits exchange movements largely due changes euro total recognised income expense us dollar yen market rates year trade receivables dividends shareholders trade receivables million increased ordinary shares issued reflecting impact strengthing overseas currencies ordinary shares purchased held translation foreign currency receivables partly offset lower vat treasury shares recoverables ordinary shares purchased cancelled derivative financial instruments liabilities consideration received shares transferred gsk held noncurrent current derivative financial esop trusts instruments held fair value million million ordinary shares acquired esop trusts relating primarily hedging exchange translation currency sharebased incentive plans assets consolidation increase reflects impact tax sharebased incentive plans euro us dollar yen currency fluctuations changes minority interest shareholdings minority interests trade payables trade payables amounting million total equity end year marginally increased impact strengthening overseas currencies translation foreign currency payables st december total equity increased partly offset decrease customer return rebate accruals million st december million increase arises principally retained earnings actuarial gains defined provisions benefit pension plans year partially offset purchases group carried deferred tax provisions shortterm treasury shares noncurrent provisions million st december million respect estimated future liabilities share purchases million related legal disputes employee share ownership plan esop trusts acquired provision made legal disputes indemnified million shares gsk plc nil shares held disposal liabilities costs restructuring programmes trusts satisfy future exercises options awards extent balance sheet date actual constructive group share option award schemes proportion shares obligation existed could reasonably estimated held trusts respect awards rules scheme require gsk satisfy exercises market purchases pensions postemployment benefits rather issue new shares shares held trusts group accounts pension postemployment matched options awards granted arrangements accordance ias net deficits allowing deferred taxation million st december esop trusts held million gsk million pension arrangements million shares future exercise share options share awards million unfunded postemployment liabilities pension carrying value million deducted liabilities decreased following improvements asset values reserves market value shares million special funding contributions uk pension funds gsk repurchased million shares held million million uk us pension schemes treasury shares purchased million cancellation strengthening longterm interest rates including increase july gsk announced increased buyback programme rate used discount uk pension liabilities billion representing billion increase compared benefits partly offset improvement mortality continuation existing programme new programme rates higher inflation assumption uk expected completed two year period including billion net debt exact amount timing future purchases extent repurchased shares held treasury shares rather cancelled determined company cash cash equivalents dependent market conditions factors st december liquid investments gsk held million shares treasury shares cost borrowings repayable within one year million deducted retained earnings borrowings repayable one year million shares purchased period st january net debt nd february cost million purchases made publicly announced buyback programme net debt increased million primarily due higher share repurchases acquisition businesses partly offset increased cash inflows operating activities gsk annual report srotcerid eht fo troper secruoser dna noitisop laicnanif financial position resources continuedbusiness review financial position resources continued commitments contingent liabilities gsk formalised agreement trustees uk financial commitments summarised note financial pension schemes make additional contributions statements commitments contingent liabilities million per year addition normal contributions four obligations respect short longterm debt set note year period ending st december order eliminate financial statements contingent liabilities note pension deficits ias basis point table financial statements net debt opposite shows commitment excludes normal ongoing annual funding requirement approximately million gsk amounts provided pensions postretirement benefits also committed eliminate future deficits may arise set note financial statements pensions rolling fiveyear period commitments postemployment benefits amounts provided restructuring made past st december information pension programmes legal environmental disputes set obligations see note financial statements pensions note financial statements provisions postemployment benefits contractual obligations commitments contingent liabilities following table sets groups contractual obligations following table sets contingent liabilities comprising commitments st december fall due payment discounted bills performance guarantees letters credit total yr yrs yrs yrs items arising normal course business expected expire loans total yr yrs yrs yrs interest loans finance lease obligations guarantees finance lease charges contingent liabilities operating lease commitments total intangible assets property plant equipment normal course business gsk provided various indemnification guarantees respect business disposals investments legal disputes subsequently arisen provision made purchase commitments reasonable estimate made likely outcome pensions dispute included note financial statements commitments provisions total groups policy provide settlement costs asserted commitments respect loans future interest payable loans claims environmental disputes reasonable estimate disclosed taking account effect derivatives may made prior point liability recorded legal environmental costs discussed risk factors pages group entered number research collaborations note financial statements legal proceedings develop new compounds pharmaceutical companies terms arrangements include upfront fees equity gsk uses best advice determining transfer pricing investments loans commitments fund specified levels methodology basis external professional advice research addition group often agree make continues believe made adequate provision payments future milestones achieved liabilities likely arise open taxation assessments ultimate agreements relate compounds early stages development liability matters may vary significantly amounts provided milestone payments continue number years dependent upon outcome litigation proceedings compounds move successfully development process negotiations relevant tax authorities discussed generally closer product marketing approval greater note financial statements taxation possibility success payments shown within intangible assets represent maximum would paid milestones achieved number new commitments made licensing agreements including arrangements anacor pharmaceuticals inc oncomed pharmaceuticals inc santaris pharma targacept inc gsk annual report srotcerid eht fo troper secruoser dna noitisop laicnanifbusiness review financial position resources continued cash flow free cash flow million increase summary consolidated cash flow statement set principally reflecting impact us tax settlement partly offset higher levels capital expenditure free cash flow amount cash generated business meeting obligations interest tax dividends paid minority interests capital expenditure noncurrent tangible net cash inflow operating activities intangible assets net cash outflow investing activities net cash outflow financing activities free cash flow used gsks management planning reporting purposes discussions presentations increasedecrease cash bank overdrafts investment analysts rating agencies gsks free cash flow exchange adjustments measure defined ifrs measure may directly comparable similarly described measures used cash bank overdrafts beginning year companies reconciliation net cash inflow operating cash bank overdrafts end year activities closest equivalent ifrs measure free cash flow shown cash bank overdrafts end year comprise reconciliation free cash flow cash cash equivalents overdrafts net cash inflow operating activities purchase noncurrent tangible assets net cash inflow operating activities taxation paid purchase noncurrent intangible assets million increase million arising mainly gross taxation payment billion billion disposal noncurrent tangible fixed assets us transfer pricing dispute settlement made interest paid see note financial statements taxation interest received dividends received joint ventures net cash outflow investing activities million associated undertaking increase million reflected increased capital dividends paid minority interests expenditure purchase businesses including reliant pharmaceuticals million domantis million free cash flow net cash acquired cash returned shareholders movements net debt net debt beginning year increasedecrease cash bank overdrafts cash outflow liquid investments net increase longterm loans net increase inrepayment shortterm loans exchange movements net debt end year gsk annual report srotcerid eht fo troper secruoser dna noitisop laicnanif dividends buybacksbusiness review financial position resources continued investment appraisal treasury management group tmg chaired groups gsk formal process assessing potential investment proposals chief financial officer meets monthly basis review treasury order ensure decisions aligned groups overall activities members receive management information relating strategy process includes analysis impact project treasury activities corporate executive team cet also review earnings return invested capital assessment monthly finance report focuses operational finance issues return based discounted cash flows discount rate used groups internal auditors review treasury internal control perform financial analysis decided internally allow determination environment regularly extent investments cover groups cost capital capital management specific investments discount rate may adjusted take gsk operates globally primarily subsidiary companies account country risk weightings established markets group trades significant capital expenditure financial investment levels patent protection groups products compete largely cash payments tangible intangible fixed assets amounted product efficacy rather price selling margins sufficient million million disposals realised million cover normal operating costs groups operating subsidiaries million cash payments acquire equity investments generally cash generative million million made year sales operating cash flow used fund investment research equity investments realised million million development new products well make routine future cash flow outflows capital expenditure tax dividends repayment group expects future operating cash flow sufficient maturing debt july gsk announced increased share buy fund operating debt service costs satisfy normal levels back programme billion period july capital expenditure meet obligations existing licensing result substantially increased borrowings agreements meet routine outflows including tax groups policy borrow centrally using variety capital dividends subject risk factors discussed pages market issues borrowing facilities meet anticipated gsk may time time additional demands finance funding requirements acquisitions access sources liquidity short longterm capital markets banks borrowings together cash generated operations financial institutions addition cash flow operations onlent contributed equity certain subsidiaries used needs fund groups billion share buyback programme due complete july payment policies liquidity group companies responsible monitoring managing group manages net borrowing requirements working capital terms sales collections supplier payments portfolio longterm borrowings including bonds together reflect local commercial practice shortterm finance us billion commercial paper programme st december group also billion uk company uk subsidiaries committed undrawn bank facilities policies ensure suppliers paid time particular uk companies seek group european medium term note programme settle terms payment suppliers agreeing terms billion billion issue st december transaction us shelf registration billion st december billion billion issue tmg monitors cashflow ensure suppliers made aware agreed terms forecast gsk monthly basis payment abide terms payment groups longterm borrowings mature dates th february gsks longterm standard policy includes arrangements accelerated payment poors debt rating revised aa negative outlook small suppliers stable time standard poors also revised gsks short payment performance term rating paper issued groups commercial paper st december average number days purchases programme moodys investors services rate gsk represented trade fixed asset creditors parent company negative outlook longterm debt p short nil nil respect company uk term debt change gsks rating moodys subsidiaries aggregate days days since th july light likely increased commercial paper issuance resulting treasury policies increased share buyback programme gsk increased glaxosmithkline plc reports sterling pays dividends committed bank facilities million billion addition sterling profits role corporate treasury gsk manage group maintains substantial cash liquid investments monitor groups external internal funding requirements amounted billion st december financial risks support group corporate objectives treasury activities governed policies procedures approved board directors recently th october gsk annual report srotcerid eht fo troper secruoser dna noitisop laicnanifbusiness review financial position resources continued financial assets liabilities analysis net debt given note financial statements net debt analysis financial assets liabilities carrying value fair value given note financial statements financial instruments related disclosures group continues benefit strong positive cash flow operating activities group net debt would decreased significantly year st december groups purchase shares market billion acquisitions approximately billion financial assets liabilities st december representative treasury policies strategies gsk applied since july time gsk announced changed financial strategy involving increased share buyback programme billion result substantially increased borrowings july onwards gsk tightened criteria holding cash equivalents liquid investments response credit crisis gsk suffered loss principal result crisis gsk annual report srotcerid eht fo troper secruoser dna noitisop laicnanif treasury operations objective treasury activity manage posttax net cost income financial operations benefit group earnings corporate treasury operate profit centre gsk uses variety financial instruments including derivatives finance operations manage market risks operations derivatives principally comprising forward foreign currency contracts interest rate currency swaps used swap borrowings liquid assets currencies required group purposes manage exposure funding risks changes foreign exchange rate interest rates gsk hold issue derivative financial instruments speculative purposes groups treasury policies specifically prohibit activity transactions financial instruments undertaken manage risks arising underlying business activities speculation foreign exchange management foreign currency transaction exposure arising normal trade flows respect external intragroup trade hedged exposure overseas operating subsidiaries transaction risk minimised matching local currency income local currency costs purpose intragroup trading transactions matched centrally intragroup payment terms managed reduce risk exceptionally foreign currency cash flows hedged selectively management corporate treasury group manages centrally shortterm cash surpluses borrowing requirements subsidiary companies uses forward contracts hedge future repayments back originating currency group seeks denominate borrowings currencies principal assets cash flows primarily denominated us dollars euros sterling certain borrowings swapped currencies required group purposes borrowings denominated swapped foreign currencies match investments overseas group assets treated hedge relevant assets ratio borrowings assets reviewed currency monthbymonth basis tmg interest rate risk management gsks policy interest rate risk management requires minimum amount net borrowings fixed rates increase ratio forecast interest payable trading profit fixed floating ratio reviewed monthly tmg group uses limited number interest rate swaps redenominate external borrowings interest rate coupon required group purposes duration swaps matches duration principal instruments interest rate derivative instruments accounted fair value cash flow hedges relevant assets liabilitiesbusiness review outlook risk factors outlook new product candidates may appear promising development significant investment fail reach market sales growth existing products launches new products limited commercial success example could key drivers gsks business sales growth key products result efficacy safety concerns inability obtain necessary seretideadvair vaccines valtrex high potential regulatory approvals difficulty excessive costs manufacture products avodart arixtra boniva expected continue erosion patent term result lengthy development period sales growth also expected newer products lovaza infringement patents intellectual property rights others cervarix tykerbtyverb rotarix veramystavamys altabax inability differentiate product adequately altargo sales growth avandia gsks product diabetes competes adversely impacted following publication may metaanalysis health authorities us fda european medicines agency japan pharmaceuticals medicines device agency typically sales existing products decline dramatically generic increased focus safety assessing benefitrisk competition introduced either patent expiry earlier balance drugs light increased scrutiny factors successful challenge groups patent generic reduction number new drugs gaining competitors coreg ir entered us market several regulatory approvals recent years example fda approved products become exposed generic competition usa new drugs lowest singleyear total since including wellbutrin xl mg requip ir lamictal ir paxil cr imitrex gsk engaged legal proceedings regarding risk unplanned loss patents validity infringement groups patents relating many patent infringement litigation products discussed risk factors groups patents common patents challenged note financial statements legal proceedings time efforts generic manufacturers may involve challenges validity enforceability patent assertions gsk expects sustained flow new products next two generic product infringe groups patents years thirteen new product opportunities currently filed group successful defending attack patents regulators include promacta usa rotarix usa treximet maintaining exclusive rights market one major usa synflorix eu international gsk currently key products particularly usa group highest assets phase iii developmentregistration turnover margins groups turnover margins would published earnings guidance gsk expects adversely affected see note financial statements legal impact lower avandia sales together increase generic proceedings discussion patentrelated proceedings competition lead midsingle digit percentage decline group involved description resolution business performance eps constant exchange rates prior proceedings affect dates generic versions groups products may introduced risks uncertainties inherent business may affect future performance including rd projects anticipated sales generic drug manufacturers seeking market generic versions growth expected earnings growth discussed risk many groups important products prior factors expiration groups patents exhibited readiness products future us launch generic risk factors products competing coreg ir zofran flonase wellbutrin xl significant impact groups overall turnover risks uncertainties relevant groups business earnings financial conditions results operations factors listed among group thinks could cause groups potential changes intellectual property laws actual results differ materially expected historical results regulations could risks uncertainties currently known proposals change existing patent data exclusivity laws group group currently deems immaterial regulations major markets group sells products continuing feature political process countries risk rd deliver commercially successful including proposals could effect making prosecution new products patents new products difficult timeconsuming continued development commercially viable new products well adversely affecting exclusivity period groups products development additional uses existing products critical including biological products proposals enacted groups ability replace sales older products decline could adverse impact groups future sales results upon expiration exclusive rights increase overall sales operations developing new products costly lengthy uncertain process new product candidate fail stage process one latestage product candidates could fail receive regulatory approval gsk annual report srotcerid eht fo troper srotcaf ksir dna kooltuobusiness review outlook risk factors continued weakness intellectual property protection instances third parties may perform analyses published certain countries clinical trial results although necessarily accurate countries group operates patent meaningful may raise questions regarding safety pharmaceutical protection may significantly weaker usa products may publicised media may result european union addition effort control public health product liability claims group currently defendant crises developing countries south africa brazil number product liability lawsuits including class actions considered plans substantial reductions scope involve substantial claims damages related groups patent protection pharmaceutical products particular pharmaceutical products litigation particularly usa countries could facilitate competition within markets inherently unpredictable excessive verdicts justified generic manufacturers would otherwise unable introduce evidence occur class actions sweep together competing products number years persons prescribed groups products inflate potential liability force numbers claims pain loss patent protection including abrogation patent rights suffering punitive damages frequently asserted product compulsory licensing likely affect adversely groups liability actions allowed represent potentially open operating results national markets expected ended exposure material group overall absence adequate patent protection could limit opportunity look markets antitrust litigation future sales growth usa become increasingly common following publicity around government investigations adverse outcome risk substantial adverse outcome litigation prosecution patent infringement actions defendants government investigations direct indirect purchasers payers initiate antitrust see note financial statements legal proceedings actions well claims direct indirect purchasers discussion proceedings governmental investigations involving payers typically filed class actions relief sought may matters proven could give rise civil andor criminal liabilities include treble damages restitution claims damages adverse group currently involved unfavourable resolution antitrust verdicts subject automatic trebling usa similar future proceedings investigations may similarly antitrust claims may brought following settlement material adverse effect groups financial condition patent litigation alleging settlements anticompetitive results operations group made material provisions violation antitrust laws related legal proceedings investigations reduced earnings group may also make additional sales marketing regulation significant provisions related legal proceedings investigations group operates globally complex legal regulatory future would reduce earnings many cases environments often vary among jurisdictions failure practice plaintiff bar claim damages amounts bear comply applicable laws rules regulations relationship underlying harm accordingly potentially jurisdictions may result civil criminal legal proceedings misleading quantify potential exposure claims proceedings rules regulations change governmental interpretation investigations type described note financial rules regulations evolve prior conduct may called statements legal proceedings question usa example group responding federal state governmental investigations pricing recent insurance loss experience including pharmaceutical product marketing reimbursement prescription drug products liability exposures increased cost narrowed investigations could result related restitution civil false coverage afforded insurance pharmaceutical companies claims act litigation behalf federal state governments generally including group well related proceedings initiated group order contain insurance costs recent years group behalf consumers private payers proceedings may continued adjust coverage profile accepting greater degree result trebling damages awarded fines respect uninsured exposure addition claims made violation law criminal proceedings may also initiated insurance policies insurers may reserve right deny coverage group companies individuals various grounds denial coverage ultimately upheld risks competition price controls limitations sales claims could result material additional charges third party competition groups earnings group operates highly competitive businesses product liability litigation pharmaceuticals business faces competition proprietary preclinical clinical trials conducted development products large international manufacturers producers potential products determine safety efficacy generic pharmaceuticals significant product innovations technical products use humans following approval regulatory advances intensification price competition competitors bodies notwithstanding efforts drugs vaccines could adversely affect groups operating results group introduced marketplace unanticipated side effects may predict timing impact competitive products become evident potential impact sales groups products continued consolidation pharmaceutical industry could adversely affect groups competitive position continued consolidation among groups customers may increase pricing pressures gsk annual report srotcerid eht fo troper srotcaf ksir dna kooltuobusiness review outlook risk factors continued group eight products million annual global regulatory controls sales among products augmentin ir respect group must comply broad range regulatory controls group generic competition avandia imitrex testing approval manufacturing marketing many lamictal valtrex respect groups intellectual pharmaceutical consumer healthcare products particularly property rights usa currently subject litigation usa countries european union affect settlement agreements related litigation group cost product development also time required generic competition usa coreg ir another significant reach market uncertainty successfully health product since september authorities increased focus safety assessing benefit riskbalance drugs context initial product groups major products become approval also context approval additional indications subject problem unplanned loss patent protection review information regarding marketed products stricter unexpected side effects regulatory proceedings publicity affecting regulatory controls also heighten risk changes product doctor patient confidence pressure competitive products profile withdrawal regulators basis postapproval new effective treatment introduced concerns product safety could reduce revenues adverse impact groups revenues operating results could result product recalls product liability lawsuits also significant particular group faces intense competition greater regulatory scrutiny especially usa advertising manufacturers generic pharmaceutical products major promotion particular directtoconsumer advertising markets generic products often enter market upon expiration patents data exclusivity periods groups products addition cases group may voluntarily cease marketing introduction generic products typically leads dramatic loss product face declining sales based concerns efficacy sales reduces groups revenues margins proprietary safety example declines sales avandia following products expiration dates patents groups major publicity around questions regarding risks associated products description litigation settlements may affect product whether scientifically justified even absence dates generic versions groups products may regulatory action development postapproval adverse introduced set legal proceedings involving event profile product product class may major patent challenges set note financial statements impact marketing sale product legal proceedings risk interruption product supply governmental payer controls manufacture pharmaceutical products constituent pharmaceutical products subject price controls pressures materials requires compliance good manufacturing practice restrictions many markets including japan germany regulations groups manufacturing sites subject review spain france italy governments intervene directly approval fda regulatory agencies compliance setting prices addition markets major purchasers failure suppliers key services materials groups pharmaceutical products whether governmental agencies private manufacturing facilities could lead product recalls seizures health care providers economic power exert substantial interruption production delays approvals new products pressure prices terms access formularies pending resolution manufacturing issues noncompliance also result fines disgorgement profits interruption group predict whether existing controls pressures supply fines disgorgement remedy could materially adversely restrictions increase new controls pressures restrictions affect groups financial results example resolution introduced reduce groups margins affect fda observations deficiencies manufacturing practices adversely ability introduce new products profitably groups cidra puerto rico facility referred note example usa group highest margins financial statements legal proceedings supplies certain products sales country pricing pressures could significantly manufactured site curtailed constricted increase experience develops outpatient pharmaceutical adverse impact sales programme covering medicare beneficiaries began although group undertakes business continuity planning single private insurers coverage offered sourcing certain components bulk active materials finished enormous purchasing power programme could demand products creates risk failure supply event regulatory discounts may implicitly create price controls prescription noncompliance physical disruption manufacturing sites drugs changes enabling legislation could afford us government direct role negotiating prices medicare risk concentration sales wholesalers programme additionally number states proposed usa line pharmaceutical companies group implemented various schemes control prices senior sells products small number wholesalers addition citizens programmes including importation countries hospitals pharmacies physicians groups sales bulk purchases drugs growth number patients three largest wholesalers amounted approximately covered large managed care institutions usa groups us pharmaceutical sales st december group increased implementation medicare benefit also trade receivables due three wholesalers totalling increases pricing pressures groups products trends million st december million group exposed may adversely affect groups revenues margins sales concentration credit risk respect wholesalers usa one affected financial difficulty could materially adversely affect groups financial results gsk annual report srotcerid eht fo troper srotcaf ksir dna kooltuobusiness review outlook risk factors continued reliance information technology accounting standards group increasingly dependent information technology new revised accounting standards rules interpretations systems including internetbased systems internal communication promulgated time time international standard setting well communication customers suppliers board could result changes recognition income significant disruption systems whether due computer expense may adversely impact groups reported financial viruses outside incursions could materially adversely results international standard changes market valuation affect groups operations certain financial instruments equity collar linked groups investment quest diagnostics impairments taxation equity investments reflected groups reported results effective tax rate groups earnings benefits fact gains losses actually realised could portion earnings taxed favourable rates significant impact income statement given period also jurisdictions outside uk changes tax laws accounting deferred taxation intercompany inventory may application respect matters transfer pricing foreign give rise volatility depending upon ownership inventory dividends controlled companies restriction tax relief allowed balance sheet date interest intragroup debt could increase groups effective tax rate adversely affect financial results group regulators regularly review financial statements listed open issues revenue authorities uk usa companies like gsk compliance accounting regulatory japan canada matters discussed note requirements financial statements taxation group believes complies appropriate regulatory disruption pandemic influenza requirements concerning financial statements disclosures event pandemic influenza group could subject however companies experienced investigations disruption range factors national governments may potential noncompliance accounting disclosure willing abrogate intellectual property rights medicines requirements resulted restatements previously might otherwise short supply country afflicted reported results sometimes significant penalties pandemic flu would risk employees families human resources affected consequence sales distribution group approximately employees around manufacturing activities could shut supply continuity world subject laws regulations concerning active ingredients finished goods affected employees ranging discrimination harassment environmental liabilities personal privacy labour relations vary significantly environmental laws various jurisdictions impose actual jurisdiction jurisdiction group faces intense competition potential obligations group remediate contaminated sites qualified individuals pharmaceutical biotechnology group also identified potentially responsible party companies universities governmental entities us comprehensive environmental response compensation research institutions failure continue recruit retain liability act number sites remediation costs relating right people maintain culture compliance could groups use ownership sites failure manage properly significant adverse effect group environmental risks could result additional remedial costs could materially adversely affect groups operations see note financial statements legal proceedings discussion environmentalrelated proceedings group involved global political economic conditions group conducts substantial portion operations outside uk groups management foreign exchange rates discussed business review foreign exchange management see fluctuations exchange rates sterling currencies especially us dollar euro japanese yen could materially affect groups financial results group control changes inflation interest rates foreign currency exchange rates controls economic factors affecting businesses possibility political unrest legal regulatory changes nationalisation jurisdictions group operates factors could materially affect groups future results operations gsk annual report srotcerid eht fo troper srotcaf ksir dna kooltuobusiness review financial review accordance us sec disclosure requirements pharmaceutical turnover following discussion compares results year st december growth rates included review turnover constant results year st december exchange rates cer unless otherwise stated sterling growth growth rates constant exchange rates cer unless rates may found tables pharmaceutical turnover total otherwise stated sterling growth rates may found pharmaceutical turnover million compared tables pharmaceutical turnover therapeutic area million increase cer sterling terms total pharmaceutical turnover increased less cer exchange due principally strength sterling major international currencies currencies influence groups results us dollar euro japanese yen pharmaceutical turnover therapeutic area us dollar fell pound gsks ability deliver continued pharmaceutical turnover yearend yearend rates euro weakened growth primarily due exceptionally broad product portfolio japanese yen sterling highvalue growth products coupled sales marketing excellence growth products include seretideadvair world market pharmaceuticals avandia product group vaccines lamictal valtrex coreg requip global pharmaceutical sales increased avodart boniva billion respiratory world market value growth gsk continued global leader respiratory pharmaceuticals geographic region bn total sales three key products seretideadvair flixotideflovent serevent amounting billion total sales usa seretideadvair asthma copd rose billion europe usa sales grew billion europe sales grew france billion international markets sales grew germany million market share value antiasthma copd uk therapy class europe usa increase italy percentage points europe flat market share growth japan usa reflecting lower prescription volumes due label change asia pacific early restricted gsks ability promote product offset latin america favourable pricing changes middle east africa canada cns cns sales increased billion sales increased usa total international declined europe due generic competition total seroxatpaxil sales grew million due strong growth us market increased representing growth paxil cr usa paxil ir japan partly offset global prescription pharmaceutical market compared generic competition paxil ir europe decade earlier total wellbutrin sales grew million sales th september gsk held second position world wellbutrin xl oncedaily product grew million pharmaceutical market market share behind pfizer december generic competition wellbutrin xl market share gsk six worlds top mg tablet approximately wellbutrin sales entered pharmaceutical products avandia lamictal seretide us market advair valtrex wellbutrin zofran sales lamictal treatment epilepsy bipolar disorder world market value growth grew billion benefiting new indication top five therapeutic classes bn total cer treat one serious forms epilepsy primary generalised cardiovascular tonicclonic seizures lamictal also medicine long central nervous system term clinical data demonstrates delay onset alimentary tract metabolic depressive episodes bipolar disorder antiinfectives bacterial sales requip parkinsons disease restless legs syndrome viral fungal excluding rls grew million vaccines respiratory note data based months th september gsk annual report srotcerid eht fo troper weiver laicnanifbusiness review financial review continued pharmaceutical turnover therapeutic area total usa europe international therapeutic area growth growth growth growth major products total cer cer cer cer respiratory seretideadvair flixotideflovent serevent flixonaseflonase central nervous system seroxatpaxil paxil ir paxil cr wellbutrin wellbutrin ir sr wellbutrin xl imigranimitrex lamictal requip antivirals hiv combivir trizivir epivir ziagen agenerase lexiva epzicomkivexa herpes valtrex zovirax zeffix relenza metabolic avandia avandamet avandaryl bonvivaboniva vaccines hepatitis infanrix pediarix boostrix cardiovascular urogenital coreg levitra avodart arixtra fraxiparine antibacterials augmentin zinnatceftin oncology emesis zofran hycamtin zantac cer represents growth constant exchange rates represents growth actual exchange rates gsk annual report srotcerid eht fo troper weiver laicnanifbusiness review financial review continued antivirals oncology emesis total sales hiv products billion competition sales zofran grew million driven us market older products combivir million epivir million europe international sales declined million mostly offset strong sales respectively due generic competition generic growth new products epzicomkivexa doubled competitor zofran entered us market november million lexivaagenerase million cardiovascular urogenital sales valtrex rose million us sales sales coreg heart disease grew million avodart million driven patients switching suppression therapy benign prostatic hyperplasia enlarged prostate strong year sales increasing million metabolic gsk launched avandia treatment type diabetes antibacterials combination product avandamet blood sugar control antibacterial sales declined reflecting generic competition product group expanded february weaker flu season launch usa fixeddose combination treatment therapeutic areas avandaryl combines avandia sulfonylurea sales zantac fell million declines europe sales avandia product group grew international partially offset growth usa billion usa europe sales grew million driven consumer healthcare sales increasing use avandamet sales international markets analysis consumer healthcare sales set rose million avandia product group achieved following table market share value oral antidiabetics growth usa europe percentage points respectively cer usa avandamet prescription volume growth adversely otc medicines impacted product supply issues year analgesics resolved dermatological december gsk presented data landmark adopt study gastrointestinal demonstrated avandia effective metformin respiratory tract sulphonylurea longterm blood sugar control type smoking control diabetes data addition recently presented natural wellness support dream study showed avandia reduce risk progression type diabetes data studies oral care expected filed regulatory agencies first half nutritional healthcare gsk recorded turnover million share copromotion income consumer healthcare sales grew billion sales bonivabonviva new oncemonthly oral bisphosphonate international europe performing well total treatment postmenopausal osteoporosis developed sales usa flat improved performance roche launched fourth quarter sales vaccines otc medicines overall vaccine sales increased billion good overthecounter medicine sales grew billion performances regions us sales rose million panadol smoking control performing well european sales grew million sales international million key contributors infanrix oral care pediarix gsks combination vaccines children sales oral care sales grew million sensodyne grew strongly million sales hepatitis vaccines grew year million sales aquafresh million benefiting strong us performance havrix million following approval last year broader paediatric use nutritional healthcare sales new vaccines also helped drive overall sales growth total nutritional healthcare products sales grew million sales rotarix rotavirus boostrix prevention diphtheria lucozade grew million horlicks grew tetanus whooping cough influenza vaccines fluarix million ribena sales million flulaval reached million first full year sales flulaval following acquisition id biomedical late gsk annual report srotcerid eht fo troper weiver laicnanifbusiness review financial review continued operating profit operating profit overall operating profit margin increased percentage points analysis operating profit subsequent discussion operating profit increased sterling terms million compares results results operating profit increased constant exchange rates growth margin increased percentage points reflecting sga growth cer rate turnover growth partially offset higher costs turnover related programmes deliver future cost savings lower operating income cost sales selling general gains asset disposals million million administration costs legal matters million million research fair value movements quest collar theravance options development resulted income million million charges operating relating costsaving programmes million income million total operating profit impact items million charge compared million charge operating profit cost sales profit taxation cost sales declined percentage turnover percentage points constant exchange rates decline percentage discussion compares results points reflecting favourable price regional mix impact results selling general administration net finance costs selling general administration sga costs percentage turnover reduced percentage points constant exchange rates finance income decrease percentage points reflecting flat expenditure interest finance income compared prior year turnover growth sga fair value adjustments hedges costs flat due higher advertising promotion selling expenditure offset lower general administration expenditure advertising promotion selling increased accounted increase total sga general administration expenditure finance costs declined accounted decline total sga interest costs one percentage point due lower charges related unwinding discount liabilities legal matters one percentage point due lower costs fair value adjustments hedges related programmes deliver future cost savings research development rd expenditure increased partly result higher charges finance income increased compared predominantly due related restructuring programmes excluding restructuring costs increased income extended credit receivables increased rd grew broadly inline turnover pharmaceuticals rd interest income due higher us dollar interest rates finance costs expenditure excluding restructuring costs represented reduced due refinancing two expensive bonds december pharmaceutical turnover january well lower swap costs resulting reduced interest rate differentials operating income operating income includes royalty income equity investment share tax profits associates joint ventures disposals impairments product disposals fair value share profits associates arises principally groups adjustments quest collar theravance options holding quest diagnostics inc operating income million compared million decrease primarily due lower product asset disposal profits partially offset favourable fair value movement quest collar theravance options gsk annual report srotcerid eht fo troper weiver laicnanifbusiness review financial review continued taxation profit year million increase sterling terms profit attributable minority interests million profit attributable shareholders million uk corporation tax increase sterling terms interest cost overseas taxation share buyback adversely impacted groups earnings benefits earnings per share eps eps increased reflecting higher current taxation profits also reduction weighted average number deferred taxation shares resulting groups share buyback programme total actual rates exchange earnings per share increased unfavourable currency impact eps three percentage points charge taxation profit amounting million reflected strengthening sterling major currencies represented effective tax rate compared two percentage point unfavourable currency group balance sheet st december included tax payable impact turnover liability million tax recoverable asset million integrated nature groups worldwide operations involving significant investment research strategic manufacture limited number locations consequential crossborder supply routes numerous endmarkets gives rise complexity delay negotiations revenue authorities profits individual group companies liable tax disagreements revenue authorities intragroup transactions particular price goods transferred group companies different tax jurisdictions produce conflicting claims revenue authorities profits taxed individual territories resolution issues continuing fact life gsk group significant open issues revenue authorities usa uk japan canada th september gsk us internal revenue service agreed resolution dispute profit year growth cer profit taxation year profit attributable shareholders earnings per share pence p p earnings per ads us weighted average number shares millions diluted earnings per share pence p p diluted earnings per ads us weighted average number shares millions gsk annual report srotcerid eht fo troper weiver laicnanifcorporate governance corporate governance section discusses glaxosmithklines management structures governance procedures contains companys reporting disclosures corporate governance required combined code corporate governance financial reporting council combined code including required statement compliance section also contains companys reports compliance us laws regulations apply board corporate executive team governance policy dialogue shareholders share capital control donations political organisations eu political expenditure annual general meeting internal control framework committee reports combined code us law regulation gsk annual report srotcerid eht fo troper ecnanrevog etaroproccorporate governance continued board sir deryck maughan aged appointed st june nonexecutive director sir deryck sir christopher gent aged managing director kohlberg kravis roberts co appointed st june chairman sir christopher formerly chairman ceo citigroup international chief executive officer vodafone group plc retirement salomon brothers inc nonexecutive director reuters july nonexecutive director lehman brothers group plc blackrock inc holdings inc nonexecutive director ferrari spa member kpmgs chairmans advisory group senior adviser bain co dr daniel podolsky aged member advisory board reform appointed st july nonexecutive director dr podolsky mallinckrodt professor medicine chief gastroenterology dr jeanpierre garnier aged massachusetts general hospital harvard medical school appointed rd may retiring st may chief well chief academic officer partners healthcare system executive officer dr garnier appointed executive director also chairman board scientific cofounder smithkline beecham plc became chief executive officer gi company april nonexecutive director united technologies corporation member board overseers weill sir ian prosser aged cornell medical college appointed rd may senior independent director sir ian formerly nonexecutive director smithkline beecham plc andrew witty aged nonexecutive deputy chairman bp plc nonexecutive appointed st january ceo designate succeed director sara lee corporation member cbi dr garnier st may mr witty joined group presidents committee held senior positions asia africa europe usa january appointed president pharmaceuticals europe dr ronaldo schmitz aged served board member singapore economic appointed rd may nonexecutive director dr schmitz development board member insead uk council formerly nonexecutive director glaxo wellcome plc director office strategic coordination health research nonexecutive director legal general group plc member sits imperial college commercialisation advisory board board directors rohm haas company cabot member health innovation council uk corporation supervisory board sick ag professor sir roy anderson aged dr moncef slaoui aged appointed st october nonexecutive director professor appointed th may chairman research development anderson professor infectious disease epidemiology dr slaoui joined gsk biologicals engineered faculty medicine imperial college london september development robust vaccines pipeline phd molecular chief scientific adviser ministry defence biology immunology universit libre de bruxelles uk become rector imperial college july tom de swaan aged dr stephanie burns aged appointed st january nonexecutive director mr de appointed th february nonexecutive director dr burns swaan member managing board chief financial chairman president chief executive officer dow corning officer abn amro january member corporation also member american chemical society board directors zurich financial services vice chairman sits executive committee society chemical supervisory board chairman audit committee industry america section serves board directors royal ahold member supervisory boards royal dsm american chemistry council board directors corporate express vice chairman supervisory board society womens health research dr burns holds phd vanlanschot bankiers organic chemistry iowa state university christopher viehbacher aged lawrence culp aged appointed st january president us pharmaceuticals appointed st july nonexecutive director mr culp mr viehbacher joined group held variety president chief executive officer danaher corporation senior positions europe canada appointed prior joining danaher held positions accenture previously president us pharmaceuticals january served andersen consulting european commission approved g working group restore competitiveness eu pharmaceutical industry sir crispin davis aged board member phrma ceo roundtable cancer appointed st july nonexecutive director sir crispin chief researchamerica executive reed elsevier plc prior chief executive aegis group plc joined guinness plc sir robert wilson aged member main board group managing director united appointed st november nonexecutive director sir robert distillers spent early career procter gamble nonexecutive chairman bg group plc economist group previously executive chairman rio tinto julian heslop aged appointed st april chief financial officer mr heslop joined details membership board committees may found glaxo wellcome financial controller april january appointed senior vice president operations controller prior joining group held senior finance roles grand metropolitan gsk annual report srotcerid eht fo troper ecnanrevog etaroproccorporate governance continued corporate executive team cet duncan learmouth senior vice president corporate communications jp garnier community partnerships chief executive officer mr learmouth responsible groups investor relations chief executive officer dr garnier responsible internal external communications image partnerships management group oversees operational aspects global communities joined glaxo vice group including establishing policies objectives initiatives president global investor relations appointment directs longterm strategy formerly chief executive current position july officer smithkline beecham joined group bill louv andrew witty chief information officer ceo designate mr louv succeeded dr calhoun chief information officer mr witty appointed ceo designate october january responsible information technology global succeed jp garnier ceo may andrew joined glaxo uk function enables key business processes across parts career company held roles group joined group held number vice president general manager marketing glaxo wellcome increasingly senior roles including us pharmaceuticals inc us senior vice president asia pacific gsks rd functions appointed president pharmaceuticals europe glaxosmithkline january dan phelan senior vice president human resources rupert bondy mr phelan responsible benefits compensation recruitment senior vice president general counsel organisation development leadership development succession mr bondy responsible legal matters across group together planning human resource information systems employee health environment health safety issues security management lawyer private practice joining lawyer private practice joining smithkline beecham smith kline french leave gsk march david pulman john clarke president global manufacturing supply president consumer healthcare dr pulman responsible global manufacturing supply mr clarke responsible consumer healthcare business organisation global procurement trained microbiologist produces oral overthecounter nutritional healthcare products joined glaxo broad experience manufacturing joined beecham president futures operations previously led primary supply european group current appointment january manufacturing north american manufacturing global logistics marc dunoyer manufacturing strategy organisations president pharmaceuticals japan moncef slaoui mr dunoyer appointed president pharmaceuticals japan march chairman research development joined group senior vice president dr slaoui leads groups complex drug discovery development regional director japan current appointment activities joined group senior vice president eddie gray worldwide business development current appointment president pharmaceuticals europe june mr gray became responsible groups operations europe chris viehbacher january joined beecham prior current president us pharmaceuticals appointment senior vice president general manager mr viehbacher responsible us pharmaceuticals joined pharmaceuticals uk wellcome responsible gsks european russell greig pharmaceuticals business current appointment president pharmaceuticals international members dr greig leads pharmaceutical operations outside usa dr calhoun retired chief information officer st january japan europe covering countries mr stout left group february mr ingram continues joined group senior vice president worldwide act special consultant group attends cet meetings business development rd prior current appointment capacity march julian heslop chief financial officer mr heslop became chief financial officer st april head finance function mr heslop responsible activities financial reporting control tax treasury finance systems internal audit insurance real estate joined glaxo wellcome financial controller april gsk annual report srotcerid eht fo troper ecnanrevog etaroproccorporate governance continued governance policy board process board authority accountable shareholders board corporate executive team ensuring company appropriately managed directors listed board achieves strategic objectives sets board discharges board responsible groups system corporate responsibilities annual programme meetings governance ultimately accountable groups activities includes approval overall budgetary planning business strategy financial performance strategy board reviews companys internal controls risk management policies approves governance structure chief executive officer ceo responsible executive code ethics management group assisted cet cet meets times per year otherwise necessary members board appraises approves major financing investment responsibilities listed corporate executive team licensing decisions excess defined thresholds addition board evaluates monitors performance group board comprises five executive eleven nonexecutive directors whole includes board considers nonexecutive directors independent character judgement dr schmitz served board engaging board meetings ceo executive nine years appointed board glaxo wellcome directors members cet appropriate financial plc st january consideration annual review operating performance gsk external issues material board effectiveness meeting december board groups prospects concluded dr schmitz remained independent notwithstanding evaluating progress toward achievement groups length service opinion board dr schmitz continued financial business objectives annual plans demonstrate characteristics independence objectively challenging management taking part rigorous debate monitoring reports received directly various time possessing outstanding knowledge companys committees significant risks facing group business affairs together experience gained chairman board overall responsibility succession planning audit committee long cycle investment business ceo executive directors board given ceo gsk considered particularly important experienced broad authority operate business group ceo members board sir christopher gent appointed accountable reports board performance board deputy chairman determined board business independent upon taking chairmanship board st january accordance combined code cet members make regular presentations board areas excluded determination whether least half board responsibility board meets cet members independent nonexecutive directors sir christopher gent annual basis discuss collectively groups strategy hold position board committee independence primary element induction process new nonexecutive required combined code however appointed directors undertaken members cet nonexecutive member remuneration committee effective st january directors encouraged separate informal discussions following recent change combined code discretion cet members board considers professor sir roy anderson dr burns mr board met six times member attending culp sir crispin davis sir deryck maughan dr podolsky sir ian prosser follows dr schmitz mr de swaan sir robert wilson independent accordance recommendations combined code number meetings number name held whilst board member meetings attended date publication throughout majority sir christopher gent board members excluding chairman independent non dr jp garnier executive directors mr j heslop dr slaoui sir christopher gent succeeded sir christopher hogg st january professor sir roy anderson chaired company throughout dr garnier ceo dr burns retire board end agm st may mr l culp mr andrew witty succeed ceo mr wittys biographical sir crispin davis details found mr witty appointed board sir deryck maughan st january chairman leads board represents dr podolsky board ceo cet members necessary board sir ian prosser meetings ceo manages group implements strategy dr r schmitz policies adopted board chairman chairmen mr de swaan board committees communicate regularly ceo cet sir robert wilson members division responsibilities role chairman ceo set writing agreed board professor anderson joined board st october dr burns joined appears full companys website th february addition scheduled meetings board also met sir ian prosser appointed senior independent director sid quorate basis occasions st january held role throughout gsk annual report srotcerid eht fo troper ecnanrevog etaroproccorporate governance continued business environment development remuneration committee ensure board kept uptodate important remuneration committee determines terms service matters including legal governance regulatory developments remuneration executive directors members cet presentations made regular basis external assistance external independent advisors evaluates internal advisers makes recommendations board overall executive remuneration policy committee consists entirely independent independent advice nonexecutive directors together chairman accordance board recognises may occasions one combined code meets least four times year directors feel necessary take independent otherwise necessary information remuneration directors legal andor financial advice companys expense given remuneration report pages agreed procedure enable explained corporate governance section companys website chairman company ceo responsible evaluating making recommendations board indemnification directors remuneration nonexecutive directors qualifying third party indemnity provisions defined section companies act force benefit nominations committee directors former directors held office nominations committee reviews structure size composition board appointment members company secretary board cet makes recommendations board company secretary responsible board available appropriate committee also monitors planning succession individual directors respect board procedures company board senior management committee consists entirely secretary mr simon bicknell appointed may nonexecutive directors majority independent barrister joined group secretary meets least year otherwise necessary nominations board committees committee report given pages board committees corporate responsibility committee board established number committees provides corporate responsibility committee consists entirely non sufficient resources enable undertake duties executive executive directors provides boardlevel forum regular directors members audit remuneration nominations review external issues potential serious impact corporate responsibility committees although may invited upon groups business reputation oversight attend meetings director member corporate reputation views external stakeholders committee administration transactions financial results committees also responsible governance oversight groups worldwide membership committees shown table donations community support committee meets formally corporate three times year otherwise necessary corporate audit remuneration nominationsresponsibility responsibility committee report given sir christopher gent c c professor sir roy anderson financial results committee dr burns financial results committee reviews approves behalf mr l culp board annual report form f annual review sir crispin davis convening annual general meeting together sir deryck maughan preliminary quarterly statements trading results director member committee quorum meeting dr podolsky three members quorate meeting must include sir ian prosser chairman chairman audit committee ceo dr r schmitz chief financial officer cfo committee meets necessary mr de swaan c sir robert wilson c corporate administration transactions committee corporate administration transactions committee reviews key c chairman member approves matters connection administration following summary role terms reference groups business certain corporate transactions committee committee current full terms reference committee consists directors cet members company secretary may obtained company secretary corporate committee meets necessary governance section companys website evaluation board board committees directors audit committee performance evaluation chairman board audit committee reviews financial internal reporting committees directors undertaken sid process system internal controls management risks implemented collaboration committee chairmen external internal audit process committee also support company secretary board considered review proposes shareholders appointment external auditors conclusions meeting december agreed number directly responsible remuneration oversight minor improvements procedures operating methodology work committee consists entirely independent non audit committee chairman undertook review audit executive directors meets least four times year otherwise committee building work undertaken external necessary audit committee report pages consultants review committee gsk annual report srotcerid eht fo troper ecnanrevog etaroproccorporate governance continued dialogue shareholders holders ordinary shares entitled receive dividends declared companys reports accounts attend financial results announced quarterly speak general meetings company appoint proxies company reports formally shareholders twice year exercise voting rights halfyear fullyear results announced fullyear results restrictions transfer limitations holding included companys annual report annual review ordinary shares requirements obtain prior approval published shareholders companys half transfers ordinary shares carry special rights regard year results published national newspaper shortly control company restrictions voting release ceo cfo give presentations fullyear results rights major shareholders voting rights per share institutional investors analysts media shareholders known arrangements webcast teleconferences release first financial rights held person holder second third quarter results institutional investors analysts shares known agreements restrictions share transfers media annual report annual review quarterly voting rights results available companys website shares acquired gsk share schemes plans rank equally annual general meeting agm takes place london formal shares issue special rights trustees notification sent shareholders least one month advance companys employee share ownership plan esop trusts meeting business presentation made shareholders waived rights dividends shares held esop trusts directors able attend available formally agm change control informally afterwards questions committee chairmen ordinarily company party significant agreements would attend agm respond shareholders questions entire board take effect alter terminate upon change control following attendance companys agm may resolutions takeover bid agm decided poll required companys articles association results poll announced london stock company agreements director officer exchange posted companys website details would provide compensation loss office employment agm set section annual general meeting see resulting takeover except provisions companys notice agm published companys website share plans may cause options awards granted plans vest takeover ensure nonexecutive directors aware understand views major shareholders company interests voting rights board place process focusing sectorspecific issues stated far company aware well general shareholder preferences persons significant direct indirect holdings company information provided company pursuant ceo cfo maintain dialogue institutional shareholders financial services authoritys fsa disclosure transparency performance plans objectives programme rules dtrs published regulatory information service regular meetings companys website groups investor relations department offices london nd february company received notifications philadelphia acts focal point contact investors accordance fsas dtrs following notifiable interests throughout year voting rights companys issued share capital chairman meets regularly institutional investors hear percentage issued views discuss issues mutual importance shares capital chairman remuneration committee meets annually legal general management major shareholders discuss executive remuneration policy limited barclays plc nonexecutive directors including new appointees available meet major shareholders requested p ercentage ordinary shares issue excluding treasury shares nd february companys website provides access current financial business information group bank new york mellon depositary companys adrs listed new york stock exchange ordinary share capital control shares representing companys adr program managed depositary registered name bny details companys authorised issued share capital nominees limited details number ordinary shares held number shares held treasury st december depositary found found note financial statements share capital share premium account gsks shares listed london stock company acquired disposed interests exchange also quoted new york stock exchange shares connection companys share buyback form american depositary shares adss ads represents programme details shares purchased cancelled held two ordinary shares treasury disclosed note financial statements share capital share premium account gsk annual report srotcerid eht fo troper ecnanrevog etaroproccorporate governance continued directors officers donations eu political organisations interests directors officers connected persons eu political expenditure issued share capital company given remuneration agm may shareholders first authorised company report pages make donations eu political organisations incur eu political rules appointment replacement directors expenditure provisions political parties elections contained companys articles association companys referendums act year authority articles must approved shareholders accordance since renewed annually although company legislation force time time make intend make payments donations eu political parties within normal meaning expression articles provide directors may appointed ordinary definition legislation eu political organisation wide may resolution members resolution directors provided extend bodies company subsidiaries might wish latter instance director appointed way retires support including concerned policy review law reform first agm following appointment representation business community special interest groups articles also provide every agm least one third concerned environment donations made directors retire rotation detail circumstances eu political organisations group made donations may reelected companys members noneu political organisations totalling may remove director passing ordinary resolution special notice given director may automatically cease donations made usa director bankrupcy order made ii canada nil makes arrangement composition creditors applies australia usa largest recipient political donations interim order connection voluntary arrangement iii reflects us political system candidates sponsored solely suffering mental disorder iv missed directors donations individuals ngos companies parties meetings continuous period six months without permission directors resolve shall cease director v line us law corporate donations gsk made prohibited director law vi resigns vii federal level candidates political parties state offers resign directors accept offer viii local levels donations accepted practice usa least three directors require resign major employer heavily regulated industry important gsk engage fully political process donations one companys articles may amended special resolution ways gsk supports candidates seek members environment appropriately rewards highrisk highinvestment powers directors determined uk legislation industries believe free market principles intellectual companys memorandum articles association available property rights gsks website provided articles directors may exercise situation similar canada donations follow companys powers provided articles applicable guidelines rest world donations rare legislation stipulate powers must exercised low value members directors authorised issue allot ordinary shares pursuant articles authority also gsk political action committee pac usa make market purchases shares pursuant article powers gives political donations pacs employee organisations articles referred shareholders agm allow employees contribute fund political donations renewal shareholders also requested renew directors employees decide upon recipients pac donations power make market purchases shares agm shares total donated political purchased may cancelled held treasury shares organisations gsk pac share buyback programme annual general meeting company repurchased billion shares cancellation held treasury shares billion agm held pm wednesday st may spent queen elizabeth ii conference centre broad sanctuary westminster london swp ee business transacted july programme totalling billion share repurchases meeting include two years commenced programme covers purchases company shares cancellation held treasury shares receiving adopting glaxosmithklines accordance authority renewed shareholders annual report companys agm pproving remuneration report may company authorised purchase maximum remuneration report pages sets million shares details shares purchased held remuneration policies operated glaxosmithkline disclosures treasury shares cancelled disclosed note directors remuneration including required financial statements share capital share premium account companies act directors remuneration report regulations resolution proposed approve exact amount timing future purchases extent remuneration report repurchased shares held treasury shares rather cancelled determined company dependent market conditions factors gsk annual report srotcerid eht fo troper ecnanrevog etaroproccorporate governance continued r etirement election reelection directors extensive financial controls procedures selfassessment exercises mr witty mr viehbacher professor sir roy anderson risk activities reviewed groups internal auditors appointed directors since agm offer commercial financial responsibility however clearly delegated election board sir christopher gent sir ian prosser local business units supported regional management structure dr schmitz retire offer reelection principles designed provide environment central board article companys articles association leadership coupled local operating autonomy framework dr garnier also retiring rotation seeking exercise accountability control within group reappointment retiring board group also attaches importance clear principles procedures conclusion agm designed achieve appropriate accountability control group r eappointment remuneration auditors policy risk management legal compliance mandates resolutions proposed reappoint pricewaterhousecoopers business units establish processes managing monitoring risks llp auditors authorise audit committee determine significant businesses group remuneration internal control framework also relies following pecial business overseeing reporting risk compliance issues company seek authority risk oversight compliance council rocc make donations eu political organisations incur eu rocc council senior executives authorised board political expenditure capped assist audit committee oversee risk management internal control activities group membership comprises several allot ordinary shares company cet members heads departments internal give directors authority disapply preemption rights control risk management audit compliance responsibilities allotting new shares connection rights issues otherwise rocc meets regular basis review assess significant maximum current issued share capital risks mitigation plans provide oversight internal purchase ordinary shares maximum controls ensure compliance applicable laws regulations current issued share capital internal gsk policies rocc responding group policy adopt new articles association reflect changes referred provided business units framework introduced new companies act risk management upward reporting significant risks mitigation planning identification manager overall shareholders entitled appoint one proxies attend responsibility management given risk requirement agm speak vote behalf risk management compliance boards rmcbs details appoint appointed corporate representative risk management compliance boards rmcbs established proxy found notice agm major business units membership often comprises members published companys website senior executive team respective business unit augmented specialists appropriate rmcbs oversee management internal control framework risks considered important respective business units board recognises responsibility present balanced including risks designated significant glaxosmithkline understandable assessment groups position prospects whole thus increasing number risks actively managed structure accountability audit operated gsk across group follows rmcb regularly reports status regarding significant risks board accountability reviewing approving adequacy rocc effectiveness internal controls operated group including compliance functions financial operational compliance controls risk management number risk areas specific standards meet exceed board delegated responsibility review audit requirements applicable law established specialist audit committee receives reports individuals identified compliance functions example corporate environment committees report pages responsibility health safety global quality assurance worldwide regulatory management cet implement board policies compliance assist dissemination implementation audit risk control cet responsible identifying approving standards monitoring enforcing key policies go heart group conducts business internal control framework includes corporate ethics compliance cec central direction resource allocation risk management key rocc also supported corporate ethics compliance activities research development manufacturing marketing department responsible supporting development sales legal human resources information systems financial implementation practices facilitate employees compliance practice part framework comprehensive planning laws group policy system annual budget approved board results thrust groups compliance effort due diligence operating units reported monthly compared budget preventing detecting misconduct noncompliance law forecasts prepared regularly year regulation promoting ethical behaviour compliance laws regulations corporate responsibility levels effective compliance systems gsk annual report srotcerid eht fo troper ecnanrevog etaroproccorporate governance continued cec managed corporate compliance officer committee receives regular reports members cet reports directly ceo corporate compliance officer chairs senior managers covering key compliance activities rocc provides summary reports roccs activities group including concerning rd manufacturing sales groups significant risks cet audit committee marketing ehs regular basis corporate compliance officers direct reporting committee members exception dr podolsky bring line audit committee provides mechanism bypassing considerable financial accounting experience committees executive management need ever arise work members past employment experience either finance areas potentially significant risk accounting roles comparable experience corporate activities details risks affecting group see risk factors pages dr podolskys background worldrenowned researcher enables note financial statements legal proceedings bring scientific expertise committees deliberations effectiveness controls mr de swaan joined board committee effect internal control framework operation st january succeeded dr schmitz chairman whole year review continues operate committee effect september appointing date approval report system internal controls mr de swaan committee board determined designed manage rather eliminate risk recent relevant financial experience accordance achieving business objectives provide reasonable combined code coming conclusion board paid absolute assurance material misstatement loss particular attention mr de swaans role chief financial officer abn amro retired st december audit committee receives reports areas significant board also considers mr de swaan audit committee risk group related internal controls following financial expert defined sarbanesoxley consideration reports audit committee reports annually board effectiveness controls controls may sir deryck maughan managing director kohlberg kravis mitigate eliminate risks addition areas roberts co kkr chairman kkr asia chairman groups business necessary take risks achieve ceo citigroup international vice chairman citigroup satisfactory return shareholders investment rd inc prior creation citigroup chairman cochief acquiring new products businesses executive officer salomon smith barney also chairman chief executive officer salomon brothers inc cases groups objective apply expertise prudent management rather elimination risk directors sir ian prosser cfo later ceo bass plc member review relates company subsidiaries extend institute chartered accountants england wales material associated undertakings joint ventures investments dr schmitz chairman committee april board audit committee reviewed september prior appointment nonexecutive assessment risks internal control framework operates director company nonexecutive director glaxo glaxosmithkline considered effectiveness wellcome plc served audit committee dr schmitz system internal control operation group year also member executive board directors covered report date approval board deutsche bank ag retired board process followed board reviewing system internal charge investment banking dr schmitz formerly member controls accords guidance internal control issued executive board directors basf turnbull committee including cfo holds mba insead sir robert wilson began professional career economist committee reports chairman bg group plc held senior management positions rio tinto plc culminating appointment executive chairman audit committee report retired audit committees role flows directly boards oversight function authorised board investigate activity dr podolsky appointed committee effect st within terms reference committee written terms january worldrenowned researcher advanced reference approved board committee knowledge underlying mechanisms disease new therapies reports regularly board performance activities gastrointestinal disorders mallinkrodt professor medicine assigned committees main responsibilities include chief gastroenterology massachusetts general hospital reviewing corporate accounting financial reporting process harvard medical school well chief academic officer monitoring integrity financial statements evaluating partners healthcare system background enables system internal control management risks overseeing bring scientific rather financial accounting expertise activities groups compliance audit functions committees deliberations overseeing compliance laws regulations ethical codes committee supported company secretary attends practice committees oversight role requires address committees meetings also corporate compliance regularly relationships management internal officer available financial resources take independent external auditors understand monitor reporting professional advice considered necessary meetings relationships tiers accountability committee attended chairman ceo cfo general counsel head global internal audit gia external auditors gsk annual report srotcerid eht fo troper ecnanrevog etaroproccorporate governance continued committee worked structured programme external auditors management report regularly activities standing items committee required committee regarding extent services provided accordance consider meeting together matters focused preapproval fees services performed coincide key events annual financial reporting cycle committee may also preapprove additional services caseby external auditors reported committee critical case basis expenditure audit nonaudit services set accounting policies significant judgements practices used note financial statements operating profit company alternative accounting treatments guidelines set companys policy engaging discussed management resultant conclusion external auditors provide nonaudit services include ascertaining external auditors material written communications skills experience external auditors make management restrictions access information suitable supplier nonaudit services adequate safeguards cfo reported financial performance company place objectivity independence audit technical financial accounting matters compromised fee levels relative annual audit fee within limits set committee general counsel reported material litigation company also wellestablished policies including code company secretary corporate compliance officer ethics available website helpline facility reported corporate governance activities undertaken reporting investigation unlawful conduct waivers rocc code made heads groups compliance audit groups reported audit scope annual coverage audit resources committee met full session six times five times results audits conducted throughout year quorate basis full session attended members except sir deryck maughan unable attend one meeting company secretary chairman disclosure committee reported matters affected quality timely disclosure nominations committee report financial material information board nominations committees terms reference include responsibility public markets shareholders enabled committee proposing appointment board committee members review clarity completeness disclosures committees main focus selection published annual financial statements interim reports quarterly new ceo succeed dr garnier sir robert wilson mr de swaan preliminary results announcements formal mr culp attended committees meetings purpose announcements relating financial performance prior considering dr garniers successor implementing process release board select new ceo committee took external advice audit committee management internal auditors executive search company conducted search identify full board work together ensure quality companys potential external candidates addition internal candidates corporate accounting financial reporting committee already identified executive search company used serves primary link board external conduct degrees analysis candidates internal auditors facilitates necessary independence chairman conducted interviews number key individuals management encourages external internal auditors within outside company gain perspectives communicate freely regularly committee candidates addition dr garnier provided committee committee met collectively separately external analysis candidates auditors head gia corporate compliance officer without members management present considering chairman ceos feedback external advice benchmarking committee concluded making committee primary responsibility making recommendation board mr witty appointed recommendation shareholders appointment reappointment companys next ceo removal external auditors annually assessing qualifications expertise resources independence external committee also made recommendations board auditors effectiveness audit process appointment dr burns nonexecutive director professor sir roy anderson nonexecutive director scientific making assessment committee considers papers medical expert appointment mr viehbacher detail relevant regulatory requirements relating external auditors executive director evaluates reports external auditors compliance requirements external auditors provide non audit services committee ensures auditor objectivity independence safeguarded policy requiring preapproval audit committee services services may include audit services auditrelated services tax services services preapproval detailed particular service categories services subject specific budget gsk annual report srotcerid eht fo troper ecnanrevog etaroproccorporate governance continued following recommendations committee dr stephanie burns committee members selected relevant appointed nonexecutive director february expertise may contribute committees activities professor sir roy anderson october professor sir roy anderson committee members sir christopher gent chairman dr burns appointed one boards scientificmedical experts sir ian prosser dr podolsky mr de swaan committee supported company secretary attends committees recruiting nonexecutive directors committee considers meetings ceo general counsel senior vice president particular skills knowledge experience would benefit corporate communications community partnerships board significantly appointment broad selection head corporate responsibility also attend meetings criteria used focus achieving balance chairman reports board committees activities representation european uk us markets individuals ceo experience skills developed various year committee reviewed gsks activity number sectors specialities particular focus placed responsibility areas including access medicines community upon recruiting nonexecutive scientific medical expertise partnerships reputation management human rights supply nonexecutive ceo experience usa professional chain efficiency manufacturing processes climate change search agencies engaged specialising recruitment high risk management processes rd transparency clinical trial data calibre nonexecutive directors dossiers potential nonexecutive informed consent procedures clinical trials financial interactions appointees provided committee candidates short health care professionals animal research testing ethics listed interview considering relevant qualifications compliance initiatives policy violations discipline use social media tools employment practices customised induction process conducted new nonexecutive directors focusing particular experience committee met three times meeting taking account different backgrounds process includes attended committee members meeting members cet senior executives visiting gsks corporate responsibility report accessed particular operational facilities group website appointing new executive directors cet members committee considers skills knowledge experience required combined code particular executive position committee consider throughout company complied code provisions potential external internal candidates recommending combined code except follows board approve new appointment new directors offer election companys next agm b designing schemes performancerelated remuneration appointments announced publicly remuneration committee follow provisions schedule code item schedule states general end committee recommended appointment basic salary pensionable companys position dr podolsky audit committee appointment sir explained remuneration report pages christopher gent remuneration committee effect st january us law regulation committee also recommended appointment dr burns number provisions us law regulation apply gsk corporate responsibility committee december companys shares quoted new york stock committee met three times members exchange nyse form adss present full meetings except dr schmitz unable nyse rules attend one meeting general nyse rules permit company follow uk corporate remuneration report governance practices instead applied usa provided remuneration report found pages company explains significant variations explanation companys website nyse rules came effect corporate responsibility committee report require company file annual interim written affirmations main responsibilities corporate responsibility committee concerning audit committee companys statement review gsks policies practices anticipating significant differences corporate governance managing external issues potential impact seriously groups business reputation committee terms sarbanesoxley act reference approved board published following number corporate accounting scandals gsks website usa congress passed sarbanesoxley act sarbanesoxley sarbanesoxley wide ranging piece committee meets three times year rolling legislation concerned largely financial reporting agenda ensures progress meeting gsks corporate corporate governance responsibility principles reviewed appropriate basis four principles access medicines standards ethical conduct recommended securities exchange commission sec research innovation global community partnerships gsk established disclosure committee committee reports reviewed annually principles discussed least every ceo cfo audit committee chaired two years committee also reviews approves annual company secretary members consist senior managers corporate responsibility report committee receives regular finance legal compliance corporate communications reports members cet senior managers investor relations cover key corporate responsibility areas gsk gsk annual report srotcerid eht fo troper ecnanrevog etaroproccorporate governance continued external legal counsel external auditors invited attend meetings periodically responsibility considering materiality information timely basis determining disclosure information responsibility timely filing reports sec formal review annual report form f committee met nine times sarbanesoxley requires annual report contains statement whether member companys audit committee audit committee financial expert explanation details basis boards judgement matter refer additional disclosure requirements arise section section respect disclosure controls procedures internal control financial reporting section corporate responsibility financial reports sarbanesoxley also introduced requirement ceo cfo complete formal certifications confirming hey reviewed annual report form f b ased knowledge contains material misstatements omissions based knowledge financial statements financial information fairly present material respects financial condition results operations cash flows dates periods presented annual report form f responsible establishing maintaining disclosure controls procedures ensure material information made known evaluated effectiveness controls procedures yearend results evaluation contained annual report form f responsible establishing maintaining internal control financial reporting provides reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles disclosed annual report form f changes internal controls financial reporting period covered annual report form f materially affected reasonably likely affect materially companys internal control financial reporting disclosed based recent evaluation internal control financial reporting external auditors audit committee significant deficiencies material weaknesses design operation internal control financial reporting reasonably likely affect adversely companys ability record process summarise report financial information fraud regardless materiality involving persons significant role companys internal control financial reporting group carried evaluation supervision participation groups management including ceo cfo effectiveness design operation groups disclosure controls procedures st december gsk annual report srotcerid eht fo troper ecnanrevog etaroproc inherent limitations effectiveness system disclosure controls procedures including possibility human error circumvention overriding controls procedures accordingly even effective disclosure controls procedures provide reasonable assurance achieving control objectives ceo cfo expect complete certifications report conclusions effectiveness disclosure controls procedures th february following certificates filed sec part groups form f section managements annual report internal control financial reporting accordance requirements section sarbanes oxley following report provided management respect companys internal control financial reporting defined rules af df us securities exchange act management responsible establishing maintaining adequate internal control financial reporting group internal control financial reporting designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance ifrs management conducted evaluation effectiveness internal control financial reporting based framework internal control integrated framework issued committee sponsoring organisations treadway commission changes groups internal control financial reporting materially affected reasonably likely affect materially groups internal control financial reporting management assessed effectiveness internal control financial reporting st december conclusion filed part groups form f pricewaterhousecoopers llp audited consolidated financial statements group year ended st december also assessed effectiveness groups internal control financial reporting auditing standard public company accounting oversight board united states audit report filed groups form fgsk annual report srotcerid eht fo troper troper noitarenumer remuneration report remuneration report sets remuneration policies operated gsk respect directors corporate executive team cet members together disclosures directors remuneration including required directors remuneration report regulations regulations accordance regulations following sections remuneration report subject audit annual remuneration nonexecutive directors remuneration share options incentive plans performance criteria performance share plan share options pensions opinion thereon expressed remaining sections subject audit pages referred within audited sections report submitted shareholders board approval annual general meeting referenced notice annual general meeting throughout remuneration report executive directors cet members referred executives references glaxosmithkline shares adss mean respectively ordinary shares glaxosmithkline plc p american depository shares glaxosmithkline plc ads represents two glaxosmithkline shares introduction remuneration policy executive director terms conditions remuneration nonexecutive director terms conditions fees directors senior management remuneration annual remuneration nonexecutive directors remuneration directors interests share options incentive plans pensions directors senior management directors interests contracts remuneration report introduction two quorate meetings held year approve formal grant share options performance share awards remuneration committee committee responsible accordance gsk remuneration policy making recommendations board companys remuneration policy within terms agreed policy exception mr bicknell company secretary employees determining total individual remuneration packages company involved conduct committee executives meetings dr garnier ceo mr phelan senior vice president human resources invited attend part meetings glaxosmithklines remuneration policy designed establish committee required framework remuneration consistent companys scale scope operations meets recruitment needs deloitte touche llp deloitte appointed committee business closely aligned uk shareholder guidelines provide independent advice executive remuneration st december company second largest deloitte provided consulting services gsk year pharmaceutical company world revenue operations provide advice executive remuneration matters five continents products sold countries committee approximately sales generated usa towers perrin provided market data data analysis appropriateness gsks remuneration policy kept committee review remuneration committee part ongoing commitment committee commenced process reassess remuneration policy remuneration policy ensure continues support future direction business company announced principles appointment new ceo effective may dialogue remuneration policy gsk designed secure begun purpose reviewing alignment outstanding executive talent provide pay performance remuneration structure new business priorities set performance within transparent robust new ceo may lead changes considered coming governance structure year chairman committee continues regular committee determined gsks remuneration policy would dialogue institutional investors regarding gsks remuneration based following key principles policy material changes policy discussed major shareholders disclosed remuneration report remuneration structure must support needs business competitive market place remainder report sets gsks current u k shareholder guidelines followed maximum extent remuneration policy consistent needs business company would remuneration committee maintain regular dialogue shareholders sir robert wilson chairman committee since th global pharmaceutical companies primary pay may sir crispin davis mr culp sir christopher gent comparator group dr schmitz members committee throughout performance conditions would based measurable board deemed members committee independent delivery strong financial performance delivery nonexecutive directors accordance combined code superior returns shareholders compared exception chairman company sir christopher gent pharmaceutical companies independent appointment company high proportion total remuneration opportunity based performancerelated remuneration delivered committee met four times member medium long term attending follows remuneration would determined using projected value number meetings number meetings method see benchmarking held whilst attended name committee member committee member would one remuneration structure executive directors cet performance conditions applying sir robert wilson equally longterm incentive awards mr l culp n exgratia payments made sir crispin davis pay structures would simple consistent sir christopher gent business needs dr r schmitz overall policy intended provide median total remuneration meetings amongst items committee considered median performance opportunity earn upper terms service remuneration levels new executive quartile total remuneration exceptional performance poor appointments competitiveness companys total performance result total remuneration significantly reward package including level annual longterm pay comparator group median incentive opportunity strong alignment performance demonstrably policy aspects discussed chairman interests shareholders provides executives chairman committee annual meetings unambiguous signals importance delivering success institutional investors companys shareholders gsk annual report srotcerid eht fo troper troper noitarenumerremuneration report continued commitment performance line expectations total remuneration committee apply policy consistent transparent targeted median pay comparator group way significant changes measures used assess longterm incentive opportunity set way provides performance discussed shareholders use positioning total remuneration median group comparators pay benchmarking committee use valuation method discretion ensure remuneration levels reasonable projected value method used benchmark total remuneration believes changes may cause concern amongst method projects future value remuneration package shareholders position discussed shareholders prior different performance scenarios method taken together implementation assessment pay comparator groups incentive policies pay performance comparators several years moderates impact market fluctuations following table sets companies used pay short term strengthens focus performance performance comparison committee uses projected value method pay market benchmarking purposes enables comparison packages capitalisation company country different structural characteristics provides insight value gearing different equity instruments abbott laboratories usa individual elements remuneration amgen usa balance fixed base salary variable annual astrazeneca uk bonus longterm incentive elements remuneration changes bristolmyers squibb usa performance chart shows anticipated normal eli lilly usa range mix fixed variable pay different levels glaxosmithkline uk performance mr heslop dr slaoui years johnson johnson usa ranges may higher lower depending performance merck usa company individual novartis switzerland pfizer usa roche holdings switzerland sanofiaventis france scheringplough usa takeda pharmaceutical company japan wyeth usa included performance comparison benchmarking base salary benchmarking purposes total remuneration incorporates base salaries set reference median relevant base salary annual bonus longterm incentives market executives pharmaceutical pay comparator setting pay committee also due regard executives group actual salary levels reviewed annually influenced pension arrangements executives experience responsibility market value global pharmaceutical industry used primary pay changes usually take effect st april comparator executives appropriate marketplace table sets current base salaries take companys senior executive talent effect april first instance pay benchmarked publicly available base salary percentage base salary remuneration data companies provide additional st april increase st april context reference also made towers perrin annual global dr jp garnier pharmaceutical pay survey pharmaceutical human resources mr j heslop association phra ensure global pharmaceutical industry dr slaoui benchmark subject scrutiny review committee also regularly considers pay data global businesses primarily r garnier retire board st may consumer manufacturing sectors hese base salary increases reflect committees assessment performance respective roles since appointment prior determining annual longterm incentive opportunity mr witty mr viehbacher appointed board committee considers range payout levels may effect st january salaries time achieved based different assumptions share price growth respectively performance levels etc gsk annual report srotcerid eht fo troper troper noitarenumer base salary annual bonus longterm incentives gsk annual report srotcerid eht fo troper troper noitarenumer remuneration report continued annual bonus committee considers performance shares provide stronger annual cash bonuses determined basis formal alignment shareholder interests therefore remuneration review annual performance stretching financial targets policy places greater emphasis use performance shares based profit interest tax subject detailed lti awards determined ontarget performance assessment individual business unit group achievements half lti reward derived objectives bonus payable financial performance performance shares less target maximum annual cash bonus annual grant lti awards using one plan consistent executives earn based solely corporate performance practice pay comparator group leading uk approximately twothirds maximum bonus opportunity companies lti awards cet provided basis individual performance objectives increase decrease executive directors level annual lti opportunity bonus level factor range zero bonuses considered carefully yearonyear committee context subject upper limits executives market practice gsks policy market positioning ceo range base salary ceos performance period starts st january year award ie maximum bonus opportunity st january awards made february aim remuneration policy deliver annual cash performance shares share options delivered us resident remuneration line median pay comparator group executives form adss awards delivered form ontarget business performance ordinary shares executives resident uk countries case ceo bonus targets set board awards made plans incorporate dilution limits setting objectives ceo board takes account consistent guidelines provided association british strategies developed company set insurers national association pension funds annual report shareholder representative bodies current estimated dilution existing awards gsk employee share schemes made since reasons commercial sensitivity specific objectives set merger approximately companys share capital strategic business drivers set st december kept confidential following end financial year board reviews ceos performance generally set performance shares objectives committee determines bonus payable executives level performance shares vesting based executives ceo makes recommendations companys total shareholder return tsr relative committee regarding performance level achieved performance comparator group see threeyear objectives recommendations considered measurement period tsr chosen appropriate committee determine resultant bonus comparative measure since focuses return shareholders wellunderstood tested mechanism measure performance objectives set focused particular allows comparison companies operating continued development launch latestage pipeline assets different countries delivery commercial plans acceleration operational excellence programmes tsr measured sterling performance period represents change value share together bonus measures rd employees including dr slaoui linked value reinvested dividends paid order remove impact pipeline robust governance structure established varying tax treatments dividends different jurisdictions ensure bonus payable fairly reflects rd productivity dividends reinvested gross performance well profit targets committee reviewed new arrangements following first year implementation table sets performance share awards made agreed continue established february full disclosure made remuneration report committee took account companys success achieving market price objectives well individual executives performance executive director performance share award date grant determining bonus awards dr jp garnier looking forward order drive necessary changes mr witty shares business committee may set additional targets associated mr j heslop shares bonuses achievement specific operational goals dr slaoui adss incremental bonus form gsk shares deferred mr c viehbacher adss period exceed salary dr garnier retire board st may longterm incentives gsk ranked median performance comparator group executives eligible annual longterm incentive lti awards shares vest ranking point result remuneration policy provides normally shares vesting gsk one top two companies made performance share award share option award shares vest determining vesting levels committee regard companys underlying financial performanceremuneration report continued gsk annual report srotcerid eht fo troper troper noitarenumer graph sets vesting schedule awards made setting eps targets committee considers prior executives based performance comparator grant companys internal projections analysts forecasts group comprising companies excluding gsk gsks tsr gsks eps performance well analysts forecasts performance falls two companies vesting increases pharmaceutical industry straightline basis extensive careful consideration committee agreed annualised growth eps achieve vesting share option awards granted february would rpi following key principles govern use eps performance measure adjustments considered major items adjustments judgement committee purpose adjustments ensure performance measurement fair reasonable participants shareholders discretion exercised committee disclosed shareholders annual report committee set basis decision considers appropriate make significant adjustment table sets share option awards made february full disclosure made remuneration report provide closer link shareholder returns payments executives notional dividends reinvested paid executive director share option award option price proportion vesting award receipt dividends dr jp garnier incorporated benchmarking award levels mr witty shares addition performance shares earned executives mr j heslop shares sold except meet related tax liabilities two years dr slaoui adss following end performance period mr c viehbacher adss performance share plan awards granted executive directors dr garnier retire board st may excluding dr slaoui december performance period starting st january ending st december share options granted executives vesting increases vested part gsks relative tsr performance straightline basis eps performance hurdles set placed company median comparator group following graph awards made senior executives including dr slaoui dependent part tsr performance part eps performance tsr portion vested part eps portion vested full vesting tables performance share awards granted given b share options share options allow holder buy shares future date share price prevailing time grant share options granted managers gsk including executives vesting share options granted executives linked achievement compound annual eps growth performance period eps measured constant exchange rates cer gsks practice measure performance cer basis committee considers eps key measure performance business fully reflected business measures extended throughout group ensuring organisational alignment egatnecrep gnitsev gsk tsr ranking maximum threshold th th th th th nd median rpi pa egatnecrep gnitsev eps target exceptional superior baseline threshold rpi rpi rpi pa pa paremuneration report continued gsk annual report srotcerid eht fo troper troper noitarenumer performance condition substantially consistent uk share ownership requirements shareholder guidelines expectations demanding align interests executives shareholders compared operated global pharmaceutical executives required build significant holdings shares companies consistent policy providing pay glaxosmithkline maintain requirements performance performance important part aligning interests executives shareholders ceo required acquire shares value four times base performance measured period three financial years salary within three years appointment executive directors performance period starts year award base year required build shareholding value three times base salary preceding financial year performance retesting members cet required build shareholding value performance condition met threeyear period two times base salary top executives group options lapse required build shareholding value one times base salary share options granted vested full required confirm holding audited kpmg annual basis individuals recruited promoted new pensions shareholding requirement expected met within three years executives participate glaxosmithkline senior executive pension plans pension arrangements structured accordance shares qualify share ownership requirements plans operated executives country must held personally executive spouse except executives likely retire details individual arrangements spouse also employed gsk also subject executive directors set response requirements minor children earned deferred new pensions regime uk committee carefully considered one share programmes operated company impact change legislation decided following unexercised share options included calculation company continue fulfil obligations existing st december dr garniers holding adss pension arrangements dr slaouis adss mr heslops ordinary compensation provided participants adversely shares dr garniers holding excess share ownership affected new pension regime requirements mr heslop december dr slaoui december build holdings value three gsk pension policy executives uk times base salary n ewly employed executives benefit company contribution executives required continue satisfy shareholding base pay defined contribution plan requirements minimum twelve months following retirement together opportunity receive company matched contributions l egacy final salary plans provide twothirds final salary remuneration elements age grandfathered existing employees new executives participate various legacy glaxo wellcome entrants allowed smithkline beecham allemployee share plans either uk f capped employees benefits excess cap currently usa glaxosmithkline plans replaced provided unfunded arrangements sharesave plan sharereward plan uk hm revenue u nder legacy final salary plans actuarial reduction factors apply customs approved plans open uk employees participant leaves employment accord terms mr witty mr heslop members sharesave plan age effectively spreading value pension earned contribute month provides longer life expectancy employment terminated option buy shares end threeyear savings period company eg redundancy reduction factors apply line opportunity available uk employees usa gsk operates us cash balance plan provides mr witty mr heslop also contribute per month buy annual contribution interest sum accumulated shares sharereward plan company matches cash balance plan contractual promise provide specific number shares bought month levels retirement income executives also receive benefits including healthcare effect st january company introduced medical dental personal financial advice life assurance executive pension credit within us cash balance plan senior cash value benefits received executive directors us executives contribution rates plan range shown base salary senior us executives eligible new executive pension credit except dr garnier whose provisions th february company made conditional award grandfathered light anticipated retirement adss mr viehbacher award vest two tranches subject continued employment gsk committees capped employees usa benefits cap assessment performance vesting period adss provided unfunded nonqualified plan vest st december balance vesting st december number adss adjusted reflect dividends would accrued period award vesting extent adss vestremuneration report continued gsk annual report srotcerid eht fo troper troper noitarenumer executive director terms conditions addition except retirement dr garnier entitled receive one remuneration years worth pension contributions termination executive director contracts terms dr garniers retirement accordance policy set provides framework contracts contractual entitlements executive directors appointed since following table sets details executive directors service contracts aspect policy current directors date contract effective date expiry date notice period calendar months termination dr jp garnier employing company mr witty executive mr j heslop dr slaoui termination payment x annual salary mr c viehbacher x annual ontarget bonus dr garnier retire board st may mitigation required termination payments made respect part vesting longterm rules relevant equity incentive notice period extending beyond contract expiry dates incentives plan individual pension arrangements pension based existing arrangements individual pension arrangements executive directors refer terms relevant pension plan noncompete clause months termination entitlements notice date addition contractual provisions outlined event executive directors service agreements terminated dr garniers target bonus salary dr slaouis salary mr employing company following would apply heslops salary reviewing level severance payments committee considered investor department business enterprise regulatory case outstanding awards glaxosmithkline annual reform guidance however determined line competitive practice investment plan provided agreement terminated appropriate provide payment salary target bonus termination cause deferred amount income gains imposition month noncompete period executives considered automatically distributed soon administratively practicable vitally important company order protect groups intellectual property light noncompete clause competitor practice committee believes termination resign retire termination would appropriate provide mitigation contracts cause deferred amount distributed end minimum threeyear deferral period approved shareholders glaxosmithkline glaxo wellcome smithkline beecham appropriate n line policy applicable us senior executives dr garnier dr garnier agreed changes previous contractual entitled receive continuing medical dental insurance dr terms without compensation come broadly line new slaoui mr viehbacher members plan may contractual framework including reduction contractual notice become eligible future date receive continuing medical period calendar months however order honour dental cover retirement certain aspects previous contractual terms number following merger participants legacy share individual features retained option schemes elected exchange legacy options retained individual features include entitlement options glaxosmithkline shares receive additional cash reimbursement excise tax change control related payments benefit equal grant price original option life insurance benefit funded company age additional benefit triggered new option exercised lapses qualify additional cash benefit participants relation lti awards subject performance testing retain options least second anniversary share options performance share awards granted within effective date merger months termination notice date lapse however termination company cause retirement outside appointments executive directors resignation good reason ie resignation due outside appointments must approved chairman elected retained director company merged behalf board companys policy remuneration company result change control provided earned appointments may kept individual resignation occurs within days first anniversary executive director change control share options remain exercisable full option termremuneration report continued gsk annual report srotcerid eht fo troper troper noitarenumer nonexecutive director terms conditions fees nonexecutive directors entitled compensation appointment terminated nonexecutive directors glaxosmithkline service contracts instead letters appointment chairman agreed serve company nonexecutive director sir christopher gents letter appointment board dated conclusion annual general meeting following third th may agreed serve company anniversary appointment case extended deputy chairman st december st january term three years mutual agreement directors chairman conclusion annual general serve term longer three years without offering meeting following third anniversary appointment may reelection shareholders company aims provide extended term three years mutual agreement nonexecutive directors fees competitive receives per annum plus allocation companies equivalent size complexity shares value per annum chairman following table shows date initial letter appointment tsr performance graph nonexecutive director following graph sets performance company relative ftse index company constituent nonexecutive date letter performance comparator group st january director appointment st december graph prepared accordance professor sir roy anderson regulations indication likely vesting dr burns awards granted companys incentive plans mr l culp sir crispin davis sir deryck maughan tsr performance dr podolsky sir ian prosser dr r schmitz mr de swaan sir robert wilson fee structure nonexecutive directors follows per annum standard annual cash retainer fee supplemental fees senior independent director audit committee chairman scientificmedical experts chairmen remuneration corporate responsibility committees glaxosmithkline total return index glaxosmithkline pharma peers return index nonexecutive director undertaking ftse total return index intercontinental travel meetings per meeting exchange rate directors senior management remuneration fees paid us dollars converted rate us exchange rate applied th july following tables set directors glaxosmithkline fee arrangements approved board plc remuneration earned interests shares nonexecutive directors share allocation plan glaxosmithkline plc interests share options incentive enhance link directors shareholders glaxosmithkline plans pension benefits members cet requires nonexecutive directors receive significant part company secretary known senior management also fees form shares least nonexecutive directors participate remuneration plans executive directors total fees excluding chairman paid form shares aggregate remuneration interests directors adss allocated share account nonexecutive directors senior management also provided may also take opportunity invest part balance fees share account shares adss notionally awarded nonexecutive directors allocated interest accounts included within directors interests tables accumulated balance shares adss together notional dividends subsequently reinvested paid nonexecutive directors retirement upon retirement nonexecutive directors receive either shares adss cash amount equal value shares adss date retirementremuneration report continued gsk annual report srotcerid eht fo troper troper noitarenumer annual remuneration total total fees annual annual fees annual annual salary benefits bonus remuneration salary benefits bonus remuneration footnote executive directors dr jp garnier ab dr slaoui mr j heslop nonexecutive directors professor sir roy anderson e sir crispin davis sir christopher gent sir ian prosser dr r schmitz mr de swaan sir robert wilson dr burns e mr l culp sir deryck maughan dr podolsky former directors mr j coombe dr barzach c sir richard sykes dr yamada dr l shapiro total remuneration analysed executive directors nonexecutive directors former directors total remuneration remuneration directors us payroll reported dollars dollar amounts included totals based conversion sterling average exchange rates year f ollowing merger order encourage employees convert nonsavings related options held glaxo wellcome smithkline beecham shares adss options glaxosmithkline shares adss employees granted additional cash benefit equal grant price original option additional benefit known exchange offer incentive eoi payable new option exercised lapses market value qualify additional cash benefit participants retain options least second anniversary effective date merger year dr garnier received eoi payments result exercising options granted march november february august options would expired march november exercised full details option exercises given dr yamada received mr coombe received nil b r garnier nonexecutive director united technologies corporation respect received form deferred stock units included c r barzach received fees glaxosmithkline france healthcare consultancy provided included within fees salary lthough dr shapiro retired board th may continues member glaxosmithklines scientific advisory board received fees form adss included within fees salary e r burns joined board nonexecutive director th february professor sir roy anderson joined board st october therefore fees paid none directors received reimbursement expenses year requiring separate disclosure required regulationsremuneration report continued gsk annual report srotcerid eht fo troper troper noitarenumer nonexecutive directors remuneration total cash sharesadss total cash sharesadss fees current nonexecutive directors professor sir roy anderson sir crispin davis sir christopher gent sir ian prosser dr r schmitz mr de swaan sir robert wilson dr burns mr l culp sir deryck maughan dr podolsky former nonexecutive directors dr l shapiro total remuneration table sets remuneration received nonexecutive directors glaxosmithkline include dr shapiros fees received member glaxosmithklines scientific advisory board formation gsk nonexecutive directors required take least part total fees form shares allocated share account paid retirement board least nonexecutive directors fees except chairman see details must taken fee allocation arrangement nonexecutive directors elect receive either part remaining cash payment form shares adss total value shares adss date award together cash payment forms total fees included within annual remuneration table fees salary table sets value fees received form cash shares adss table sets accumulated number shares adss held nonexecutive directors relation fees received board members st december together movements accounts year number shares adss dividends nonexecutive directors share arrangements elected reinvested current nonexecutive directors shares professor sir roy anderson sir crispin davis sir christopher gent sir ian prosser dr r schmitz mr de swaan sir robert wilson adss dr burns mr l culp sir deryck maughan dr podolsky remuneration report continued gsk annual report srotcerid eht fo troper troper noitarenumer directors interests following interests directors connected persons company shown accordance listing rules shares adss nd february st december st january nd february st december st january footnote executive directors dr jp garnier mr witty dr slaoui mr j heslop b mr c viehbacher ae nonexecutive directors professor sir roy anderson df dr burns cf mr l culp f sir crispin davis f sir christopher gent f sir deryck maughan f dr podolsky f sir ian prosser f dr r schmitz f mr de swaan f sir robert wilson f one glaxosmithkline ads represents two glaxosmithkline shares interests abovementioned directors nd february reflect change yearend date ncludes adss purchased glaxosmithkline stock fund within us retirement savings plan us executive supplemental savings plan b ncludes shares purchased glaxosmithkline sharereward plan mr heslop totalling st december st december shares nd february mr witty held shares plan nd february c n case dr burns opening number shares shown th february date joined board p rofessor sir roy anderson joined board st october shares gsk date e mr witty mr viehbacher joined board st january holdings disclosed date nd february mr witty held options maximum shares granted companys share option schemes awards maximum shares companys incentive plans mr viehbacher held options maximum shares adss granted companys share option schemes awards maximum adss made companys incentive plans mr witty mr viehbachers actual entitlement gsk shares plans depend extent performance conditions set time grant award met end respective performance periods f ncludes shares adss received part fees described nonexecutive directors share allocation plan dividends received shares adss converted shares adss st december share options options shares granted footnote date grant exercise period grant price number exercised dr slaoui mr j heslop b options adss granted date grant exercise period grant price number exercised dr jp garnier dr slaoui ab hese details include interests dr slaouis connected person also employee gsk b part main option grant occurred th february vesting period th february th february dr slaoui awarded ads options grant price mr heslop awarded share options grant price gsk annual report srotcerid eht fo troper troper noitarenumer remuneration report continued options outstanding st december earliest latest vesting lapse dates options market price glaxosmithkline share yearend given table nominal vesting date lapse date weighted average dr jp garnier grant price number earliest latest earliest latest market price underwater yearend vested options unvested options market price yearend vested options unvested options total ads options st december nominal vesting date lapse date weighted average dr slaoui grant price number earliest latest earliest latest market price underwater yearend vested options unvested options market price yearend vested options unvested options total share options st december market price underwater yearend unvested options total ads options st december includes share options held dr slaouis connected person also employee gsk nominal vesting date lapse date weighted average mr j heslop grant price number earliest latest earliest latest market price underwater yearend vested options unvested options market price yearend vested options unvested options total share options st december subsequent nominal vesting date remuneration committee meets determine whether required performance criteria satisfied gsk grants share options executive directors senior managers annual basis directors hold options various share option plans referred note financial statements employee share schemes none directors interest option companys shares table sets grants share options respect grant years performance period whether options vested st december performance targets performance target vesting status annualised growth percentage grant performance period eps ifrs award vesting december vested rpi december unvested rpi rpi rpi remuneration report continued gsk annual report srotcerid eht fo troper troper noitarenumer table sets grants share options respect grant years performance period whether options vested st december performance targets performance target vesting status annualised growth percentage grant performance period eps ifrs award vesting february unvested rpi february unvested rpi february unvested rpi rpi rpi grant market options exercised date number price price gain gain dr jp garnier mr j heslop aggregate gain options exercised dr slaoui exercise options period th may st december mr heslop exercise options eoi benefit paid dr garnier exercise options benefit included table highest lowest closing prices year ended st december glaxosmithkline shares respectively highest lowest prices glaxosmithkline adss year ended st december respectively market price glaxosmithkline share st december st december glaxosmithkline ads st december prices nd february per glaxosmithkline share per glaxosmithkline ads incentive plans performance share plan psp awards market additional dr jp garnier adss vested deferred number price ads number unvested granted date market dividends unvested granted performance period grant number price gain lapsed reinvested dr garnier held deferred performance shares yearend included table increase balance relates dividends reinvested year market additional dr slaoui shares adss vested exercised number price shares number unvested granted date market dividends unvested granted performance period grant number price gain lapsed reinvested market additional vested exercised number price ads number unvested granted date market dividends unvested granted performance period grant number price gain lapsed reinvested includes performance shares held dr slaouis connected person also employee gsk gsk annual report srotcerid eht fo troper troper noitarenumer remuneration report continued incentive plans performance share plan psp awards market additional mr j heslop shares vested exercised number price shares number unvested granted date market dividends unvested granted performance period grant number price gain lapsed reinvested psp mediumterm incentive scheme introduced terms psp number shares actually vesting determined following end relevant threeyear measurement period dependent gsks performance period described pages performance share awards previously granted annually november december prior start performance period since grant granted february first year performance period measurement period commences st january ending three years st december awards performance period commencing st january subsequent awards dividends reinvested performance shares awarded executives throughout performance period date final award dividend reinvestment calculated exdividend date terms psp us participants may defer receipt part vested awards total gain vesting psp awards made executive directors psp awards granted executive directors excluding dr slaoui december performance period starting st january ending st december vested part gsks relative tsr performance placed company median comparator group awards made senior executives including dr slaoui dependent part tsr performance part eps performance tsr portion vested part eps portion vested full following vesting schedules apply awards made vesting schedule award performance period tsr rank companies percentage award vesting median median following vesting schedules apply awards made vesting schedule award performance period tsr rank companies percentage award vesting median median tsr measured prorata basis glaxosmithklines performance falls two comparators level vesting determined actual relative level tsr rather simple ranking dividends treated reinvested performance periodremuneration report continued gsk annual report srotcerid eht fo troper troper noitarenumer share value plan awards dr slaoui shares adss market vested exercised number price number unvested granted date market unvested granted plan year grant number price gain lapsed adss adss gain disclosed relates dr slaoui person connected capacity svp worldwide business development dr slaoui eligible participate share value plan dr slaoui connected person employee gsk received awards share value plan following announcement appointment board february ceased eligible receive awards plan awards subject three year vesting periods vesting contingent continued employment gsk vested additional ads vested deferred dividends deferred participations reinvested participations midterm incentive plan adss dr jp garnier midterm incentive plan mtip share award scheme operated smithkline beecham plan closed new entrants upon completion merger participations granted final award adss made receipt award may deferred director dr garnier deferred receipt full amounts vested year deferred awards together additional adss subsequently received dividend reinvestment included directors interests table since retained mtip paid pensions accrued annual pension benefits transfer values executive directors office st december retirement set regulations require disclosure accrued benefit end year change accrued benefit year transfer value beginning end year change transfer value year listing rules require additional disclosure change accrued benefit net inflation transfer value change pensions executive directors disclosed currency pension payable change change personal accrued transfer value accrued accrued accrued contributions transfer transfer change benefit change benefit benefit benefit made value value transfer year net accrued year year value inflation benefit executive directors dr jp garnier dr slaoui mr j heslop shown net contributions made individual dr garnier member employee us cash balance pension plan gsk makes annual contributions calculated percentage employees base salary bonus gsk makes annual contributions dr garniers annual salary bonus detailed contract fund increases interest rate set annually advance based year us treasury bond rate provide cash sum retirement cash sum used purchase pension retirement based annuity rates applicable time plan entitlement spouses pension pension increases reducing executives initial pension transfer value cash sum dr garniers plan increased year result accumulation interest contributions paid company dr garnier retire company st may remuneration report continued gsk annual report srotcerid eht fo troper troper noitarenumer pensions directors senior management effect st june dr slaoui became member information also provided compensation interests us executive cash balance pension plan gsk directors senior management group group makes annual contributions calculated percentage purpose group defined executive non executives base salary gsk makes annual contributions executive directors members cet company dr slaouis annual salary fund increases interest rate set secretary financial year total compensation annually advance based year us treasury bond rate paid members group periods provide cash sum retirement cash sum used purchase served capacity aggregate increase pension retirement based annuity rates applicable accrued pension benefits net inflation time plan entitlement spouses pension aggregate payment defined contribution schemes pension increases reducing executives also accrued year amount initial pension relating compensation loss office respect associated pension contributions transfer value cash sum dr slaouis plan increased year result accumulation members group granted interest contributions paid company share options ads options share option scheme shares adss performance dr slaoui active participant belgium fortis plan share plan awarded shares adss st may plan defined benefit plan lump share value plan members group also awarded sum payable normal retirement age plan shares adss reinvestment dividends years age transfer value cash sum dr slaouis plan performance share plan increased year result accumulation interest nd february group comprising persons owned shares adss constituting less mr heslop participates glaxo wellcome defined benefit issued share capital company group also held plan accrual rate th final pensionable salary per date options purchase shares annum benefits accrued glaxo wellcome adss shares adss awarded uk pension arrangements augmented trustees performance share plan including shares adss plans reflect distribution surplus augmentation vested deferred vested deferred adss apply element mr heslops pension earnings legacy smithkline beecham midterm incentive plan st march shares adss awarded share value mr heslops transfer value calculated basis plan holdings issued various executive share actuarial advice accordance actuarial guidance note gn option plans described note financial statements transfer value represents present value future payments employee share schemes made pension plan mr heslops annual accrued benefit increased excluding effects directors interests contracts inflation transfer value less personal contributions except described note financial statements related increased year increase mr heslops party transactions end financial year pensionable salary primary reason increase director connected person material interest transfer value contract significance relation groups business dr garnier dr slaoui also members us retirement group company savings plan k savings scheme open us employees executive supplemental savings plan savings scheme open executives accrue benefits us government limits imposed directors remuneration report approved retirement savings plan contributions plans board directors signed behalf invested range funds value accumulated funds paid retirement contributions paid two schemes gsk respect dr garnier respect dr slaoui contributions sir christopher gent paid scheme chairman th february gsk annual report stnemetats laicnanif financial statements directors statements responsibility independent auditors report financial statements consolidated income statement consolidated balance sheet consolidated cash flow statement consolidated statement recognised income expense notes financial statements presentation financial statements accounting policies key accounting judgements estimates new accounting requirements exchange rates segment information restructuring costs operating income operating profit employee costs finance income finance costs associates joint ventures taxation earnings per share dividends property plant equipment goodwill intangible assets investments associates joint ventures investments noncurrent assets inventories trade receivables cash cash equivalents assets held sale trade payables pensions postemployment benefits provisions noncurrent liabilities contingent liabilities net debt share capital share premium account movements equity related party transactions reconciliation profit tax operating cash flows reconciliation net cash flow movement net debt acquisitions disposals commitments post balance sheet events financial instruments related disclosures employee share schemes principal group companies legal proceedings financial statements glaxosmithkline plc prepared uk gaap directors statements responsibility directors statement responsibility relation directors remuneration consolidated financial statements remuneration report pages sets remuneration directors responsible policies operated glaxosmithkline disclosures directors remuneration disclosable information relating directors ensuring maintenance proper accounting records officers interests prepared accordance disclose reasonable accuracy financial position group companies acts complies section time financial statements prepared b combined code corporate governance comply companies acts article ias regulation going concern basis preparing financial statements financial period making enquiries directors reasonable give true fair view accordance ifrs adopted expectation group adequate resources continue use european union state affairs group operational existence foreseeable future reason end financial period profit loss continue adopt going concern basis preparing period financial statements ensuring operation systems internal control taking reasonable steps safeguard assets group internal control preventing detecting fraud irregularities board audit committee reviewed directors confirm complied assessment risks internal control framework operates requirements preparing financial statements glaxosmithkline considered effectiveness system internal control operation group year financial statements year ended st december covered report date approval comprising principal statements supporting notes set board directors financial statements pages report directors confirm suitable accounting policies combined code consistently applied preparation financial statements board considers glaxosmithkline plc applies principles supported reasonable prudent judgements estimates combined code corporate governance financial necessary reporting council described corporate governance responsibilities auditors relation financial pages complied provisions except statements set independent auditors report described opposite required listing rules financial services authority financial statements year ended st december auditors considered directors statement compliance included annual report published hard relation points combined code specified copy printed form made available website directors review responsible maintenance integrity annual report website accordance uk legislation governing annual report preparation dissemination financial statements access annual report year ended st december website available outside uk comparable comprising report directors remuneration report legislation may different financial statements additional information investors approved board directors signed behalf disclosure information auditors directors office date report confirmed far aware relevant audit information companys auditors unaware director taken steps heshe ought taken director make himselfherself aware relevant sir christopher gent audit information establish companys auditors chairman aware information th february confirmation given interpreted accordance provisions section za companies act gsk annual report stnemetats laicnanif ytilibisnopser fo stnemetats srotceridindependent auditors report members glaxosmithkline plc audited group financial statements glaxosmithkline basis audit opinion year ended st december comprise primary conducted audit accordance international standards financial statements consolidated income statement auditing uk ireland issued auditing practices board consolidated balance sheet consolidated cash flow statement audit includes examination test basis evidence relevant consolidated statement recognised income expense amounts disclosures group financial statements also related notes group financial statements includes assessment significant estimates judgements made prepared accounting policies set therein directors preparation group financial statements reported separately parent company financial whether accounting policies appropriate groups statements glaxosmithkline year ended st december circumstances consistently applied adequately disclosed information directors remuneration report planned performed audit obtain described audited information explanations considered necessary order provide us sufficient evidence give reasonable respective responsibilities directors assurance group financial statements free material auditors misstatement whether caused fraud irregularity error directors responsibilities preparing annual report forming opinion also evaluated overall adequacy group financial statements accordance applicable law presentation information group financial statements international financial reporting standards ifrss adopted european union set statement directors opinion responsibilities opposite opinion responsibility audit group financial statements group financial statements give true fair view accordance relevant legal regulatory requirements accordance ifrss adopted european union international standards auditing uk ireland report state groups affairs st december including opinion prepared companys profit cash flows year ended members body accordance section companies act purpose giving opinion group financial statements properly prepared accept assume responsibility purpose accordance companies act article ias person report shown whose hands may come regulation save expressly agreed prior consent writing information given report directors consistent report opinion whether group financial group financial statements statements give true fair view whether group financial statements properly prepared accordance separate opinion relation ifrss companies act article ias regulation also report explained note group financial statements group whether opinion information given report addition complying legal obligation comply directors consistent group financial statements ifrss adopted european union also complied addition report opinion received ifrss issued international accounting standards board information explanations require audit opinion group financial statements give true fair information specified law regarding directors remuneration view accordance ifrss state groups affairs transactions disclosed st december profit cash flows year review whether corporate governance statement reflects ended companys compliance nine provisions combined code specified review listing rules financial services authority report required consider whether boards statements internal pricewaterhousecoopers llp control cover risks controls form opinion chartered accountants registered auditors effectiveness groups corporate governance procedures london risk control procedures th february read information contained annual report consider whether consistent audited group financial statements notes information comprises financial summary joint maintenance integrity glaxosmithkline website statement chairman chief executive financial trends responsibility directors work carried auditors involve consideration matters accordingly auditors accept ratios business review corporate governance statement responsibility changes may occurred financial consider implications report become aware statements since initially presented website apparent misstatements material inconsistencies b legislation united kingdom governing preparation dissemination group financial statements responsibilities extend financial information may differ legislation jurisdictions information gsk annual report stnemetats laicnanif troper srotidua tnednepedni gsk annual report stnemetats laicnanif tnemetats emocni detadilosnoc consolidated income statement year ended st december business restructuring notes performance costs total turnover cost sales gross profit selling general administration research development operating income operating profit finance income finance costs share tax profits associates joint ventures profit taxation taxation profit taxation year profit attributable minority interests profit attributable shareholders basic earnings per share pence p p p diluted earnings per share pence p p p calculation business performance supplemental nonifrs measure described note presentation financial statementsconsolidated balance sheet st december notes noncurrent assets property plant equipment goodwill intangible assets investments associates joint ventures investments deferred tax assets derivative financial instruments noncurrent assets total noncurrent assets current assets inventories current tax recoverable trade receivables derivative financial instruments liquid investments cash cash equivalents assets held sale total current assets total assets current liabilities shortterm borrowings trade payables derivative financial instruments current tax payable shortterm provisions total current liabilities noncurrent liabilities longterm borrowings deferred tax liabilities pensions postemployment benefits provisions derivative financial instruments noncurrent liabilities total noncurrent liabilities total liabilities net assets equity share capital share premium account retained earnings reserves shareholders equity minority interests total equity approved board th february sir christopher gent chairman gsk annual report stnemetats laicnanif teehs ecnalab detadilosnoc gsk annual report stnemetats laicnanif tnemetats wofl hsac detadilosnoc consolidated cash flow statement year ended st december notes cash flow operating activities cash generated operations taxation paid net cash inflow operating activities cash flow investing activities purchase property plant equipment proceeds sale property plant equipment proceeds sale intangible assets purchase intangible assets purchase equity investments proceeds sale equity investments share transactions minority shareholders purchase businesses net cash acquired disposal businesses interest associates investments associates joint ventures interest received dividends associates joint ventures net cash outflow investing activities cash flow financing activities increasedecrease liquid investments proceeds shares employee share options shares acquired esop trusts issue share capital purchase shares cancellation purchase treasury shares increase longterm loans repayment longterm loans net increase inrepayment shortterm loans net repayment obligations finance leases interest paid dividends paid shareholders dividends paid minority interests financing cash flows net cash outflow financing activities increasedecrease cash bank overdrafts exchange adjustments cash bank overdrafts beginning year cash bank overdrafts end year cash bank overdrafts end year comprise cash cash equivalents overdrafts consolidated statement recognised income expense year ended st december exchange movements overseas net assets tax exchange movements fair value movements availableforsale investments deferred tax fair value movements availableforsale investments exchange movements goodwill reserves actuarial gainslosses defined benefit plans deferred tax actuarial movements defined benefit plans fair value movements cash flow hedges deferred tax fair value movements cash flow hedges net profitslosses recognised directly equity profit year total recognised income expense year total recognised income expense year attributable shareholders minority interests gsk annual report stnemetats laicnanif esnepxe dna emocni desingocer fo tnemetats detadilosnoc gsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot seton notes financial statements presentation financial statements accounting principles policies preparation financial statements conformity description business generally accepted accounting principles requires management glaxosmithkline major global healthcare group engaged make estimates assumptions affect reported amounts creation discovery development manufacture assets liabilities disclosure contingent assets liabilities marketing pharmaceutical products including vaccines overthe date financial statements reported amounts counter otc medicines healthrelated consumer products revenues expenses reporting period actual results gsks principal pharmaceutical products include medicines could differ estimates following therapeutic areas respiratory central nervous system antivirals antibacterials metabolic vaccines cardiovascular financial statements prepared accordance urogenital antibacterial oncology emesis groups accounting policies approved board described note accounting policies information application compliance applicable law ifrs accounting policies including areas estimation judgement financial statements prepared accordance given note key accounting judgements estimates companies act article ias regulation group implemented ifrs financial instruments international accounting standards ias international financial disclosures amends adds previous disclosures relating reporting standards ifrs related interpretations adopted financial instruments european union parent company financial statements financial statements also compliance ifrs issued financial statements parent company glaxosmithkline international accounting standards board plc prepared accordance uk gaap uk composition financial statements accounting presentation company balance sheet presented consolidated financial statements drawn sterling functional currency glaxosmithkline plc accordance ifrs accounting presentation financial statements comprise accounting policies consolidated income statement consolidation consolidated balance sheet consolidated financial statements include consolidated cash flow statement assets liabilities results cash flows consolidated statement recognised income expense company subsidiaries including esop trusts notes financial statements groups share results net assets associates accounting convention joint ventures financial statements prepared using historical cost financial statements entities consolidated made st convention modified revaluation certain items stated december year accounting policies entities group power govern financial financial period operating policies accounted subsidiaries financial statements cover financial year st january group ability exercise joint control entities st december comparative figures financial years accounted joint ventures group ability st january st december appropriate exercise significant influence accounted associates st january st december results assets liabilities associates joint ventures composition group incorporated consolidated financial statements using list subsidiary associated undertakings opinion equity method accounting directors principally affected amount profit net interests acquired entities consolidated date assets group given note principal group companies group acquires control interests sold deconsolidated presentation business performance date control ceases columnar presentation adopted income transactions balances subsidiaries eliminated statement order illustrate underlying business performance profit tax taken sales subsidiaries sales business performance supplemental nonifrs measure joint ventures associates products sold customers primary performance measure used management outside group deferred tax relief unrealised intragroup profit presented excluding costs relating new operational accounted extent considered recoverable excellence programme commenced october significant acquisitions management believes exclusion goodwill arising acquisition interests subsidiaries joint items provides better reflection way business ventures associates representing excess acquisition managed gives useful indication underlying cost groups share fair values identifiable performance group information provided assets liabilities contingent liabilities acquired capitalised addition total results prepared ifrs given assist separate item case subsidiaries part cost shareholders gain clearer understanding underlying investment case joint ventures associates goodwill performance business increase comparability denominated currency operation acquired periods presented cost acquisition fair value net assets acquired difference recognised directly income statementnotes financial statements continued accounting policies continued research development research development expenditure charged income foreign currency translation statement period incurred development foreign currency transactions booked functional currency expenditure capitalised criteria recognising asset group company exchange rate ruling date met usually regulatory filing made major transaction foreign currency monetary assets liabilities market approval considered highly probable property plant retranslated functional currency rates exchange ruling equipment used research development depreciated balance sheet date exchange differences included accordance groups policy income statement environmental expenditure consolidation assets liabilities including related goodwill environmental expenditure related existing conditions resulting overseas subsidiaries associates joint ventures translated past current operations current future sterling rates exchange ruling balance sheet date benefit discernible charged income statement group results cash flows overseas subsidiaries associates joint recognises liability sitebysite basis reliably ventures translated sterling using average rates exchange estimated liability includes groups portion total costs exchange adjustments arising opening net assets also portion potentially responsible parties costs profits year retained overseas subsidiaries associates probable able satisfy respective joint ventures translated sterling less exchange differences shares cleanup obligation recoveries reimbursements arising related foreign currency borrowings hedge recorded assets virtually certain groups net investment operations taken separate component equity legal disputes provision made anticipated settlement costs legal translating sterling assets liabilities results cash disputes group outflow resources flows overseas subsidiaries associates joint ventures considered probable reasonable estimate made reported currencies hyperinflationary economies adjustments likely outcome addition provision made legal made reflect current price levels loss net monetary expenses arising claims received disputes assets charged consolidated income statement respect product liability claims related products revenue sufficient history claims made settlements incurred revenue recognised income statement goods reported ibnr actuarial technique used determine services supplied made available external customers reasonable estimate groups exposure unasserted claims orders received title risk loss passed customer products provision made basis reliable estimates made relevant deductions turnover provision made unasserted claims represents net invoice value deduction discounts obligation exists dispute possible make allowances given accruals estimated future rebates reasonable estimate costs associated claims made returns methodology assumptions used estimate rebates group third parties charged income statement returns monitored adjusted regularly light incurred contractual legal obligations historical trends past experience projected market conditions market conditions evaluated pensions postemployment benefits using wholesaler thirdparty analyses market research costs providing pensions defined benefit schemes data internally generated information turnover also includes co calculated using projected unit credit method spread promotion income group records share revenue period benefit expected derived related cost sales value added tax sales taxes employees services accordance advice qualified excluded revenue actuaries pension obligations measured present value estimated future cash flows discounted rates reflecting yields expenditure high quality corporate bonds expenditure recognised respect goods services received supplied accordance contractual terms provision pension scheme assets measured fair value balance sheet made obligation exists future liability respect date actuarial gains losses differences expected past event amount obligation actual returns assets effect changes actuarial reliably estimated manufacturing startup costs validation assumptions recognised statement recognised income achievement normal production expensed expense year arise groups contributions incurred advertising promotion expenditure charged defined contribution plans charged income statement income statement incurred shipment costs intercompany incurred transfers charged cost sales distribution costs sales costs postemployment liabilities calculated customers included selling general administrative similar way defined benefit pension schemes spread expenditure restructuring costs recognised provided period benefit expected derived appropriate respect direct expenditure business employees services accordance advice reorganisation plans sufficiently detailed well qualified actuaries advanced appropriate communication affected undertaken gsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot setonnotes financial statements continued accounting policies continued goodwill goodwill stated cost less impairments goodwill deemed employee share plans indefinite useful life tested impairment annually incentives form shares provided employees share option share award schemes fair value interest acquired entitys assets liabilities contingent liabilities exceeds consideration fair values options awards calculated paid excess recognised immediately gain grant dates using blackscholes option pricing model charged income statement income statement relevant vesting periods intangible assets group provides finance esop trusts purchase company intangible assets stated cost less provisions amortisation shares open market meet obligation provide shares impairments employees exercise options awards costs running esop trusts charged income statement shares held licences patents knowhow marketing rights separately esop trusts deducted reserves transfer acquired acquired part business combination amortised made reserves retained earnings vesting estimated useful lives using straightline basis periods related share options awards reflect ultimate time available use estimated useful lives proceeds receivable employees exercise determining amortisation charge take account patent lives applicable well value obtained periods property plant equipment nonexclusivity asset lives reviewed appropriate property plant equipment ppe stated cost purchase adjusted annually development costs incurred group construction less provisions depreciation impairment associated acquired licences patents knowhow marketing financing costs capitalised rights written income statement incurred unless depreciation calculated write cost less residual value criteria recognition internally generated intangible asset ppe excluding freehold land using straightline basis met usually regulatory filing made major expected useful life residual values lives reviewed market approval considered highly probable appropriate adjusted annually normal expected useful acquired brands valued independently part fair value lives major categories ppe businesses acquired third parties brand value substantial longterm brands freehold buildings years sold separately rest businesses acquired brands leasehold land lease term years amortised estimated useful lives except buildings considered useful economic life indefinite plant machinery years fixtures equipment years costs acquiring developing computer software internal use internet sites external use capitalised intangible disposal ppe cost related accumulated depreciation fixed assets software site supports significant business impairments removed financial statements system expenditure leads creation durable asset net amount less proceeds taken income statement erp systems software amortised seven years leases computer software three five years leasing agreements transfer group substantially impairment noncurrent assets benefits risks ownership asset treated finance carrying values noncurrent assets reviewed leases asset purchased outright assets impairment indication assets might included ppe computer software capital elements impaired additionally goodwill intangible assets indefinite leasing commitments shown obligations finance useful lives intangible assets yet available use leases assets held finance leases depreciated basis tested impairment annually provision impairment consistent similar owned assets lease term shorter charged income statement year concerned interest element lease rental included income statement leases operating leases rental costs investments associates joint ventures charged income statement straightline basis investments associates joint ventures carried lease term consolidated balance sheet groups share net assets date acquisition postacquisition retained profits losses together goodwill arising acquisition gsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot setonnotes financial statements continued accounting policies continued taxation current tax provided amounts expected paid applying availableforsale investments tax rates enacted substantively enacted liquid investments investments classified available balance sheet date forsale investments initially recorded fair value plus transaction costs remeasured subsequent reporting deferred tax provided full using liability method dates fair value unrealised gains losses availablefor temporary differences arising tax bases assets sale investments recognised directly equity impairments liabilities carrying amounts financial statements arising significant prolonged decline fair value deferred tax assets recognised extent probable investment reduce carrying amount asset directly future taxable profits available temporary charged income statement disposal impairment differences utilised investments gains losses deferred deferred tax provided temporary differences arising equity recycled income statement dividends equity investments subsidiaries associates joint ventures except investments recognised income statement timing reversal temporary difference groups right receive payment established equity investments controlled probable temporary difference recorded noncurrent assets unless expected reverse foreseeable future sold within one year deferred tax provided using rates tax enacted purchases sales equity investments accounted substantively enacted balance sheet date deferred tax trade date purchases sales availableforsale liabilities assets discounted investments accounted settlement date derivative financial instruments hedging inventories derivative financial instruments used manage exposure inventories included financial statements lower market risks treasury operations principal derivative cost including raw materials direct labour direct costs instruments used glaxosmithkline foreign currency swaps related production overheads net realisable value cost interest rate swaps forward foreign exchange contracts generally determined first first basis prelaunch inventory group hold issue derivative financial instruments held asset high probability regulatory trading speculative purposes approval product point provision made carrying value recoverable amount provision derivative financial instruments classified heldfortrading reversed point high probability regulatory carried balance sheet fair value derivatives designated approval determined hedging instruments classified inception cash flow hedges net investment hedges fair value hedges trade receivables trade receivables carried original invoice amount less changes fair value derivatives designated cash flow provisions doubtful debts provisions made hedges recognised equity extent hedges evidence risk nonpayment taking account ageing effective ineffective portions recognised profit loss previous experience general economic conditions immediately amounts deferred equity recycled income trade receivable determined uncollectable written statement hedged item affects profit loss firstly provision available income net investment hedges accounted similar way cash statement subsequent recoveries amounts previously provided flow hedges credited income statement longterm receivables discounted effect material changes fair value derivatives designated fair value hedges recorded income statement together trade payables changes fair value hedged asset liability trade payables held amortised cost equates nominal value longterm payables discounted effect changes fair value derivative instruments material qualify hedge accounting recognised immediately income statement cash cash equivalents cash cash equivalents comprise cash hand current balances discounting banks similar institutions highly liquid investments time effect money material balances discounted original maturities three months less readily current values using appropriate rates interest unwinding convertible known amounts cash insignificant discounts recorded finance incomecosts risk changes value gsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot seton gsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot seton notes financial statements continued key accounting judgements estimates companys directors taken legal advice established provisions taking account relevant facts preparing financial statements management required circumstances matter accordance accounting make estimates assumptions affect amounts assets requirements provisions product liability claims certain liabilities revenue expenses reported financial statements products made incurred reported basis actual amounts results could differ estimates sufficient history claims made settlements available following considered key accounting judgements estimates made provisions made unasserted claims claims reasonable estimate likely outcome turnover yet made ultimate liability pending unasserted claims revenue recognised title risk loss passed may vary amounts provided dependent upon customer reliable estimates made relevant deductions outcome litigation proceedings investigations possible gross turnover reduced rebates discounts allowances settlement negotiations product returns given expected given vary product arrangements buying groups arrangements property plant equipment purchasing organisations dependent upon submission carrying values property plant equipment reviewed claims time initial recognition sale accruals impairment indication values made time sale estimated rebates discounts assets might impaired impairment determined reference allowances payable returns made based available higher fair value less costs sell value use measured market information historical experience amounts assessing riskadjusted future cash flows discounted using appropriate estimated may fully reflect final outcome interest rates future cash flows based business forecasts amounts subject change dependent upon amongst therefore inherently judgemental future events could cause things types buying group product sales mix level assumptions used impairment reviews change accrual reviewed adjusted regularly light contractual consequent adverse effect future results group legal obligations historical trends past experience projected intangible assets market conditions market conditions evaluated using wholesaler intangible assets acquired gsk third parties thirdparty analyses market research data internally costs acquisition capitalised licences compounds generated information future events could cause assumptions development amortised point accruals based change could affect available use estimated useful lives may future results group include periods nonexclusivity estimated useful lives reviewed group copromotes product third party records annually impairment tests undertaken events occur sale group records share revenue copromotion call question carrying values assets brands acquired income within turnover nature copromotion activities businesses capitalised independently group records costs sales pharmaceutical turnover separable expected life one year brands includes copromotion revenue million million amortised estimated useful lives exceeding million years except end useful economic life foreseen brands amortised subject taxation annual impairment tests impairment tests based riskadjusted current tax provided amounts expected paid future cash flows discounted using appropriate interest rates deferred tax provided temporary differences future cash flows based business forecasts therefore tax bases assets liabilities carrying amounts inherently judgemental future events could cause values rates enacted substantively enacted intangible assets impaired would adverse balance sheet date effect future results group group open tax issues number revenue authorities pensions postemployment benefits gsk uses best advice determining transfer pricing costs providing pensions postemployment benefits methodology seeking manage transfer pricing issues charged income statement accordance ias satisfactory conclusion basis external professional period benefit derived employees advice continues believe made adequate provision services costs assessed accordance advice received liabilities likely arise open assessments open issues independent actuaries basis assumptions selected exist ultimate liability matters may vary amounts management assumptions include future earnings provided dependent upon outcome negotiations pension increases discount rates expected long term rates relevant tax authorities necessary litigation proceedings return assets disclosed note pensions legal disputes postemployment benefits expected long term rates return gsk provides anticipated settlement costs reasonable bonds determined based portfolio mix indexlinked estimate may made likely outcome dispute legal government corporate bonds equity risk premium added expenses arising claims group equitiesnotes financial statements continued key accounting judgements estimates continued ifrs revised business combinations issued january apply business combinations arising st january discount rates based appropriate longterm indices including amongst changes new standard require iboxx year aa index uk moodys aa index recognition subsequent changes fair value contingent usa sensitivity analysis provided note pensions consideration income statement rather goodwill postemployment benefits reduction transaction costs recognised immediately income discount rate would lead increase net pension statement fair value gains losses existing investments deficit approximately million increase annual acquired company recognised income statement pension cost approximately million selection different date acquisition assumptions could affect future results group ias revised consolidated separate financial statements new accounting requirements issued january implemented time ifrs revised respect transactions non following ifrs ifric interpretations issued controlling interests group entities result change iasb likely affect future annual reports although none control revised standard requires difference expected material impact results financial position consideration paid received recorded noncontrolling group interest recognised equity case divestment ifric ifrs group treasury share transactions issued subsidiary retained interest remeasured fair value november required implemented gsk difference fair value previous carrying value st january interpretation provides guidance recognised immediately income statement whether sharebased transactions involving group entities ifrs revised ias revised applied prospectively accounted equity settled cash settled transactions transactions occurring implementation date therefore ifric ias limit defined benefit asset minimum possible assess advance impact financial funding requirements interaction issued july statements group effective st january interpretation exchange rates provides general guidance amount pension surplus may recognised asset group uses average exchange rates prevailing period translate results cash flows overseas subsidiaries ifrs operating segments issued november joint ventures associated undertakings sterling period required implemented gsk st january end rates translate net assets undertakings standard replaces ias aligns segmental reporting currencies influence translations relevant requirements equivalent us standard new exchange rates standard adopts management approach segmental information disclosed basis used internal reporting purposes average rates us ias revised borrowing costs issued march euro implemented prospectively st january requires yen borrowing costs attributable acquisition construction certain assets capitalised option currently taken gsk period end rates expensing costs incurred longer available us euro ias revised presentation financial statements issued yen september effective st january amendments standard mandate various presentation formats disclosures many already adopted gsk movements equity presented statement changes equity rather note financial statements amendment ifrs sharebased payment relating vesting conditions cancellations issued january amendment apply retrospectively st january specifies cancellations sharebased payment arrangements including employee counterparty receive accounting treatment requiring immediate recognition income statement charge would otherwise recognised remainder service period gsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot seton gsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot seton notes financial statements continued segment information groups primary segment reporting business sector geographical reporting secondary format business sectors consist pharmaceuticals prescription pharmaceuticals vaccines consumer healthcare oral care otc medicines nutritional healthcare geographical sectors usa europe international rest world markets reflect groups significant regional markets consistent groups regional market management reporting structure business sector data includes allocation corporate costs sector appropriate basis sales business sectors groups activities organised global basis geographical sector figures therefore influenced location groups operating resources particular manufacturing research variations time intragroup trading funding arrangements turnover shown business sector location customer location subsidiary operating profit shown business sector location subsidiary geographic information given location subsidiary turnover business sector pharmaceuticals consumer healthcare turnover profit business sector pharmaceuticals consumer healthcare operating profit finance income finance costs share tax profits associates joint ventures pharmaceuticals consumer healthcare profit taxation taxation profit taxation year investments associates joint ventures business sector pharmaceuticals consumer healthcare investment associates joint ventures property plant equipment intangible assets business sector additions pharmaceuticals consumer healthcare total additions depreciationamortisation pharmaceuticals consumer healthcare total depreciationamortisation impairment pharmaceuticals consumer healthcare total impairment impairment reversal pharmaceuticals consumer healthcare total impairment reversal notes financial statements continued segment information continued total assets business sector pharmaceuticals consumer healthcare total operating assets investments associates joint ventures liquid investments derivative financial instruments cash cash equivalents current deferred taxation tangible assets held sale total assets total liabilities business sector pharmaceuticals consumer healthcare total operating liabilities shortterm borrowings longterm borrowings derivative financial instruments current deferred taxation total liabilities net assets business sector pharmaceuticals consumer healthcare net operating assets net debt investments associates joint ventures derivative financial instruments current deferred taxation tangible assets held sale net assets turnover location customer usa europe international turnover gsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot seton gsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot seton notes financial statements continued segment information continued turnover location subsidiary undertaking usa europe international turnover including intersegment turnover usa europe international intersegment turnover usa europe international external turnover operating profit location subsidiary undertaking usa europe international operating profit property plant equipment intangible asset additions location usa europe international total additions total assets location usa europe international intersegment trading balances total operating assets gsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot seton notes financial statements continued segment information continued net operating assets location usa europe international net operating assets uk segment uk included groups europe market region turnover location customer turnover including intersegment turnover intersegment turnover turnover location subsidiary noncurrent assets gsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot seton notes financial statements continued restructuring costs gsk undertaken significant new operational excellence programme improve effectiveness productivity operations programme expected deliver total annual pretax savings million savings realised across business manufacturing gsk reduce overall number sites operating network simplify processes site activities reduce capacity group also continue seek opportunities outsource manufacturing existing products lowcost sourcing materials whilst focusing capability new products gsk conducted several sales force pilot initiatives assess new sales structures selling techniques results initiatives provided gsk new opportunities evolve traditional selling methods competitively including adopting tailored customised sales approaches developed emerging markets rd gsk continue invest development promising latestage pipeline increase investment key areas future growth biopharmaceuticals oncology vaccines neuroscience emerging markets china cost savings rd focused simplification streamlining support infrastructure total oneoff costs implementation new programme expected approximately billion incurred period addition december gsk acquired reliant pharmaceuticals inc usa rationalisation restructuring programme initiated part integration reliant pharmaceuticals group although costs incured programme asset staff impairment reductions total cost sales selling general administration research development effect profit taxation effect taxation effect earnings restructuring costs reported middle column income statement operating income royalty milestone income impairment equity investments disposal equity investments disposal assets legal settlements fair value adjustments derivative financial instruments income royalty milestone income principally core recurring income outlicensing intellectual property fair value adjustments derivative financial instruments include movements quest collar theravance put call optionsnotes financial statements continued operating profit following items included operating profit employee costs note advertising distribution costs depreciation property plant equipment amortisation intangible assets net foreign exchange gainslosses inventories cost inventories included cost sales writedown inventories reversal prior year writedown inventories operating lease rentals minimum lease payments contingent rents sublease payments fees payable companys auditor audit parent company consolidated financial statements fees payable companys auditor associates services reversals prior year writedowns inventories principally arise reassessment usage demand expectations prior inventory expiration fees payable companys auditor associates services audit accounts groups uk overseas subsidiaries related pension schemes company pursuant legislation assurance services pursuant legislation tax services services including regulatory compliance treasury related services st december amount due pricewaterhousecoopers llp associates fees yet invoiced million comprising statutory audit million taxation services million services million fees respect glaxosmithkline uk pension schemes included audit services gsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot seton gsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot seton notes financial statements continued employee costs wages salaries social security costs pension postemployment costs including augmentations note cost sharebased incentive plans severance costs integration restructuring activities group provides benefits employees commensurate local practice individual countries including markets healthcare insurance subsidised car schemes personal life assurance average number persons employed group including directors year number number number manufacturing selling general administration research development average number group employees excludes temporary contract staff number group employees end financial year given financial record average number persons employed glaxosmithkline plc nil nil compensation directors senior management members cet company secretary aggregate follows wages salaries social security costs pension postemployment costs cost sharebased incentive plans finance income interest income arising cash cash equivalents availableforsale investments derivatives fair value profit loss loans receivables realised gains liquid investments fair value adjustments derivatives fair value profit loss net investment hedge ineffectiveness unwinding discounts assets derivatives fair value profit loss designated effective hedging instruments see note financial instruments related disclosures classified heldfortrading financial instruments ias interest income arising derivatives fair value profit loss relates swap interest incomenotes financial statements continued finance costs interest expense arising financial liabilities amortised cost derivatives fair value profit loss fair value hedges fair value adjustments derivatives designated hedging instruments fair value adjustments hedged items fair value adjustments derivatives fair value profit loss unwinding discounts provisions derivatives fair value profit loss except designated effective hedging instruments classified heldfortrading financial instruments ias associates joint ventures associates share tax profits quest diagnostics inc share tax losses associates share tax profitslosses joint ventures share turnover joint ventures sales joint ventures associates summarised income statement information respect groups associates set total turnover total profit gsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot seton gsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot seton notes financial statements continued taxation taxation charge based profits year uk corporation tax uk statutory rate less double taxation relief overseas taxation current taxation deferred taxation reconciliation taxation rate group profits uk statutory rate taxation overseas taxes benefit special tax status rd credits intercompany stock profit impact share based payments tax profit associates differences prior year items restructuring tax rate group operates countries tax rate differs uk tax rate impact overseas taxes companys overall rate tax shown profits arising certain operations singapore puerto rico ireland accorded special status taxed reduced rates compared normal rates tax territories effect reduction taxation charge increased earnings per share p p p group required ifrs create deferred tax asset respect unrealised intercompany profit arising inventory held group yearend applying tax rate country inventory held rather tax rate country profit originally made tax paid practice uk us gaap result difference accounting treatment group tax rate ifrs decreased decrease increase result changes workinprogress finished goods integrated nature groups worldwide operations involving significant investment research strategic manufacture limited number locations consequential crossborder supply routes numerous endmarkets gives rise complexity delay negotiations revenue authorities profits individual group companies liable tax resolution issues continuing fact life gsk groups main open tax issues uk us canada japan gsk continues dispute hmrc primarily respect transfer pricing controlled foreign companies cfc matters years date hmrc yet formalised claims respect matters gsk seeking resolve discussions hmrc continues however wide difference group hmrc positions may ultimately need settled litigation following audit period irs notices proposed adjustment challenged deductions arising intercompany financing arrangements years gsk disagrees vigorously contest gsk estimates irs claim tax interest st december net federal tax relief years million gsk believes supported external professional advice claim merit adjustment warranted contrary gsks view irs prevailed argument court company would expect additional liability four year unaudited period proportionate liability three year audited period event company able resolve issue irs court decision would expected lower courts japan upheld claims tax authorities yen billion million relating japanese cfc legislation company paid fully provided full tax pursuing claim refund japanese supreme court canada court hearing respect transfer pricing early completed july gsk still awaiting courts judgementgsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot seton notes financial statements continued taxation continued gsk uses best advice determining transfer pricing methodology seeking manage transfer pricing taxation issues satisfactory conclusion basis external professional advice continues believe made adequate provision liabilities likely arise open assessments ultimate liability matters may vary amounts provided dependent upon outcome litigation proceedings negotiations relevant tax authorities provision made taxation would arise distribution profits retained overseas subsidiary associated undertakings grounds remittance profit retained st december required way incremental tax arise aggregate amount unremitted profits balance sheet date approximately billion billion payable recoverable net movement current tax account st january exchange adjustments charge year cash paid transfer tofrom deferred tax movements st december movement deferred tax assets liabilities pensions manu share accelerated intra post legal facturing stock option net offset deferred taxation capital group retirement tax restruct valuation award temporary within allowances intangibles profit benefits losses disputes uring adjustments schemes differences countries total assetliability deferred tax asset st january deferred tax liability st january st january exchange adjustments creditcharge income statement creditcharge equity transfer tofrom current tax acquisitions st december deferred tax assets st december deferred tax liability st december deferred tax credit income relating changes tax rates million deferred tax movements arise origination reversal temporary differences net temporary differences include accrued expenses provisions st december group recognised deferred tax asset million million respect income tax losses approximately million million losses million million due expire million nil due expire million million due expire million million available indefinitely st december group recognised deferred tax asset respect income tax losses approximately million million million million due expire million million due expire million million available indefinitely group capital losses st december approximately billion respect deferred tax asset recognised substantial part income tax capital losses still subject agreement relevant tax authorities deferred tax assets recognised probable future taxable profit available utilise losses gsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot seton notes financial statements continued earnings per share pence pence pence basic earnings per share adjustment restructuring costs business performance earnings per share basic diluted earnings per share adjustment restructuring costs business performance earnings per share diluted basic adjusted earnings per share calculated dividing profit attributable shareholders weighted average number shares issue period deducting shares held esop trusts treasury shares adjusted earnings per share calculated using business performance earnings calculation business performance supplemental nonifrs measure described note presentation financial statements diluted earnings per share calculated adjusting weighted average number shares used basic calculation assume conversion potentially dilutive shares potentially dilutive share forms part employee share schemes exercise price average market price gsk shares period performance conditions attaching scheme met balance sheet date numbers shares used calculating basic diluted earnings per share reconciled weighted average number shares issue millions millions millions basic dilution share options diluted shares held esop trusts excluded trustees waived rights dividends shares held esop trusts dividends first interim second interim third interim fourth interim total total dividend dividend per share pence paidpayable th july th october th january th april total dividend dividend per share pence paid th july th october th january th april total dividend dividend per share pence paid th july th october th january th april ifrs interim dividends recognised financial statements paid declared gsk normally pays dividend two quarters quarter relates one quarter declared financial statements recognise dividends paid namely third fourth interim dividends first second interim dividends amounts recognised year follows dividends shareholders notes financial statements continued property plant equipment plant land equipment assets buildings vehicles construction total cost st january exchange adjustments additions additions business combinations disposals writeoffs reclassifications transfer assets held sale cost st december exchange adjustments additions additions business combinations disposals writeoffs reclassifications transfer assets held sale cost st december depreciation st january exchange adjustments provision year disposals writeoffs transfer assets held sale depreciation st december exchange adjustments provision year disposals writeoffs transfer assets held sale depreciation st december impairment st january exchange adjustments disposals writeoffs impairment losses reversal impairments impairment st december exchange adjustments disposals writeoffs impairment losses reversal impairments impairment st december total depreciation impairment st december total depreciation impairment st december net book value st january net book value st december net book value st december net book value st december groups land buildings comprises freehold properties million million properties leases years million million properties leases less years million million gsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot seton gsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot seton notes financial statements continued property plant equipment continued included land buildings st december leased assets cost million million accumulated depreciation million million net book value million million included plant equipment vehicles st december leased assets cost million million accumulated depreciation million million net book value million st january million lease agreements include renewal purchase options escalation clauses impairment losses principally arise decisions rationalise facilities calculated based either fair value less costs sell value use value use calculations determine net present value projected riskadjusted posttax cash flows relevant asset cash generating unit applying discount rate group posttax weighted average cost capital adjusted appropriate country specific risks impairment indicated pretax cash flow calculation expected give materially different result test would reperformed using pretax cash flows pretax discount rate impairment losses charged cost sales million rd million sga million reversals impairment arise subsequent reviews impaired assets conditions gave rise original impairments deemed longer apply reversals credited cost sales principal component reversals relates suzhou pharmaceuticals manufacturing facility planned withdrawal manufacturing key product terminated recoverable amount calculated applying value use calculation discount rate goodwill cost st january exchange adjustments additions business combinations impairments cost st december net book value st january net book value st december additions year comprise million acquisition reliant pharmaceuticals inc million acquisition domantis limited million acquisition praecis pharmaceuticals inc see note acquisitions disposals details impairments year million relate europharm business located romania determined using fair value less costs sell model carrying value goodwill made balances arising acquisition following companies id biomedical corporation reliant pharmaceuticals inc domantis limited cns inc glaxosmithkline kk polfa poznan sa corixa corporation others goodwill allocated cash generating units tested impairment least annually recoverable amounts cash generating units assessed using value use fair value less costs sell model depending nature unit value use calculated net present value projected riskadjusted fiveyear posttax cash flows plus terminal value cash generating unit goodwill allocated initially posttax discount rate based groups weighted average cost capital adjusted appropriate country specific risks applied calculate net present value posttax cash flows indicates recoverable value unit close carrying value impairment test reperformed using pretax discount rate pretax cash flows order determine impairment exists establish magnitude fair value calculated using discounted cash flow approach case based groups acquisition valuation model posttax discount rate based groups weighted average cost capital applied adjusted appropriate country specific risks rate applied projected riskadjusted posttax cash flowsgsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot seton notes financial statements continued goodwill continued cash generating units carrying amount goodwill allocated unit significant comparison total goodwill balance vaccines consumer healthcare us pharmaceuticals worldwide pharmaceuticals japan poland total goodwill million million principally relating acquisitions id biomedical corixa allocated vaccines unit recoverable value unit determined using fair value less costs sell model goodwill arising acquisition minority interest glaxosmithkine kk million million acquisition polfa poznan million million allocated japan poland cash generating units respectively recoverable value units determined using value use model goodwill arising acquisition cns inc december allocated consumer healthcare cash generating unit domantis limited research operation goodwill arising acquisition allocated worldwide pharmaceuticals cash generating unit goodwill arising acquisition reliant pharmaceuticals inc december allocated us pharmaceuticals cash generating unit intangible assets computer licences amortised indefinite life software patents etc brands brands total cost st january exchange adjustments additions additions business combinations disposals asset writeoffs cost st december exchange adjustments additions additions business combinations disposals asset writeoffs transfer assets held sale cost st december amortisation st january exchange adjustments provision year disposals asset writeoffs amortisation st december exchange adjustments provision year disposals asset writeoffs transfer assets held sale amortisation st december impairment st january exchange adjustments impairment losses disposals asset writeoffs impairment st december exchange adjustments impairment losses disposals asset writeoffs impairment st december total amortisation impairment st december total amortisation impairment st december net book value st january net book value st december net book value st december gsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot seton notes financial statements continued intangible assets continued amortisation impairment charged income statement follows amortisation impairment cost sales selling general administration research development total amortisation impairment additions business combinations year million include million respect lovaza acquired acquisition reliant pharmaceuticals see note acquisitions disposals included within additions internally generated costs million million relating computer software million nil relating intangible assets st december net book value included million million internally generated costs million million related computer software million nil related intangible assets amortised brands include otc rights relating alli acquired roche million million indefinite life brands comprise portfolio products acquired acquisitions sterling winthrop inc block drug company inc cns inc book values major brands follows panadol sensodyne breathe right polident corega poligrip solpadeine others brands considered indefinite life given strength durability brand level marketing support brands relatively similar stable profitable market sectors similar risk profiles size diversification market shares mean risk marketrelated factors causing reduction lives brands considered relatively low group aware material legal regulatory contractual competitive economic factor could limit useful lives accordingly amortised brand tested annually impairment applying fair value less costs sell methodology using five year posttax cash flow forecasts terminal value calculation discount rate equal group posttax weighted average cost capital adjusted appropriate countryspecific risks main assumptions include future sales prices volumes product contribution future expenditure required maintain products marketability registration relevant jurisdiction products useful economic life assumptions reviewed part managements budgeting strategic planning cycle changes market conditions sales erosion competition investments associates joint ventures joint associated ventures undertakings total total st january exchange adjustments additions fair value adjustment retained lossprofit year st december principal associated undertaking quest diagnostics inc us clinical laboratory business listed new york stock exchange investment book value st december million million market value million million st december group owned quest although group holds less ownership interest voting control quest group ability exercise significant influence significant shareholding nominated directors active participation quest board directors board subcommitteesnotes financial statements continued investments associates joint ventures continued summarised balance sheet information respect groups associates set total assets total liabilities net assets groups share associates net assets investments joint ventures comprise million share gross assets million million share gross liabilities million principally arise interests two joint ventures shionogiglaxosmithkline holdings lp developing specified chemical compounds glaxosmithkline shire canada primarily comarkets combivir trizivir epivir certain territories together interest another joint venture pharmaceutical insurance limited mutual insurance company covering pharmaceutical property risk gsk hedged part equity value holding quest diagnostics inc series variable sale forward contracts contracts equity collar renewed structured five series two million quest shares mature fair value contracts st december liability million million second series hedging contracts additional million shares entered th february contracts also structured five series two million quest shares mature fair value contracts st december asset million investments st january exchange adjustments additions net fair value movements impairments disposals st december investments comprise noncurrent equity investments availableforsale investments recorded fair value balance sheet date investments traded active market fair value determined reference relevant stock exchange quoted bid price investments fair value estimated reference current market value similar instruments reference discounted cash flows underlying net assets equity investments recorded noncurrent assets unless expected sold within one year case recorded current assets group holds number equity investments entities group entered research collaborations investments include listed investments million million offer group opportunity return dividend income fair value gains disposal investments fair value movements reclassified reserves income statement based average cost impairment losses recorded tables recognised income statement year within operating income together amounts recycled fair value reserve note operating income recognition impairments impairments initially result prolonged significant declines fair value equity investments acquisition cost subsequent declines fair value immediately taken income statement st december impaired assets fair value million million included investments noncurrent assets amounts recoverable insurance contracts pension schemes surplus receivables gsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot seton gsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot seton notes financial statements continued inventories raw materials consumables work progress finished goods trade receivables trade receivables prepaid pension contributions prepayments accrued income interest receivable employee loans advances receivables trade receivables include million million due associates joint ventures bad doubtful debt provision st january exchange adjustments charge year subsequent recoveries amounts provided utilised st december cash cash equivalents cash bank hand shortterm deposits commercial paper assets held sale land buildings plant equipment vehicles equity investments trade payables trade payables wages salaries social security payables deferred income customer return rebate accruals accruals gsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot seton notes financial statements continued trade payables continued customer return rebate accruals provided group point sale respect estimated rebates discounts allowances payable customers principally usa provisions made time sale actual amounts paid based claims made time initial recognition sale amounts estimated may fully reflect final outcome amounts subject change dependent upon amongst things types buying group product sales mix level provision reviewed adjusted quarterly light historical experience actual rebates discounts allowances given returns made changes arrangements future events could cause assumptions provisions based change could affect future results group pensions postemployment benefits pension postemployment costs uk pension schemes us pension schemes overseas pensions schemes unfunded postretirement healthcare schemes postemployment costs analysed funded defined benefithybrid pension schemes unfunded defined benefit pension schemes unfunded postretirement healthcare schemes defined benefit schemes defined contribution pension schemes postemployment costs costs defined benefit pension postretirement healthcare schemes charged income statement follows cost sales selling general administration research development gsk entities operate pension arrangements cover groups material obligations provide pensions retired employees arrangements developed accordance local practices countries concerned pension benefits provided state schemes defined contribution schemes whereby retirement benefits determined value funds arising contributions paid respect employee defined benefit schemes whereby retirement benefits based employee pensionable remuneration length service hybrid defined benefit schemes also include defined contribution sections contributions defined benefit schemes determined accordance advice independent professionally qualified actuaries pension costs defined benefit schemes accounting purposes assessed accordance independent actuarial advice using projected unit method certain countries pension benefits provided unfunded basis administered trustee companies liabilities generally assessed annually accordance advice independent actuaries formal independent actuarial valuations groups main plans undertaken regularly normally least every three years actuarial movements year recognised full statement recognised income expense uk discount rate based iboxx year aa index us discount rate based corporate bond yields reflect term expected benefit payments expected rate return bonds reflects portfolio mix indexlinked government corporate bonds equity risk premium added longer term government bond yields give expected rate return equities projected inflation rate pension increases longterm predictions based yield gap longterm indexlinked fixed interest gilts uk mortality rates determined adjusting pa standard mortality tables reflect recent scheme experience rates projected reflect improvements life expectancy line medium cohort ie improvements recently observed higher levels assumed continue minimum improvements thereafter per year males females usa mortality rates calculated using rp fully generational table projected using scale aa white collar adjustment mortality assumptions uk us schemes set following review december gsk expects review december gsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot seton notes financial statements continued pensions postemployment benefits continued average life expectancy assumed individual age projected apply individual age follows uk usa male female male female years years years years current projected assets funded schemes generally held separately administered trusts insured assets invested different classes order maintain balance risk return investments diversified limit financial effect failure individual investment following asset liability study group decided adopt strategy reduce gradually allocation investment equities uk proposed strategy linked funding levels schemes considered trustees uk schemes allocation equities property us scheme reduced total uk defined benefit pension schemes operated benefit former glaxo wellcome employees former smithkline beecham employees remain separate schemes closed new entrants subsequent uk employees entitled join defined contribution scheme usa former glaxo wellcome smithkline beecham defined benefit schemes merged addition group operates number postretirement healthcare schemes principal one usa group applied following financial assumptions assessing defined benefit liabilities uk usa rest world pa pa pa pa pa pa pa pa pa rate increase future earnings discount rate expected pension increases na na na cash balance creditconversion rate na na na inflation rate amounts recorded income statement statement recognised income expense three years ended st december relation defined benefit pension postretirement healthcare schemes follows postretirement pensions benefits uk usa rest world group group amounts charged operating profit current service cost past service cost expected return pension scheme assets interest scheme liabilities settlements curtailments actuarial gains recorded statement recognised income expense postretirement pensions benefits uk usa rest world group group amounts charged operating profit current service cost past service cost expected return pension scheme assets interest scheme liabilities settlements curtailments actuarial gains recorded statement recognised income expense gsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot seton notes financial statements continued pensions postemployment benefits continued postretirement pensions benefits uk usa rest world group group amounts charged operating profit current service cost past service cost expected return pension scheme assets interest scheme liabilities settlements curtailments actuarial losses recorded statement recognised income expense total actuarial losses recorded statement recognised income expense since st january amount million fair values assets liabilities uk us defined benefit pension schemes together aggregated data defined benefit pension schemes group follows uk usa rest world group st december average expected rate fair expected rate fair expected rate fair fair return value return value return value value equities property bonds assets fair value assets present value scheme obligations included noncurrent assets included pensions postemployment benefits actual return plan assets uk usa rest world group st december average expected rate fair expected rate fair expected rate fair fair return value return value return value value equities property bonds assets fair value assets present value scheme obligations included noncurrent assets included pensions postemployment benefits actual return plan assets gsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot seton notes financial statements continued pensions postemployment benefits continued uk usa rest world group st december average expected rate fair expected rate fair expected rate fair fair return value return value return value value equities property bonds assets fair value assets present value scheme obligations included noncurrent assets included pensions postemployment benefits actual return plan assets postretirement pensions benefits uk usa rest world group group movements defined benefit obligations obligations st january exchange adjustments service cost interest cost settlements curtailments actuarial losses scheme participants contributions benefits paid obligations st december exchange adjustments service cost interest cost settlements curtailments actuarial lossesgains scheme participants contributions benefits paid obligations st december exchange adjustments service cost interest cost settlements curtailments actuarial gains scheme participants contributions benefits paid transfers recognised balance sheet st december unrecognised past service costs obligations st december uk defined benefit schemes include defined contribution sections obligations totalling million st december million milliongsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot seton notes financial statements continued pensions postemployment benefits continued liability us postretirement healthcare scheme assessed using assumptions us pension scheme together assumption future medical inflation reducing per year thereafter us postretirement healthcare scheme amended main change increase cap company costs yearend plan obligation million however accordance ias unvested part benefit improvement recognised immediately balance sheet recognised gradually income statement yearend unrecognised amount million amount recognised balance sheet therefore million million million group provides certain medical benefits disabled employees spouses usa obligations benefits transferred value million shown within provisions defined benefit pension obligation analysed follows funded unfunded postretirement benefits unfunded postretirement pensions benefits uk usa rest world group group movements fair values assets assets st january exchange adjustments expected return assets actuarial gains employer contributions scheme participants contributions benefits paid assets st december exchange adjustments expected return assets settlements curtailments actuarial gains employer contributions scheme participants contributions benefits paid assets st december exchange adjustments expected return assets settlements curtailments actuarial gains employer contributions scheme participants contributions benefits paid assets st december uk defined benefit schemes include defined contribution sections account balances totalling million st december million million group made special funding contributions uk pension schemes totalling million million uk us pension schemes gsk formalised agreement trustees uk defined benefit pension schemes make additional contributions million per year addition normal contributions fouryear period ending st december order eliminate pension deficits ias basis employer contributions including special funding contributions estimated approximately million respect defined benefit pension schemes million respect postretirement benefits gsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot seton notes financial statements continued pensions postemployment benefits continued postretirement pensions benefits uk usa rest world group group history experience gains losses experience gainslosses scheme assets percentage scheme assets st december experience gainslosses scheme liabilities percentage scheme obligations st december fair value assets present value scheme obligations deficitssurpluses schemes experience gains scheme assets percentage scheme assets st december experience lossesgains scheme liabilities percentage scheme obligations st december fair value assets present value scheme obligations deficitssurpluses schemes experience gains scheme assets percentage scheme assets st december experience losses scheme liabilities percentage scheme obligations st december fair value assets present value scheme obligations deficits schemes experience gains scheme assets percentage scheme assets st december experience lossesgains scheme liabilities percentage scheme obligations st december fair value assets present value scheme obligations deficits schemes experience gains scheme assets percentage scheme assets st december experience lossesgains scheme liabilities percentage scheme obligations st december fair value assets present value scheme obligations deficits schemes gsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot seton notes financial statements continued pensions postemployment benefits continued sensitivity analysis effect changes assumptions used annual defined benefit pension postretirement costs benefit obligations decrease discount rate would following approximate effect increase annual pension cost increase annual postretirement benefits cost increase pension obligation increase postretirement benefits obligation one year increase life expectancy would following approximate effect increase annual pension cost increase annual postretirement benefits cost increase pension obligation increase postretirement benefits obligation decrease expected rates returns assets would following approximate effect increase annual pension cost increase rate future healthcare inflation would following approximate effect increase annual postretirement benefits cost increase postretirement benefits obligation increase inflation would following approximate effect increase annual pension cost increase pension obligation provisions integration legal new operational employee excellence related manufacturing disputes programme provisions reorganisation provisions total st january exchange adjustments charge year reversed unused unwinding discount utilised reclassifications movements st december settled within one year settled one year st december gsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot seton notes financial statements continued provisions continued legal disputes gsk involved number legal disputes including notification possible claims set note legal proceedings provisions legal disputes include amounts relating us antitrust product liability contract terminations selfinsurance environmental cleanup property rental companys directors taken legal specialist advice established provisions taking account insurance agreements regard relevant facts circumstances matter accordance accounting requirements discount provisions decreased million million increase calculated using riskadjusted projected cash flows riskfree rates return movement includes decrease million arising change discount rate year number products history claims made settlements makes possible use ibnr incurred reported actuarial technique determine reasonable estimate groups exposure unasserted claims relation products apart ibnr provision provisions made unasserted claims ultimate liability matters may vary amounts provided dependent upon outcome litigation proceedings investigations possible settlement negotiations nature groups business number matters including provided using ibnr actuarial technique may subject negotiation litigation several years largest individual amounts provided expected settled within three years st december expected million million provision made legal disputes reimbursed third party insurers amount included within current noncurrent assets discussion legal issues refer note legal proceedings new operational excellence programme october gsk announced significant new billion operational excellence programme improve effectiveness productivity operations new programme expected deliver annual pretax savings million gsk expects realise majority annual savings within first two years programme approximately million expected million savings partly mitigate expected impact earnings generic competition lower avandia sales associated adverse impact gsks gross margin costs recognised provision principally respect identified severances sites announced manufacturing activities reduced cease expected incurred mainly asset retirement obligations recognised provision amount million year costs asset writedowns recognised impairments property plant equipment employee related provisions employee related provisions includes exchange offer incentive programme operated time merger encourage staff convert glaxo wellcome smithkline beecham share options glaxosmithkline share options incentive paid either employees exercise relevant options options lapse discount provision increased million million calculated using riskfree rates return group provides certain medical benefits disabled employees spouses usa transferred postretirement benefits value million year reflected total reclassifications movements figure million st december provision benefits amounted million employee benefits reflect variety provisions severance costs jubilee awards longservice benefits integration manufacturing reorganisation group recognised costs previous years respect plans integration glaxo wellcome smithkline beecham businesses implementation integration following merger substantially complete costs recognised remaining merger integration provision respect identified severances expected incurred smaller costsaving initiatives since merger included within category noncurrent liabilities accruals deferred income payables contingent liabilities st december contingent liabilities comprising guarantees letters credit discounted bills items arising normal course business amounted million million st december million million financial assets pledged collateral contingent liabilities discussions tax legal issues refer note taxation note legal proceedingsgsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot seton notes financial statements continued net debt current assets liquid investments cash cash equivalents shortterm borrowings us medium term note european medium term note european medium term note commercial paper bank loans overdrafts loans obligations finance leases longterm borrowings european medium term note european medium term note european medium term note european medium term note european medium term note us us medium term note european medium term note european medium term note european medium term note us us medium term note european medium term note loan stock bank loans loans private financing obligations finance leases net debt current assets liquid investments classified availableforsale investments st december included redeemable shares collateralised highly rated bonds billion million billion million government bonds effective interest rate liquid investments st december approximately approximately liquid investment balances st december earning interest floating fixed rates amount million million respectively million million effective interest rate cash cash equivalents st december approximately approximately cash cash equivalents balances st december earning interest floating fixed rates amount million million respectively million million july onwards gsk tightened criteria holding cash equivalents liquid investments response credit crisis gsk suffered loss principal result crisis gsks policy regarding credit quality cash cash equivalents referred note financial instruments related disclosures gsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot seton notes financial statements continued net debt continued shortterm borrowings commercial paper comprises us billion programme billion billion issue st december nil backed committed facilities days duration billion billion million million renewable annually liquid investments cash cash equivalents shown table weighted average interest rate current bank loans overdrafts st december longterm borrowings yearend gsk longterm borrowings billion billion billion billion falls due five years longterm borrowings repayable five years carry interest effective rates repayment dates range average effective interest rate notes st december approximately approximately secured loans gsk loans secured charges noncurrent current assets year nil finance lease obligations rental payments due within one year rental payments due one two years rental payments due two three years rental payments due three four years rental payments due four five years rental payments due five years total future rental payments future finance charges total finance lease obligations finance lease obligations st december bearing interest floating fixed rates amount million million respectively million milliongsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot seton notes financial statements continued share capital share premium account share ordinary shares p premium number share capital authorised st december st december st december share capital issued fully paid st january issued share option schemes st december issued share option schemes st december issued share option schemes share capital purchased cancelled st december st december st december st december number shares issuable outstanding options note number unissued shares option st december issued share capital shares held esop trust shares held treasury shares shares free issue issued shares fully paid nominal carrying market values shares held esop trust disclosed note employee share schemes july group increased share buyback programme billion expected completed twoyear period exact amount timing future purchases whether repurchased shares held treasury shares cancelled determined company dependent market conditions factors group also commenced close period share buybacks operating specific irrevocable agreements put place brokers prior start close period total billion spent company st january st december buying shares cancellation held treasury shares billion spent million shares purchased cancelled period st january nd february cost million purchases made publicly announced buyback programme table sets monthly purchases share buyback programme average share price excluding number shares commission stamp duty month january february march april may june july august september october november december total shares purchased million million held treasury shares million million cancelled details substantial shareholdings refer substantial shareholdings gsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot seton notes financial statements continued movements equity shareholders equity share share retained total minority total capital premium earnings reserves interests equity st january recognised income expense year changes minority shareholdings distributions minority shareholders dividends shareholders ordinary shares issued ordinary shares purchased held treasury shares ordinary shares transferred esop trusts writedown shares held esop trusts sharebased incentive plans tax share based incentive plans st december recognised income expense year changes minority shareholdings distributions minority shareholders dividends shareholders ordinary shares issued ordinary shares purchased held treasury shares ordinary shares transferred esop trusts writedown shares held esop trusts sharebased incentive plans tax sharebased incentive plans st december recognised income expense year distributions minority shareholders dividends shareholders ordinary shares issued ordinary shares purchased cancelled ordinary shares purchased held treasury shares ordinary shares acquired esop trusts ordinary shares transferred esop trusts writedown shares held esop trusts sharebased incentive plans tax sharebased incentive plans st december gsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot seton notes financial statements continued movements equity continued retained earnings reserves amounted million st december million million million million million relates company million million million relates joint ventures associated undertakings cumulative translation exchange equity shown following table net translation exchange included total fair value retained minority translation reserve earnings interest exchange st january exchange movements overseas net assets exchange movements goodwill reserves st december exchange movements overseas net assets exchange movements goodwill reserves st december exchange movements overseas net assets exchange movements goodwill reserves st december analysis reserves follows cash flow esop trust fair value hedge shares reserve reserve reserves total st january transferred income expense year disposals net fair value movement year ordinary shares transferred esop trusts writedown shares held esop trusts st december transferred income expense year disposals transferred income expense year impairment net fair value movement year ordinary shares transferred esop trusts writedown shares held esop trusts st december transferred income expense year disposals transferred income expense year impairment net fair value movement year ordinary shares purchased cancelled ordinary shares acquired esop trusts ordinary shares transferred esop trusts writedown shares held esop trusts st december reserves include merger reserve created merger glaxo wellcome smithkline beecham amounting million st december million million reserves also include capital redemption reserve created result share buyback programme amounting million st december million million gsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot seton notes financial statements continued related party transactions glaxosmithkline held interest quest diagnostics inc st december group quest diagnostics parties longterm contractual relationship quest diagnostics primary provider clinical laboratory testing support groups clinical trials testing requirements worldwide quest diagnostics provided services million million group st december balance payable glaxosmithkline quest diagnostics million million group shionogi co ltd entered transactions us joint venture company support research development activities conducted joint venture company glaxosmithkline provided services joint venture million million st december balance due glaxosmithkline joint venture million million dr shapiro former nonexecutive director glaxosmithkline plc received fees form adss subsidiary company membership groups scientific advisory board fees included within annual remuneration remuneration report pages aggregate compensation directors cet company secretary given note employee costs reconciliation profit tax operating cash flows profit tax tax profits share tax profits associates joint ventures finance incomecosts depreciation impairment assets written amortisation intangible assets profit sale property plant equipment profit sale intangible assets profit sale equity investments changes working capital increasedecrease inventories increase trade receivables decreaseincrease trade payables decrease pension provisions sharebased incentive plans cash generated operations reconciliation net cash flow movement net debt net debt beginning year implementation accounting financial instruments ias increasedecrease cash bank overdrafts cash outflowinflow liquid investments net increase longterm loans net increase inrepayment shortterm loans net repayment obligations finance leases net noncash funds subsidiary undertakings acquired exchange adjustments noncash movements movement net debt net debt end year gsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot seton notes financial statements continued reconciliation net cash flow movement net debt continued exchange acquisitions cash flow analysis changes net debt liquid investments cash cash equivalents overdrafts debt due within one year commercial paper eurobonds mediumterm notes debt due one year eurobonds mediumterm notes private financing net debt information significant changes net debt see note net debt acquisitions disposals details acquisition disposal subsidiary associated undertakings joint ventures businesses given acquisitions reliant pharmaceuticals inc th december group acquired issued share capital reliant pharmaceuticals inc pharmaceutical company based usa cash consideration million company specialises development marketing speciality medicines combat heart disease includes us rights lovaza treatment adult patients high levels triglycerides transaction accounted purchase method accounting goodwill arising acquisition reflects potential product growth throughout usa puerto rico expected synergies group reliant pharmaceuticals inc turnover million profit tax million year million turnover million profit tax related period since acquisition included group accounts fair values set based provisional valuations may subject change future book fair value fair value adjustment value net assets acquired intangible assets property plant equipment assets including cash cash equivalents deferred tax provision liabilities goodwill total consideration gsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot seton notes financial statements continued acquisitions disposals continued domantis limited th january group acquired issued share capital domantis limited drug discovery company based uk cash consideration million company developing next generation antibody therapies transaction accounted purchase method accounting goodwill arising acquisition reflects potential combining worldleading technology domantis development programme already place within gsk put group forefront biotechnology domantis limited turnover nil loss tax million year nil turnover million loss tax related period since acquisition included group accounts book fair value fair value adjustment value net assets acquired intangible assets property plant equipment assets including cash cash equivalents deferred tax provision liabilities goodwill total consideration praecis pharmaceuticals inc th february group acquired issued share capital praecis pharmaceuticals inc biopharmaceutical company based usa cash consideration million company developed efficient method identifying drug leads targeting human disease using proprietary technology transaction accounted purchase method accounting praecis pharmaceuticals inc turnover nil loss tax million year nil turnover million loss tax related period since acquisition included group accounts book fair value fair value adjustment value net assets acquired intangible assets property plant equipment assets including cash cash equivalents deferred tax asset liabilities goodwill total consideration reliant domantis praecis total cash flows cash consideration cash cash equivalents acquired net cash payment acquisitions reliant domantis praecis acquired beginning year combined group turnover year would million combined group profit year would milliongsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot seton notes financial statements continued acquisitions disposals continued acquisitions cns inc th december group acquired issued share capital cns inc consumer healthcare company based usa cash consideration million company markets breathe right nasal dilator strips fiberchoice dietary fibre supplements key intangible assets acquired valued using discounted cash flow calculation transaction accounted purchase method accounting goodwill arising acquisition reflects potential expansion brands overseas markets expected synergies group cns inc turnover million million profit million profit million million turnover nil profit related period since acquisition included group accounts book fair value fair value adjustment value net assets acquired intangible assets property plant equipment assets including cash cash equivalents deferred tax provision liabilities goodwill total consideration euclid sr partners lp additional million invested euclid sr partners lp associate group share shionogiglaxosmithkline holdings ltd additional million invested shionogi glaxosmithkline holdings ltd joint venture group share pliva research institute ltd may group purchased entire share capital pliva research institute ltd cash consideration million amount million deferred payment made phase clinical trials initiated glaxosmithkline kk august japanese subsidiary group made cash payment million complete purchase remaining share capital held minority shareholder payment preceded year dividend minority shareholders million representing additional consideration shionogi pliva euclid sr glaxosmithkline research glaxosmith cns partners lp holdings ltd institute kline kk total cash flows cash consideration cash cash equivalents acquired net cash payment acquisitions net cash proceeds disposals gsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot seton notes financial statements continued acquisitions disposals continued acquisitions id biomedical corporation th december group acquired issued share capital id biomedical corporation biotechnology company based canada specialising development manufacture vaccines particularly influenza vaccines cash consideration million transaction accounted purchase method accounting goodwill arising acquisition results benefits separately quantified recorded including immediate access additional flu vaccines manufacturing capacity particularly event pandemic skilled workforce good relations us canadian governments regarding supply flu vaccines id biomedical corporation turnover million million loss million loss million year million turnover million loss related period since acquisition included group accounts book fair value fair value adjustment value net assets acquired intangible assets property plant equipment assets deferred tax provision liabilities goodwill total consideration total consideration included directly attributable costs million corixa corporation th july group acquired issued share capital corixa corporation biotechnology company specialising developing vaccine adjuvants immunology based products cash consideration million investment increased groups holding corixa group number business relationships corixa prior acquisition date principally relation adjuvant developed corixa used groups vaccines transaction accounted purchase method accounting existing investment corixa book value million previously classified availableforsale investment forms part investment subsidiary existing issued share capital acquired previous years cash consideration million corixa corporation turnover million loss million year million turnover million loss related period since acquisition included group accounts book fair value fair value adjustment value net assets acquired intangible assets assets liabilities goodwill existing investment total consideration total consideration included directly attributable costs milliongsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot seton notes financial statements continued acquisitions disposals continued euclid sr partners lp additional million invested euclid sr partners lp associate group interest glaxosmithkline consumer healthcare limited april indian subsidiary group purchased share capital held minority shareholders cash consideration million glaxosmithkline pharmaceuticals limited may june indian subsidiary group purchased share capital held minority shareholders cash consideration million glaxosmithkline biologicals shanghai limited chinese subsidiary group purchased share capital held minority shareholders cash consideration million disposals ideapharm sa december group disposed ideapharm sa subsidiary located romania cash proceeds million received january net assets disposed year included cash million aseptic technologies sa april group disposed aseptic technologies sa societe regionale dinvestissement de wallonie sa cash proceeds million gsk gsk gsk biologicals aseptic pharma consumer euclid id cash flows shanghai tech ceuticals healthcare ideapharm sr corixa biomedical total cash consideration cash cash equivalents acquired net cash payment acquisitions cash cash equivalents disposed net cash proceeds disposals gsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot seton notes financial statements continued commitments contractual obligations commitments contracted provided financial statements intangible assets plant property equipment investments purchase commitments business combinations pensions theravance put option agreement commitments interest loans finance lease charges commitments related intangible assets include milestone payments dependent successful clinical development represent maximum would paid milestones achieved number commitments made licensing agreements including arrangements anacor pharmaceuticals inc oncomed pharmaceuticals inc santaris pharma targacept inc gsk formalised agreement trustees uk pension schemes make additional contributions million per year addition normal contributions fouryear period ending st december order eliminate pension deficits ias basis point table shows commitment excludes normal ongoing annual funding requirement approximately million gsk also committed eliminate future deficits may arise rolling fiveyear period commitments made past st december st december group party put option agreement whereby theravances shareholders could sell half theravance shares gsk predetermined price given maximum number shares subject put option groups obligation capped million put option expired unexercised august group also commitments principally relate revenue payments made licences alliances commitments respect future interest payable loans disclosed taking account effect interest rate swaps commitments operating leases rental payments due within one year rental payments due one two years rental payments due two three years rental payments due three four years rental payments due four five years rental payments due five years total commitments operating leases post balance sheet events th january fda issued approvable letter respect mercks nda seeking approval overthecounter mevacor triggered repayment gsk upfront fee gsk paid merck us otc rights th february gsks longterm standard poors debt rating revised aa negative outlook stable standard poors also revised gsks shortterm rating paper issued groups commercial paper programme agsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot seton notes financial statements continued financial instruments related disclosures liquidity risk group manages net borrowing requirements glaxosmithkline plc reports sterling pays dividends portfolio longterm borrowings including bonds together sterling profits role corporate treasury gsk manage shortterm finance us billion commercial paper monitor groups external internal funding requirements programme st december group also billion financial risks support group corporate objectives treasury committed undrawn bank facilities activities governed policies procedures approved board directors recently th october group european medium term note programme billion billion issue st december treasury management group tmg chaired groups us shelf registration billion st december chief financial officer meets monthly basis review treasury billion billion issue tmg monitors cashflow activities members receive management information relating forecast gsk monthly basis treasury activity corporate executive team cet also review monthly finance report focuses operational finance issues groups longterm borrowings mature dates groups internal auditors review treasury internal control th february gsks longterm standard poors environment regularly debt rating revised aa negative outlook stable time standard poors also revised gsks shortterm rating gsk uses variety financial instruments including derivatives paper issued groups commercial paper programme finance operations manage market risks moodys investors services rate gsk negative operations derivatives principally comprising forward foreign outlook longterm debt p shortterm debt currency contracts interest rate currency swaps used change gsks rating moodys since th july swap borrowings liquid assets currencies required group purposes manage exposure funding risks changes light likely increased commercial paper issuance resulting foreign exchange rates interest rates increased share buyback programme gsk increased committed bank facilities million billion addition gsk hold issue derivative financial instruments group maintains substantial cash liquid investments speculative purposes groups treasury policies specifically st december amounted billion prohibit activity transactions financial instruments undertaken manage risks arising underlying business market risk activities speculation interest rate risk management gsks policy interest rate risk management requires minimum capital management amount net borrowings fixed rates increase ratio capital structure group consists net debt see note forecast interest payable trading profit fixed floating ratio net debt shareholders equity see note movements reviewed monthly tmg equity group manages capital ensure entities group able operate going concerns optimise group uses limited number interest rate swaps return shareholders appropriate balance debt redenominate external borrowings interest rate coupon equity july gsk announced increased share buyback required group purposes duration swaps matches programme billion period july duration principal instruments interest rate derivative result substantially increased borrowings board reviews instruments accounted fair value cash flow hedges groups dividend policy funding requirements annually relevant assets liabilities gsk operates globally primarily subsidiary companies foreign exchange risk management established markets group trades foreign currency transaction exposure arising normal trade flows significant levels patent trademark protection groups respect external intragroup trade hedged products compete largely product efficacy rather price exposure overseas operating subsidiaries transaction risk selling margins sufficient cover normal operating costs minimised matching local currency income local currency groups operating subsidiaries generally cash generative none costs purpose intragroup trading transactions matched entities group subject externally imposed capital centrally intragroup payment terms managed reduce risk requirements exceptional foreign currency cash flows hedged selectively management corporate treasury operating cash flow used fund investment research development new products well make routine group manages centrally shortterm cash surpluses borrowing outflows capital expenditure tax dividends repayment requirements subsidiary companies uses forward contracts maturing debt hedge future repayments back originating currency groups policy borrow centrally using variety capital group seeks denominate borrowings currencies market issues borrowing facilities meet anticipated funding principal assets cash flows primarily denominated requirements us dollars euros sterling certain borrowings swapped currencies required group purposes borrowings together cash generated operations onlent within group contributed equity certain subsidiaries used fund groups billion share buyback programme gsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot seton notes financial statements continued financial instruments related disclosures fair value financial assets liabilities continued table presents carrying amounts fair values groups financial assets liabilities st december borrowings denominated swapped foreign currencies st december match investments overseas group assets treated hedge relevant assets ratio borrowings assets fair values financial assets liabilities included reviewed currency month month basis tmg amount instrument could exchanged current transaction willing parties forced credit risk liquidation sale following methods assumptions used group considers maximum credit risk million estimate fair values million total groups financial assets exception investments bear cash cash equivalents approximates carrying credit risk us treasury bills bonds notes classified within amount cash cash equivalents liquid investments l iquid investments based quoted market prices case marketable securities based principal amounts case us treasury bills bonds notes held directly nonmarketable securities short repricing periods us treasuriesonly money market funds bear credit exposure us government see details groups total investments investments traded active market financial assets determined reference relevant stock exchange quoted bid price investments determined reference treasuryrelated credit risk current market value similar instruments reference credit risk increased following global subprime crisis gsk discounted cash flows underlying net assets suffered loss investment principal result crisis hortterm loans overdrafts approximates carrying group invests centrally managed liquid assets government bonds amount short maturity instruments shortterm corporate debt instruments minimum shortterm credit rating ap bank deposits treasuriesonly money market l ongterm loans based quoted market prices case funds credit rating aaaaaa standard poorsmoodys eurobonds fixed rate borrowings approximates investors services structured investments carrying amount case floating rate bank loans loans report relationship banks credit ratings presented forward exchange contracts based market prices exchange annually tmg approval rates balance sheet date aggregate credit risk respect financial instruments currency swaps based market data balance sheet date group may one counterparty limited reference longterm credit ratings assigned counterparty moodys q uest equity collar theravance put call options based standard poors blackscholes option pricing model uses assumptions respect price volatility dividend yield interest rates wholesale retail credit risk nterest rate swaps based net present value discounted usa line pharmaceutical companies group cash flows sells products small number wholesalers addition hospitals pharmacies physicians groups sales three receivables payables approximates carrying amount largest wholesalers amount approximately groups us lease obligations approximates carrying amount pharmaceutical sales st december group trade receivables due three wholesalers totalling million fair value investments gsk shares million group exposed concentration st december esop trusts held gsk shares credit risk respect wholesalers one carrying value million million fair encounters financial difficulty could materially adversely value million million based quoted affect groups financial results market price shares represent purchases esop trusts satisfy future exercises options awards employee groups credit risk monitoring activities relating wholesalers incentive schemes carrying value lower cost includes review quarterly financial information standard expected proceeds shares recognised poors credit ratings development gsk internal risk ratings deduction reserves st december gsk held establishment periodic review credit limits however group treasury shares cost million million believes credit risk provision required excess deducted retained earnings normal provision bad doubtful debts see note trade receivables outside usa customers account committed facilities trade receivables balance group committed facilities back commercial paper programme billion billion million million days duration renewable annually st december undrawn committed facilities totalled billion billion million milliongsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot seton notes financial statements continued financial instruments related disclosures continued carrying fair carrying fair value value value value cash cash equivalents availableforsale investments liquid investments redeemable shares government bonds total liquid investments investments loans receivables trade receivables noncurrent assets scope ias heldfortrading financial assets derivatives designated accounting hedges derivatives total financial assets financial liabilities measured amortised cost borrowings bonds designated hedging relationship bonds commercial paper bank loans overdrafts loans private financing obligations finance leases total borrowings trade payables noncurrent liabilities scope ias heldfortrading financial liabilities derivatives designated accounting hedges derivatives total financial liabilities net financial assets financial liabilities notes financial statements continued financial instruments related disclosures continued trade receivables noncurrent assets scope ias following table reconciles trade receivables noncurrent assets fall within scope ias relevant balance sheet amounts assets include tax receivables pension surplus balances prepayments outside scope ias financial assets predominantly noninterest earning trade receivables note noncurrent assets note analysed financial assets scope ias assets following table shows age financial assets past due provision bad doubtful debts raised past due days past due days past due days past due days past due days amounts past due greater days total million million balance million million relates receivables due state hospital authorities certain european countries group raised bad doubtful debt provisions amounts considered recoverable trade payables noncurrent liabilities scope ias following table reconciles trade payables noncurrent liabilities fall within scope ias relevant balance sheet amounts liabilities include payments account tax social security payables outside scope ias financial liabilities predominantly noninterest bearing trade payables note noncurrent liabilities note analysed financial liabilities scope ias liabilities gsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot setonnotes financial statements continued financial instruments related disclosures continued debt interest rate repricing table following table sets exposure group interest rates debt effect interest rate swaps maturity analysis fixed rate debt stated contractual maturity floating rate debt interest rate repricing dates purpose table debt defined classes borrowings obligations finance leases effect effect interest interest debt rate swaps total debt rate swaps total floating fixed rate debt less one year one two years two three years three four years four five years greater five years total original issuance profile fixed rate interest floating rate interest total interest bearing noninterest bearing sensitivity analysis sensitivity analysis prepared assumption amount net debt ratio fixed floating interest rates debt derivatives portfolio proportion financial instruments foreign currencies constant basis hedge designations place st december financial instruments affected market risk include borrowings deposits derivative financial instruments following analyses intended illustrate sensitivity financial instruments changes relevant foreign exchange interest rates foreign exchange sensitivity table shows groups sensitivity foreign exchange rates us dollar euro yen financial instruments excluding trade payables trade receivables nonderivative financial instruments net debt obligations finance leases present material exposure three currencies major currencies gsks financial instruments denominated gsk considered movements currencies last two years concluded movement rates reasonable benchmark table financial instruments considered sensitive foreign exchange rates functional currency entity holds intercompany loans fully hedged maturity currency swap excluded analysis increase reduction increase reduction income equity income equity appreciation us dollar appreciation euro appreciation yen depreciation stated currencies would equal opposite effect movements income statement relate primarily hedging instrument us dollar legal provision whilst economic hedge provision financial instrument therefore included table movements equity relate foreign exchange positions used hedge group assets denominated us dollar euro yen therefore depreciation currency swap would give rise corresponding appreciation group asset foreign exchange sensitivity group assets financial instruments included gsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot seton gsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot seton notes financial statements continued financial instruments related disclosures continued interest rate sensitivity table shows groups sensitivity interest rates floating rate sterling us dollar euro financial instruments currencies gsk historically issued debt held investments gsk considered movements interest rates last two years concluded increase reasonable benchmark debt maturity less one year floating rate calculation movement interest rates deemed material effect equity increasedecrease increasedecrease income income increase sterling interest rates increase us dollar interest rates increase euro interest rates decrease interest rates would equal opposite effect interest rate movements obligations finance leases foreign currency interest rate derivatives trade payables trade receivables financial instruments net debt present material exposure groups balance sheet based increase decrease interest rates contractual cash flows nonderivative financial liabilities derivative instruments following analysis anticipated contractual cash flows including interest payable groups nonderivative financial liabilities undiscounted basis purpose table debt defined classes borrowings except obligations finance leases interest calculated based debt held st december without taking account future issuance floating rate interest estimated using prevailing interest rate balance sheet date cash flows foreign currencies translated using spot rates st december finance charge trade obligations obligations interest finance finance payables debt debt leases leases net debt total st december due less one year one two years two three years three four years four five years greater five years gross contractual cash flows finance charge trade obligations obligations interest finance finance payables debt debt leases leases net debt total st december due less one year one two years two three years three four years four five years greater five years gross contractual cash flows following table provides analysis anticipated contractual cash flows groups derivative instruments excluding embedded derivatives equity options using undiscounted cash flows cash flows foreign currencies translated using spot rates st december receivables payables receivables payables less one year one two years two three years three four years four five years greater five years gross contractual cash flows gsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot seton notes financial statements continued financial instruments related disclosures continued derivative financial instruments hedging programmes following table sets principal amounts fair values derivatives held gsk fair value fair value principal principal amount assets liabilities amount assets liabilities cash flow hedges cross currency swaps fair value hedges interest rate swaps net investment hedges foreign exchange contracts cross currency swaps derivatives designated accounting hedges foreign exchange contracts equity related instruments options warrants equity collar embedded derivatives derivatives total derivative instruments analysed current noncurrent total derivative financial instruments principal amount foreign exchange contracts calculated based outstanding positions balance sheet date calculated net currency buysell side position majority contracts periods months less included equity related instruments variable sale forward contracts quest diagnostics inc various equity warrants st december group also held put call options theravance inc information quest theravance derivatives provided gsk hedged part equity value holdings quest associated undertaking series variable sale forward contracts contracts equity collar renewed structured five series two million quest shares mature fair value contracts st december liability million million million million second series hedging contracts additional million shares entered th february contracts also structured five series two million quest shares mature fair value contracts st december asset million million st december group held put option agreement whereby theravances shareholders could sell half theravance shares gsk predetermined price st december option recorded liability million million option expired unexercised august st december group held call option agreement whereby could purchase half outstanding theravance shares issue predetermined price st december option recorded asset million million option expired unexercised july st december group held outstanding foreign exchange contracts consisting primarily currency swaps total fair value million million liability represent hedges intercompany loans deposits designated accounting hedges changes fair value taken profit loss period offset exchange gains losses related intercompany lending borrowing gsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot seton notes financial statements continued financial instruments related disclosures employee share schemes continued group operates share option schemes whereby options cash flow hedges granted employees acquire shares adss glaxosmithkline plc group entered cross currency swap designated grant price savingsrelated share option schemes share cash flow hedge converting fixed euro interest payable annually award schemes whereby awards granted employees fixed yen payments bond matures risk hedged acquire shares adss glaxosmithkline plc cost subject variability cash flows arising currency fluctuations achievement group specified performance targets ineffectiveness assumed hedge group introduced new share award scheme share value plan whereby awards granted employees acquire cash flows relating hedge expected occur within shares adss glaxosmithkline plc cost three year next two years amounts recognised equity recycled vesting period granting restricted share awards replaced income statement offset exchange gains losses granting options certain employees cost period underlying bond result revaluation scheme readily equates potential gain made balance sheet date employee amount recognised equity cross currency interest grants share option schemes normally exercisable rate swaps million credit million credit three ten years date grant grants restricted shares amount recycled equity income statement share awards normally exercisable end three cross currency interest rate swaps offset exchange loss year vestingperformance period grants savingsrelated share underlying bond recognised income statement million option schemes normally exercisable three years saving million net fair value movements cash flow options share option schemes granted market hedges disclosed consolidated statement recognised price ruling date grant accordance uk practice income expense majority options savingsrelated share option schemes fair value hedges granted price market price ruling group designated interest rate swaps interest date grant element one two cross currency swaps fair value hedge share options awarded directors effect risk hedged variability fair value bonds grant cet subject performance criteria arising interest rate fluctuations gains losses fair value hedges disclosed note finance costs net investment hedges foreign exchange contracts currency element one groups two cross currency swaps designated net investment hedges respect foreign currency translation risk principally arising consolidation groups net investment us dollar euro yen foreign operations addition euro loan capital issued year billion million previous years designated nonmonetary net investment hedge respect foreign currency translation risk principally arising consolidation groups net investment euro operations net investment hedge ineffectiveness disclosed note finance incomegsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot seton notes financial statements continued employee share schemes continued option pricing purposes valuing options arrive stockbased compensation charge blackscholes option pricing model used assumptions used model follows riskfree interest rate dividend yield volatility expected lives options granted share option schemes years years years savingsrelated share option schemes years years years weighted average share price grants year ordinary shares adss volatility determined based three year share price history fair value performance share plan grants take account market conditions expected lives options determined based weighted average historic exercises options share option share option savingsrelated options outstanding schemes shares schemes adss share option schemes weighted weighted weighted weighted weighted weighted number exercise fair number exercise fair number exercise fair price value price value price value st january options granted options exercised options lapsed st december options granted options exercised options lapsed st december options granted options exercised options lapsed st december range exercise prices weighted average remaining contractual life years years years gsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot seton notes financial statements continued employee share schemes continued order encourage employees convert options excluding savingsrelated share options held glaxo wellcome smithkline beecham shares adss glaxosmithkline shares adss programme established give additional cash benefit exercise price original option provided employee voluntarily leave group two years date merger exercise option earlier six months expiry date original option two years date merger cash benefit also paid options expire unexercised market price exercise price date expiry options outstanding share option share option savingsrelated st december schemes shares schemes adss share option schemes weighted latest weighted latest latest number exercise exercise number exercise exercise number exercise exercise year grant price date price date price date total options exercisable except options shares adss granted savingsrelated share options granted change effective exercise price outstanding options year options exercisable share option share option savingsrelated st december schemes shares schemes adss share option schemes weighted weighted weighted number exercise number exercise number exercise price price price st december st december st december gsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot seton notes financial statements continued employee share schemes continued glaxosmithkline share award schemes performance share plan group operates performance share plan whereby awards granted directors senior executives cost percentage award vests based upon performance group three year measurement period performance conditions consist two parts applies award awards granted first part condition compares gsks total shareholder return tsr period tsr companies uk ftse index period awards granted subsequent years first part condition compares gsks tsr period tsr pharmaceutical companies comparator group period awards second part performance condition compares gsks earnings per share growth increase uk retail prices index three year performance period awards granted directors members cet th december subject single performance condition compares gsks tsr period tsr companies comparator group period shares weighted adss weighted number shares adss issuable number fair value number fair value st january awards granted awards exercised awards cancelled st december awards granted awards exercised awards cancelled st december awards granted awards exercised awards cancelled st december share value plan group operates share value plan whereby awards granted form shares certain employees cost awards vest three years performance criteria attached shares weighted adss weighted number shares adss issuable number fair value number fair value st january awards granted awards exercised awards cancelled st december awards granted awards exercised awards cancelled st december awards granted awards exercised awards cancelled st december gsk annual report stnemetats laicnanif stnemetats laicnanfi eht ot seton notes financial statements continued employee share schemes continued employee share ownership plan trusts group sponsors employee share ownership plan esop trusts acquire hold shares glaxosmithkline plc satisfy awards made employee incentive plans options granted employee share option schemes trustees esop trusts purchase shares open market finance provided group way loans contributions costs running esop trusts charged income statement shares held esop trusts deducted reserves held value proceeds receivable employees exercise deemed permanent diminution value reflected transfer retained earnings trusts also acquire hold shares meet notional dividends reinvested deferred awards smithkline beecham midterm incentive plan trustees waived rights dividends shares held esop trusts shares held share award schemes number shares nominal value carrying value market value shares held share option schemes number shares nominal value carrying value market value gsk annual report stnemetats laicnanif stnemetats laicnanif eht ot seton notes financial statements continued principal group companies following represent principal subsidiary associated undertakings glaxosmithkline group st december details given principal country operation location headquarters business segment business activities equity share capital undertakings wholly owned group except percentage interest shown otherwise companies incorporated principal country operation except stated europe location subsidiary segment activity england brentford glaxosmithkline holdings limited phch h brentford glaxosmithkline holdings one limited phch h brentford glaxosmithkline services unlimited phch brentford glaxosmithkline finance plc phch f brentford glaxosmithkline capital plc ph f brentford smithkline beecham plc phch e h p r brentford wellcome limited phch h greenford glaxo group limited ph h greenford glaxo operations uk limited ph p brentford glaxo wellcome international bv phch h brentford glaxo wellcome investments bv phch h brentford glaxosmithkline export limited ph e brentford glaxosmithkline research development limited ph r brentford glaxosmithkline uk limited ph p brentford smithkline beecham investments limited phch f brentford setfirst limited phch h greenford wellcome foundation limited ph p cambridge domantis limited ph r brentford smithkline beecham overseas limited ph h brentford smithkline beecham holdings uk limited ph h brentford glaxosmithkline netherlands bv ph h austria vienna glaxosmithkline pharma gmbh ph belgium genval glaxosmithkline sa ph rixensart glaxosmithkline biologicals sa ph e p r czech republic prague glaxosmithkline sro phch denmark orestadt glaxosmithkline consumer healthcare ch brndby glaxosmithkline pharma ph finland espoo glaxosmithkline oy ph france marly le roi groupe glaxosmithkline sas ph h marly le roi laboratoire glaxosmithkline sas ph r marly le roi glaxo wellcome production sas ph p marly le roi glaxosmithkline sante grand public sas ch germany buehl glaxosmithkline consumer healthcare gmbh co kg ch h p r munich glaxosmithkline gmbh co kg ph h p r greece athens glaxosmithkline aebe phch guernsey st peter port setfirst limited phch h hungary budapest glaxosmithkline medicine healthcare products limited phch e italy verona glaxosmithkline spa ph h r milan glaxosmithkline consumer healthcare spa ch h verona glaxosmithkline manufacturing spa ph p luxembourg mamer glaxosmithkline international luxembourg sa phch f h netherlands zeist glaxosmithkline bv ph utrecht glaxosmithkline consumer healthcare bv ch gsk annual report stnemetats laicnanif stnemetats laicnanif eht ot seton notes financial statements continued principal group companies continued europe location subsidiary segment activity norway oslo glaxosmithkline ph poland poznan glaxosmithkline pharmaceuticals sa ph p poznan gsk services spzoo ph warsaw glaxosmithkline consumer healthcare spzoo ch e portugal alges glaxosmithklineprodutos farmaceuticos limitada ph republic carrigaline smithkline beecham cork limited ii ph p r ireland cork glaxosmithkline trading services limited ii ph e dublin glaxosmithkline consumer healthcare ireland limited ii ch dublin glaxosmithkline ireland limited ph russian moscow glaxosmithkline trading zao ph federation moscow glaxosmithkline healthcare zao ch spain madrid glaxosmithkline sa ph madrid glaxosmithkline consumer healthcare sa ch aranda de duero glaxo wellcome sa ph p sweden solna glaxosmithkline ab ph switzerland muenchenbuchsee glaxosmithkline ag ph usa usa hamilton corixa corporation ph p pittsburgh cns inc ch philadelphia smithkline beecham corporation phch e h p r pittsburgh glaxosmithkline consumer healthcare lp ch p pittsburgh block drug company inc ch h wilmington glaxosmithkline holdings americas inc phch h liberty corner reliant pharmaceuticals inc ph r wilmington glaxosmithkline capital inc ph f americas bermuda hamilton glaxosmithkline insurance ltd phch canada mississauga glaxosmithkline inc ph p r oakville glaxosmithkline consumer healthcare inc ch laval id biomedical corporation ph p r laval id biomedical corporation quebec ph p r asia pacific australia boronia glaxosmithkline australia pty ltd phch e p r china hong kong glaxosmithkline limited phch tianjin sinoamerican tianjin smith kline french laboratories ltd ph p r india mumbai glaxosmithkline pharmaceuticals limited ph p nabha glaxosmithkline consumer healthcare limited iii ch p malaysia petaling jaya glaxosmithkline pharmaceutical sdn bhd ph petaling jaya glaxosmithkline consumer healthcare sdn bhd ch new zealand auckland glaxosmithkline nz limited phch pakistan karachi glaxosmithkline pakistan limited phch p e philippines makati glaxosmithkline philippines inc phch singapore singapore glaxochem pte ltd ph h singapore glaxo wellcome manufacturing pte ltd ph p singapore glaxosmithkline pte ltd phch mgsk annual report stnemetats laicnanif stnemetats laicnanif eht ot seton notes financial statements continued principal group companies continued asia pacific location subsidiary segment activity south korea seoul glaxosmithkline korea limited ph p thailand bangkok glaxosmithkline thailand limited phch japan japan tokyo glaxosmithkline kk phch p latin america argentina buenos aires glaxosmithkline argentina sa phch p brazil rio de janeiro glaxosmithkline brasil ltda phch e p colombia bogota glaxosmithkline colombia sa phch mexico delegacion tlalpan glaxosmithkline mexico sa de cv phch e p puerto rico guaynabo glaxosmithkline puerto rico inc ph cidra sb pharmco puerto rico inc ph p venezuela caracas glaxosmithkline venezuela ca phch middle east africa egypt cairo glaxosmithkline sae ph p south africa bryanston glaxosmithkline south africa pty ltd phch p turkey istanbul glaxosmithkline ilaclari sanayi ticaret ph p usa location associate business usa madison quest diagnostics incorporated iv clinical testing incorporated netherlands ii exempt provisions section companies amendment act ireland iii c onsolidated subsidiary undertaking accordance section companies act grounds dominant influence iv equity accounted grounds significant influence directly held wholly owned subsidiary glaxosmithkline plc key business segment ph pharmaceuticals ch consumer healthcare business activity development e exporting f finance h holding company insurance marketing p production r research service full details group subsidiary associated undertakings attached companys annual return filed registrar companies glaxosmithkline capital inc glaxosmithkline capital plc whollyowned finance subsidiary company company fully unconditionally guaranteed securities issued glaxosmithkline capital inc glaxosmithkline capital plc gsk annual report stnemetats laicnanif stnemetats laicnanif eht ot seton notes financial statements continued legal proceedings complaint based threat market salmeterolfluticasone combination product germany prior patent expiry basic patent group involved significant legal administrative covering combination product seretide expires september proceedings principally product liability intellectual property subject supplementary protection certificate extends tax antitrust governmental investigations related private protection september action early stages litigation group makes provision proceedings regular basis summarised notes group may make argatroban additional significant provisions legal proceedings required december encysive pharmaceuticals inc mitsubishi kasei event developments matters consistent corporation group filed action us district court generally accepted accounting principles litigation particularly southern district new york barr laboratories inc usa inherently unpredictable excessive awards infringement mitsubishis pharmaceutical composition patent may justified evidence may occur group could covering argatroban pursuant license mitsubishi encysive future incur judgements enter settlements claims developed argatroban treatment heparininduced could result payments exceed current provisions thrombocytopenia holds new drug application approved amount would material adverse effect groups us fda encysive licensed us marketing rights argatroban financial condition results operations andor cash flows group mitsubishi patent expires june barr filed abbreviated new drug application anda fda intellectual property claims include challenges validity certification invalidity unenforceability noninfringement enforceability groups patents various products processes mitsubishi patent fda approval anda stayed earlier assertions noninfringement patents loss may resolution patent infringement action case cases could result loss patent protection product early stages issue consequences loss could significant decrease sales product could materially affect future avandia avandamet avandaryl results operations group august group filed action us district court district new jersey teva pharmaceuticals usa inc legal expenses incurred provisions related legal claims infringement groups patent relating maleate salt charged selling general administration costs provisions form rosiglitazone active ingredient avandia expires made taking appropriate legal specialist advice september group filed comparable action reasonable estimate made likely outcome court dr reddys laboratories alleging infringement dispute group established actuarially determined patent actions filed response anda filings provision product liability claims incurred yet reported fda dr reddys laboratories teva certifications described note provisions st december groups maleate salt patent invalid unenforceable groups aggregate provision legal disputes infringed teva subsequently filed similar certification including tax matters described note taxation challenging groups basic compound patent rosiglitazone billion ultimate liability legal claims may vary january group commenced action teva amounts provided dependent upon outcome litigation court infringement patent proceedings investigations possible settlement negotiations january group filed action us district court significant matters described district new jersey teva infringement intellectual property two patents basic compound maleate salt patents advairseretide rosiglitazone teva filed anda fda generic september group applied us patent version avandamet certification patents trademark office uspto reissue combination patent invalid unenforceable infringed advair inhaled combination salmeterol fluticasone may group filed action us district court propionate expires september followed district new jersey teva infringement internal review concluded language patent groups patent related maleate salt form rosiglitazone may accurately described circumstances groups basic patent rosiglitazone teva filed anda invention may claimed invention precisely fda generic version avandaryl certification could objective seeking reissuance strengthen patents invalid unenforceable infringed protection afforded patent uspto reissued patent february reissued patent september june group voluntarily dismissed infringement claims expiration date original composition patent listed respect patent covering maleate salt form rosiglitazone register pharmaceutical patents maintained us fda since dr reddys challenged basic compound patent orange book dismissal maleate salt claim dismissed claims dr reddys respect avandia october group filed complaint patent dispute chamber regional court dsseldorf germany neolab uk infringement german patent claiming compositions containing combination salmeterol fluticasone propionate used seretide known viani germanygsk annual report stnemetats laicnanif stnemetats laicnanif eht ot seton notes financial statements continued legal proceedings continued groups action urlmutual amended include claim infringement reissued patent fda approval url respect groups patent infringement actions teva mutuals anda stayed earlier june resolution respect basic compound maleate salt form patents patent infringement action event approval august parties reached settlement provides issue prior expiration data exclusivity period april teva may enter us market generic versions avandia case early stages avandamet avandaryl oral tablets late first quarter terms settlement remain confidential paxilseroxat usa number distributors generic drugs filed applications avodart fda market generic versions paxilseroxat paroxetine february group filed action us district court hydrochloride prior expiration groups district delaware barr laboratories infringement patent paroxetine hyrdrochloride hemihydrate response basic patent covering active ingredient avodart group filed number patent infringement actions compound generally use treat benign prostate hypertrophy concluded resolved except described one bph basic compound patent expires november distributor apotex launched generic product usa two patents expire september barr filed september additional generic products launched anda fda certification invalidity unenforceability defendants march noninfringement three patents fda approval barrs anda stayed earlier july resolution group filed two separate patent infringement actions patent infringement action case early stages apotex one us district court northern district illinois eastern district pennsylvania appeals boniva group us court appeals federal circuit cafc september roche laboratories commenced actions hears appeals us district courts patent matters us district court district new jersey seven generic cases remand matter panel drug manufacturers us district court northern one case relevant claim patent paroxetine hydrochloride district illinois eighth manufacturer case hemihydrate ruled invalid claims patents alleging infringement roche patents relating boniva tablets ruled invalid andor infringed cases appeals defendants filed anda fda certification pending planned claims pending trial invalidity unenforceability noninfringement least one roche patents one manufacturer challenged basic europe generic products containing paroxetine hydrochloride compound patent expires march final fda approval market european countries whilst andas stayed earlier november resolution products subject continuing litigation actions relevant patent infringement action group participates concluded settled respect two manufacturers marketing boniva pursuant copromotion agreement synthon bv fal litigation ongoing counterclaims roche cases early stages unfair competition asserted group combivir following litigation canada apotex several november group filed action district court patents related paroxetine apotex launched generic product district delaware teva pharmaceuticals infringement canada october apotex alleged result one patents relating combivir patent covers litigation enjoined launching product combination azt lamivudine treat hiv expires may receipt regulatory approval action apotex recover damages teva filed anda fda certification related delay occasioned injunctions ongoing invalidity unenforceability noninfringement combination paxil cr patent teva challenge two patents relating combivir november mylan pharmaceuticals filed anda paxil expire case early stages cr paroxetine hydrochloride controlled release formulation coreg cr certification invalidity unenforceability noninfringement several february group filed action us district court patents listed fda orange book certification eastern district pennsylvania united research respect patent covering paroxetine hydrochloride hemihydrate laboratories incmutual pharmaceuticals company inc respect mylan admitted active ingredient product patent groups patent relating crystalline salt form carvedilol expired june giving effect grant paediatric exclusivity active ingredient coreg cr url mutual filed anda fda group file patent infringement action fda certification invalidity unenforceability mylan within day period provided hatchwaxman noninfringement patents covering crystalline salt form month stay fda approval mylan anda delayed release technology used manufacturing product new us patent covering delayed controlled release formulation expire respectively january uspto paroxetine hydrochloride paxil cr issued group june issued groups patent method use administration listed fda orange book thereafter group filed carvedilol therapeutic agents reissued patent action us district court district new jersey listed orange book expires mylan infringement newly issued patent gsk annual report stnemetats laicnanif stnemetats laicnanif eht ot seton notes financial statements continued legal proceedings continued march biovail announced following review us federal trade commission ftc requested parties subsequently parties reached settlement permits mylan comprehensive settlement anchen pharmaceuticals impax enter market strengths paxil cr later st laboratories watson pharmaceuticals teva pharmaceutical october terms settlement remain confidential industries certain aspects settlements remain confidential requip parties disclose defined exceptions anchen impax april group commenced action us district watson teva may market generic version mg court district delaware teva pharmaceutical usa inc strength wellbutrin xl alleging infringement groups compound patent ropinirole fda given final approval anchens anda generic hydrochloride active ingredient requip method use version wellbutrin xl impax generic mg tablet patent treatment parkinsons disease listed product mg generic product launched usa fda orange book compound patent expired december end december generic version mg tablet method use patent expires may defendant launched date report filed anda fda certification patents invalid unenforceable infringed december uspto action judge ruled conclusion trial groups patent october group filed action us patent method use ropinirole treat parkinsons disease novel trademark office us district court eastern nonobvious rejecting tevas claims grounds tevas original district virginia requesting court enjoin office challenge groups basic compound patent withdrawn implementing new regulations affecting substantive rights related teva accepted fda approve product prior filing obtaining patents regulations due expiration patent addition teva stipulated become effective st november october groups method use patent valid enforceable tevas court issued order enjoining implementation rules generic version would infringe teva waived right appeal full hearing could held parties crossmotions summary december judgement favour group agreed judgement final decision rendered hearing held wait expiration groups patent may th february decision reported launching generic product date report valtrex product liability may group commenced action us district court preclinical clinical trials conducted development district new jersey ranbaxy laboratories alleging potential products determine safety efficacy infringement groups compound patent valacyclovir products use humans following approval regulatory active ingredient valtrex patent expires defendant bodies notwithstanding efforts drugs vaccines filed anda fda certification groups introduced marketplace unanticipated side effects may compound patent invalid unenforceable infringed become evident group currently defendant number case settled terms permit ranbaxy enter product liability lawsuits related groups pharmaceutical market late taking account expected paediatric exclusivity products significant matters described respect groups basic composition matter patent avandia wellbutrin xl may new england journal medicine nejm published december biovail commenced actions us district court article avandia author based metaanalysis central district california anchen pharmaceuticals clinical trials raises concerns use drug rosiglitazone us district court southern district florida avandia may associated increased risk heart attack abrika pharmaceuticals case alleging infringement biovail cardiovascular death comparison use placebo formulation patents wellbutrin xl april biovail filed antidiabetic therapies following publication nejm article action us district court eastern district pennsylvania group named product liability lawsuits behalf impax laboratories infringement patents individuals purported class action cases asserting consumer fraud patents expire anchen abrika impax filed andor personal injury claims behalf purchasers users anda fda certification invalidity noninfringement avandia federal cases part multidistrict litigation mdl biovail patents group licensee patents proceeding pending us district court eastern district pennsylvania cases also filed state courts august judge granted anchens motion ruled litigation early stage anchens anda product infringe biovails patent biovail appealed decision cafc group party actions september biovail commenced actions us district court southern district new york watson laboratories alleging infringement biovail formulation patents watsons third party counterclaim group based listing activities associated fda orange book dismissed october gsk annual report stnemetats laicnanif stnemetats laicnanif eht ot seton notes financial statements continued legal proceedings continued group received numerous claims lawsuits alleging treatment paxil caused homicidal suicidal behaviour exhibited baycol users product class certification denied january august bayer ag withdrew baycol cerivastatin sodium purported personal injury class action lawsuit january worldwide light reports adverse events including deaths fda approved boxed warning antidepressants increased involving rhabdomyolysis group participated marketing risk suicidal thoughts behaviour paediatric patients baycol usa pursuant copromotion agreement bayer strengthened warnings ssri products including paxil licence holder manufacturer product class may paxil us label updated warn young following withdrawal bayer group named adults especially major depressive disorder may defendants thousands lawsuits filed state federal courts increased risk suicidal behaviour treatment paroxetine usa behalf individuals putative classes august fda required updated us labels antidepressants former baycol users number suits allege plaintiffs class state boxed warning antidepressants increased suffered personal injuries including rhabdomyolsis risk suicidal thinking behaviour children adolescents use baycol others claim persons took baycol although young adults increase shown beyond age injured may risk future injury may suffered reduction risk adults aged older economic damages purchasing using baycol plaintiffs seek depression psychiatric disorders associated remedies including compensatory punitive statutory damages increased risk creation funds medical monitoring group received lawsuits filed state federal courts group bayer corporation principal us subsidiary usa canada behalf thousands plaintiffs including bayer ag signed allocation agreement purported class actions alleging paroxetine active ingredient bayer corporation agreed pay settlements paxil addictive causes dependency withdrawal reactions compensatory damages judgements party retaining us federal cases consolidated mdl proceeding responsibility attorneys fees punitive damages january conditional settlement agreement became effective federal cases consolidated mdl proceeding group admit liability respect allegations us district court district minnesota date two state lawsuits virtually us actions resolved wide class actions certified medical monitoring case one purported class action consumer fraud lawsuit focused pennsylvania consumer fraud deceptive business practices discontinuation symptoms appeal denial class act case illinois medical monitoring action dismissed certification california state court purported class action court summary judgement another class action litigation canada group also defending litigation gsk named defendant certified oklahoma commenced uk behalf hundreds plaintiffs claims death serious injury settled allege paroxetine caused suffer withdrawal thousands others alleging muscle aches pains reactions dependency voluntarily involuntarily dismissed thimerosal paxil paxil cr group along number pharmaceutical companies group received lawsuits claims alleging use paxil named defendant numerous individual personal injury paroxetine pregnancy resulted birth child lawsuits state federal district courts usa alleging birth defects health issues separately group received thimerosal preservative used manufacture vaccines causes lawsuits claims patients took paxil committed neurodevelopmental disorders injuries including autism attempted commit suicide andor acts violence group also two cases purported class actions although received lawsuits claims filed behalf patients alleging determination whether cases permitted suffered symptoms discontinuing treatment paxil proceed class action number purported class actions jurisdictions withdrawn dismissed plaintiffs seek group received numerous lawsuits claims alleging remedies including compensatory punitive statutory damages use paxil pregnancy resulted birth child cost fund medical monitoring research congenital malformation persistent pulmonary hypertension date report limited number cases newborn september us label paxil updated approached trial dates vaccine manufacturers manufacturers reflect new information suggested increased risk thimerosalcontaining medicinal products congenital malformations particularly cardiovascular malformations successful excluding testimony plaintiffs expert witnesses infants born mothers took paxil first trimester causation grounds plaintiffs failed establish pregnancy december paxil us label updated hypothesized link thimerosal neurodevelopmental include new data strengthen pregnancy warning disorders generally accepted reliable within relevant scientific category c category indicates evidence risk community date report cases scheduled foetus potential benefits use drug trial group defendant pregnant women may outweigh risk may paxil us label updated include class warning concerning persistent pulmonary hypertension newborn arising mothers took selective serotonin reuptake inhibitor ssri antidepressants th week pregnancy gsk annual report stnemetats laicnanif stnemetats laicnanif eht ot seton notes financial statements continued legal proceedings continued group agreed pay government civil settlement million respect marketing zofran kytril sales marketing regulation included settlement amounts states claims marketing promotion settled part settlement corporate integrity february group received subpoena us agreement group party amended address attorneys office colorado regarding groups sales issues raised course government investigation promotional practices relating nine largest selling products period january present particular subsequent initial subpoenas number states government inquired alleged promotion drugs respective attorneys general counties new offlabel uses well group sponsored continuing medical york state filed civil lawsuits state federal courts gsk education programmes speaker events special issue boards many drug companies actions claim behalf advisory boards speaker training programmes clinical studies states payers cases behalf instate related grants fees travel entertainment although original patients consumers damages restitution due awpbased subpoena issued us attorneys office colorado price reporting pharmaceutical products covered states scope inquiry nationwide government also inquiring medicaid programmes cases governmental groups response october letter programmes addition private payer class action lawsuits fdas division drug marketing advertising communication filed gsk multiple federal district state courts requesting information groups alleged promotion federal cases consolidated mdl proceeding us wellbutrin sr offlabel use group cooperating district court district massachusetts investigation providing requested information august judge mdl proceeding granted part february verona public prosecutor commenced criminal denied part privatepayer plaintiffs motion class investigation groups sales marketing practices italy certification thereby narrowing scope class claims specific areas investigation include medical education programmes august group reached civil settlements resolve class clinical studies congresses well interaction action litigation certain state attorney general claims groups representatives physicians public prosecutor group agreed nationwide settlement million proposed number physicians representatives resolve claims approved trial court august group face criminal charges hearing set group separately resolved potential awp claims state october us securities exchange commission sec medicaid programmes twothirds states staff initiated investigation allegations group procedures established doj settlement awp lawsuits cooperating investigations filed threatened number state attorneys general also fully resolved litigation concerning awp issues continuing following united nations report alleging bribes paid ten states well new york counties iraqi government officials connection un oil food programme group received subpoena sec february nominal pricing respect groups participation programme group responded two letter requests us senate us department justice also initiated investigation december committee finance dated april february uk serious fraud office issued formal notice documents information relating nominal price exception group requiring production documents related groups best price reporting requirements medicaid drug rebate participation programme group cooperating programme january committee released findings investigations providing documents responsive subpoena pharmaceutical manufacturers inappropriately used notice nominal price exception contrary committees interpretation congressional intent may group advised average wholesale price us department justice investigating certain gsk responded subpoenas office inspector groups nominal pricing bundled sales arrangements determine general us department health human services hhs whether arrangements qualify exception best us department justice states texas california price reporting requirements violate civil statutes laws connection allegations pharmaceutical companies including gsk violated federal fraud abuse laws group cooperating investigation provided federal false claims act comparable state laws respect documents information department justice regarding texas california result way average wholesale arrangements number groups products march price awp determined reported certain drugs group received two subpoenas delaware attorney way medicare medicaid programmes reimburse generals office seeking documents related nominal price contracts drugs september group reached civil settlement hospitals healthcare providers located delaware us department justice us attorney district pharmaceutical companies received similar subpoenas massachusetts office inspector general hhs group providing documents responsive subpoenas doj settlement addition governmental investigations allegations concerning nominal pricing made certain government payers part awp litigationgsk annual report stnemetats laicnanif stnemetats laicnanif eht ot seton notes financial statements continued legal proceedings continued april group received subpoena us attorneys office boston requesting production records regarding paxilseroxat manufacturing cidra site covering information following announcement new york state attorney generals similar seized us government puerto rico office states lawsuit subsequently settled august subsequently august january group received alleging failure disclose data use paxil children two additional subpoenas government related cidra adolescents similar cases purport class actions facility group cooperating us attorneys office filed state federal canadian courts private producing records responsive subpoenas addition plaintiffs seeking recover amounts paid paxil purchased use july group learned us district court district patients age canadian litigation dismissed massachusetts unsealed complaint brought former group reached class settlement agreement illinois state employee federal false claims act claiming monetary court action includes persons usa bought paxil damages result alleged failure cidra facility someone age group denies liability comply gmp manufacture various products agreement relates cost purchasing paxil use paediatric patients include personal injury claims group also named two purported consumer fraud class settlement approved court april remaining action lawsuits one filed california state court four lawsuits seeking recovery behalf insurance companies us district court district puerto rico alleging paxil thirdparty payers payments prescriptions paxil products manufactured according gmp plaintiffs seek children adolescents group granted partial summary economic statutory punitive damages along request judgement dismissing class claims one cases discovery injunctive relief yet determination whether underway state court action california pending hearing either case permitted proceed class action class certification antitrust uk investigation remains pending uk medicines paxilseroxat healthcare products regulatory agency mhra determine paroxetine patent infringement actions brought group whether group complied pharmacovigilance described intellectual property apotex certain obligations reporting data clinical trials seroxatpaxil companies filed antitrust unfair competition counterclaims children adolescents group us district court eastern district pennsylvania based allegations group monopolised market cidra puerto rico manufacturing site paxil bringing allegedly sham patent litigation allegedly following fda inspections october november abusing regulatory procedures listing patents fda resulted observations possible deficiencies manufacturing orange book whilst apotex matter remains discovery stage practices groups manufacturing facility cidra puerto rico matters companies resolved march fda seized certain lots paxil cr avandamet due manufacturing issues fda observations related certain aspects november ftc staff advised group production controls process validation laboratory investigations conducting nonpublic investigation determine whether group violating section federal trade commission april group reached agreement fda act monopolising attempting monopolise market consent decree consent decree provides independent paroxetine hydrochloride preventing generic competition expert review manufacturing processes site compliance paxil requested group submit certain information fda good manufacturing practice gmp requirements connection investigation october ftc closed provided consent decree september group investigation basis finding action provided report fda deficiencies identified warranted following public reference ftc investigation review setting corrective plan timetable completion regarding paxil number governmental private civil actions group anticipates completion work identified plan claims initiated usa resolved mid march fda completed general gmp exception private indirect purchaser optout lawsuit brought inspection resulted four inspectional observations minnesota courts matter discovery phase group advised fda groups response additionally class actions filed provincial courts inspectional observations satisfactory canada behalf direct indirect purchasers cases october group announced plans cease operations early stages cidra site expects continue production paxil cr october competition directorate european site production transferred another facility commission initiated inspection concerning allegations group currently expects take place production group abused dominant position marketplace products site discontinued end concerning enforcement intellectual property rights litigation october us federal government executed search surrounding regulatory approvals marketing seroxat warrant cidra facility seized records relating europe october commission made formal request manufacturing operations site information group responded request end gsk annual report stnemetats laicnanif stnemetats laicnanif eht ot seton notes financial statements continued legal proceedings continued relenza may biota holdings limited filed complaint victorian january european commission announced inquiry supreme court australia alleging group failed fulfil certain aspects competition pharmaceutical sector development promotion production obligations zanamivir initiated inspections premises number innovative relenza terms licence agreement generic pharmaceutical companies including group group group biota biota seeking substantial cash damages cooperating commission investigation group believes adhered obligations licence wellbutrin sr agreement parties involved extensive discovery court december january february lawsuits ordered parties mediate end july several purported class actions filed us scheduled trial commence august district court eastern district pennsylvania overtime claims group behalf direct indirect purchasers wellbutrin sr december two purported class actions filed complaints allege violations us antitrust laws sham group behalf groups us pharmaceutical sales litigation fraud patent office group obtaining representatives actions filed transferred enforcing patents covering wellbutrin sr complaints us district court central district california allege follow introduction generic competition wellbutrin sr representatives exempt employees california april district appellate court rulings generic law andor us fair labor standards act consequently entitled manufacturer infringe groups patents parties overtime pay suits seek double damages overtime involved discovery allegedly worked groups sales representatives three secondary wholesaler year period together attorneys fees cases early july rxusa wholesale inc secondary wholesaler filed stages similar actions filed pharmaceutical suit group many pharmaceutical manufacturers companies several actions courts found favour wholesalers us district court eastern district companies dismissed actions dismissals new york complaint alleges defendants engaged appeal conspiracy refuse supply pharmaceutical products rxusa environmental matters violation federal state antitrust laws groups motion gsk notified potential responsibility relating past dismiss complaint remains pending operations past waste disposal practices certain sites commercial corporate primarily usa matters subject securities class actions litigation including proceedings initiated us federal state september attorneys representing purported class governments waste disposal site remediation costs tort purchasers glaxosmithkline shares american depositary actions brought private parties shares adss filed second amended securities class action complaint gsk advised may responsible party group us district court southern district approximately sites appear national priority new york alleging group violated us securities laws list created comprehensive environmental response failure disclose unfavourable clinical data studies paxil compensation liability act superfund misrepresentation remaining patent protection paxil augmentin violation federal false claims act basis proceedings seek require operators hazardous groups recent awp settlement government october waste facilities transporters waste sites generators judge entered order dismissing complaint plaintiffs hazardous waste disposed sites clean sites filed appeal us court appeals second circuit reimburse government cleanup costs instances gsk oral argument appeal set th march involved alleged generator hazardous waste although sites gsk involved current former operator november attorneys purporting represent class facility although superfund provides defendants purchasers glaxosmithkline shares adss filed amended jointly severally liable cleanup costs proceedings consolidated complaint group senior officers frequently resolved basis nature quantity waste us district court southern district new york alleging disposed site generator gsks proportionate liability group individual defendants violated us securities cleanup costs substantially determined laws artificially inflated price glaxosmithklines stock sites referred misleading investors safety avandia amended consolidated complaint also alleges several current former gsks potential liability varies greatly site site cost senior officers members group engaged insider trading investigation study remediation sites could time motion dismiss complaint filed behalf substantial gsk routinely accrues amounts related share group individual defendants liability mattersfinancial statements glaxosmithkline plc directors statements responsibility directors statement responsibility relation directors remuneration companys financial statements remuneration report pages sets remuneration directors policies operated glaxosmithkline disclosures directors remuneration disclosable information relating directors responsible ensuring maintenance proper accounting officers interests prepared accordance records disclose reasonable accuracy financial companies acts complies section position company time financial b combined code corporate governance statements prepared comply companies acts going concern basis required law prepare financial statements financial making enquiries directors reasonable period give true fair view state affairs expectation company adequate resources continue company end financial period profit operational existence foreseeable future reason loss period continue adopt going concern basis preparing responsible also ensuring operation systems financial statements internal control taking reasonable steps safeguard assets company preventing detecting fraud combined code irregularities board considers glaxosmithkline plc applies principles balance sheet year ended st december combined code corporate governance financial supporting notes set pages report reporting council described corporate governance pages complied provisions except directors confirm suitable accounting policies described consistently applied preparation financial statements supported reasonable prudent judgements estimates required listing rules financial services authority necessary applicable accounting standards followed auditors considered directors statement compliance financial statements prepared going relation points combined code specified concern basis review responsibilities auditors relation financial statements set independent auditors report annual report published hardcopy printed form made available website directors responsible maintenance integrity annual report website accordance uk legislation governing preparation sir christopher gent dissemination financial statements access website chairman available outside uk comparable legislation may th february different disclosure information auditors directors office date report confirmed far aware relevant audit information companys auditors unaware director taken steps heshe ought taken director make himselfherself aware relevant audit information establish companys auditors aware information confirmation given interpreted accordance provisions section za companies act gsk annual report stnemetats laicnanif ytilibisnopser fo stnemetats srotceridfinancial statements glaxosmithkline plc independent auditors report members glaxosmithkline plc audited parent company financial statements basis audit opinion glaxosmithkline plc year ended st december conducted audit accordance international standards comprise balance sheet related notes auditing uk ireland issued auditing practices board parent company financial statements prepared audit includes examination test basis evidence relevant accounting policies set therein also audited amounts disclosures parent company financial information directors remuneration report described statements part directors remuneration report audited audited also includes assessment significant estimates reported separately group financial statements judgements made directors preparation glaxosmithkline year ended st december parent company financial statements whether accounting policies appropriate companys circumstances consistently respective responsibilities directors applied adequately disclosed auditors planned performed audit obtain directors responsibilities preparing annual report information explanations considered necessary order directors remuneration report parent company financial provide us sufficient evidence give reasonable assurance statements accordance applicable law united kingdom parent company financial statements part accounting standards united kingdom generally accepted directors remuneration report audited free material accounting practice set statement directors misstatement whether caused fraud irregularity error responsibilities forming opinion also evaluated overall adequacy presentation information parent company financial responsibility audit parent company financial statements statements part directors remuneration report part directors remuneration report audited audited accordance relevant legal regulatory requirements international standards auditing uk ireland report opinion including opinion prepared companys members body accordance section opinion companies act purpose parent company financial statements give true fair giving opinion accept assume responsibility view accordance united kingdom generally accepted purpose person report shown accounting practice state companys affairs whose hands may come save expressly agreed prior st december consent writing parent company financial statements part report opinion whether parent company directors remuneration report audited properly financial statements give true fair view whether prepared accordance companies act parent company financial statements part directors remuneration report audited properly prepared information given report directors consistent accordance companies act also report parent company financial statements whether opinion information given report directors consistent parent company financial statements addition report opinion company kept proper accounting records received pricewaterhousecoopers llp information explanations require audit chartered accountants registered auditors information specified law regarding directors remuneration london transactions disclosed th february read information contained annual report consider whether consistent audited parent company financial statements information comprises notes financial summary joint statement chairman chief maintenance integrity glaxosmithkline website executive financial trends ratios business review corporate responsibility directors work carried auditors governance statement unaudited parts remuneration involve consideration matters accordingly auditors accept report consider implications report become responsibility changes may occurred financial aware apparent misstatements material inconsistencies statements since initially presented website parent company financial statements responsibilities b legislation united kingdom governing preparation dissemination extend information financial information may differ legislation jurisdictions gsk annual report stnemetats laicnanif troper srotidua tnednepednifinancial statements glaxosmithkline plc company balance sheet uk gaap st december notes fixed assets investments debtors e cash bank current assets creditors amounts due within one year f net current liabilities net assets capital reserves called share capital g share premium account g reserves h profit loss account h equity shareholders funds approved board th february sir christopher gent chairman gsk annual report stnemetats laicnanif paag ku teehs ecnalab ynapmocfinancial statements glaxosmithkline plc notes company balance sheet uk gaap presentation financial statements share based payments issuance company subsidiaries grant description business companys options represents additional capital contributions glaxosmithkline plc parent company gsk major global company subsidiaries additional investment subsidiaries healthcare group engaged creation discovery results corresponding increase shareholders equity development manufacture marketing pharmaceutical additional capital contribution based fair value grant products including vaccines overthecounter otc medicines issued allocated underlying grants vesting period healthrelated consumer products taxation preparation financial statements current tax provided amounts expected paid applying financial statements drawn accordance uk generally tax rates enacted substantially enacted accepted accounting principles uk gaap uk accounting balance sheet date presentation st december comparative figures st december company accounts taxation deferred accelerated reason timing differences originated permitted companies act profit loss reversed balance sheet date deferred tax assets account company presented annual report recognised extent considered recoverable accounting convention standards future taxable profits balance sheet prepared using historical cost deferred tax measured average tax rates expected convention complies applicable uk accounting standards apply periods timing differences expected accounting principles policies reverse deferred tax liabilities assets discounted preparation balance sheet conformity financial guarantees generally accepted accounting principles requires management financial guarantees issued company subsidiaries make estimates assumptions affect reported held fair value amortised life guarantee amounts assets liabilities disclosure contingent assets liabilities date balance sheet actual c operating profit amounts could differ estimates fee relating audit balance sheet prepared accordance company charged operating profit companys accounting policies approved board described note b b accounting policies foreign currency transactions foreign currency transactions recorded exchange rate ruling date transaction forward rate hedged forward exchange contract foreign currency assets liabilities translated rates exchange ruling balance sheet date forward rate dividends paid received dividends paid received included accounts period related dividends actually paid received expenditure expenditure recognised respect goods services received supplied accordance contractual terms provision made obligation exists future liability respect past event amount obligation reliably estimated investments subsidiary companies investments subsidiary companies held cost less provision impairment impairment investments carrying value investments reviewed impairment indication investment might impaired provision resulting impairment review charged income statement year concerned gsk annual report stnemetats laicnanif paag ku teehs ecnalab ynapmoc eht ot setonfinancial statements glaxosmithkline plc notes company balance sheet uk gaap continued fixed assets shares glaxosmithkline services unlimited shares glaxosmithkline holdings one limited shares glaxosmithkline holdings limited capital contribution relating share based payments financial guarantees e debtors amounts due within one year uk corporation tax recoverable amounts owed group undertakings f creditors amounts due within one year bank overdraft amounts owed group undertakings creditors g share capital share premium account share ordinary shares p premium number share capital authorised st december st december share capital issued fully paid st january issued share option schemes st december issued share option schemes purchased cancelled st december st december st december number shares issuable outstanding options number unissued shares option st december issued share capital shares held esop trust shares held treasury shares shares free issue issued shares fully paid nominal carrying market values shares held esop trust disclosed note employee share schemes gsk annual report stnemetats laicnanif paag ku teehs ecnalab ynapmoc eht ot setonfinancial statements glaxosmithkline plc notes company balance sheet uk gaap continued h reserves profit reserves loss account total st january profit attributable shareholders dividends shareholders ordinary shares purchased held treasury shares capital contribution relating share based payments st december profit attributable shareholders dividends shareholders ordinary shares purchased cancelled ordinary shares purchased held treasury shares capital contribution relating share based payments st december profit glaxosmithkline plc year million million dividends million million gave retained profit million profit million cost shares purchased cancelled million nil cost shares purchased held treasury shares million million profit loss account reserve st december stood million million million unrealised million gsk annual report stnemetats laicnanif paag ku teehs ecnalab ynapmoc eht ot setoninvestor information investor information section includes financial record presenting historical information prepared accordance ifrs adopted european union section also discusses shareholder return form dividends share price movements provides information shareholders financial record quarterly trend five year record shareholder information taxation information shareholders gsk annual report noitamrofni rotsevni gsk annual report noitamrofni rotsevni drocer laicnanif financial record quarterly trend unaudited analysis provided quarter group results pharmaceutical sales therapeutic area sterling financial year income statement total months q q q q cer cer cer cer cer turnover pharmaceuticals consumer healthcare total turnover cost sales selling general administrative research development operating income operating profit finance income finance costs share tax profits associates joint ventures profit taxation taxation tax rate profit taxation period profit attributable minority interests profit attributable shareholders basic earnings per share pence p p p p p diluted earnings per share pence p p p p p income statement business performance turnover pharmaceuticals consumer healthcare total turnover cost sales selling general administrative research development operating income operating profit finance income finance costs share tax profits associates joint ventures profit taxation taxation tax rate profit taxation period profit attributable minority interests profit attributable shareholders adjusted earnings per share pence p p diluted earnings per share pence p p calculation business performance supplemental nonifrs measure described note financial statements presentation financial statementsgsk annual report noitamrofni rotsevni drocer laicnanif financial record continued income statement total months q q q q cer cer cer cer cer turnover pharmaceuticals consumer healthcare total turnover cost sales selling general administrative research development operating income operating profit finance income finance costs share tax profits associates joint ventures profit taxation taxation tax rate profit taxation period profit attributable minority interests profit attributable shareholders basic earnings per share pence p p p p p diluted earnings per share pence p p p p p income statement business performance turnover pharmaceuticals consumer healthcare total turnover cost sales selling general administrative research development operating income operating profit finance income finance costs share tax profits associates joint ventures profit taxation taxation tax rate profit taxation period profit attributable minority interests profit attributable shareholders adjusted earnings per share pence p p diluted earnings per share pence p p gsk annual report noitamrofni rotsevni drocer laicnanif financial record continued pharmaceutical turnover total group q q q q cer cer cer cer respiratory seretideadvair flixotideflovent serevent flixonaseflonase central nervous system seroxatpaxil paxil ir paxil cr wellbutrin wellbutrin ir sr wellbutrin xl imigranimitrex lamictal requip antivirals hiv combivir trizivir epivir ziagen agenerase lexiva epzicomkivexa herpes valtrex zovirax zeffix relenza metabolic avandia avandamet avandaryl bonvivaboniva vaccines hepatitis influenza infanrix pediarix boostrix rotarix cervarix cardiovascular urogenital coreg coreg cr coreg ir levitra avodart arixtra fraxiparine vesicare antibacterials augmentin oncology emesis zofran hycamtin tykerb zantac total pharmaceutical turnover includes copromotion incomegsk annual report noitamrofni rotsevni drocer laicnanif financial record continued pharmaceutical turnover usa q q q q cer cer cer cer respiratory seretideadvair flixotideflovent serevent flixonaseflonase central nervous system seroxatpaxil paxil ir paxil cr wellbutrin wellbutrin ir sr wellbutrin xl imigranimitrex lamictal requip antivirals hiv combivir trizivir epivir ziagen agenerase lexiva epzicomkivexa herpes valtrex zovirax zeffix relenza metabolic avandia avandamet avandaryl bonvivaboniva vaccines hepatitis influenza infanrix pediarix boostrix rotarix cervarix cardiovascular urogenital coreg coreg cr coreg ir levitra avodart arixtra fraxiparine vesicare antibacterials augmentin oncology emesis zofran hycamtin tykerb zantac total pharmaceutical turnover includes copromotion income gsk annual report noitamrofni rotsevni drocer laicnanif financial record continued pharmaceutical turnover europe q q q q cer cer cer cer respiratory seretideadvair flixotideflovent serevent flixonaseflonase central nervous system seroxatpaxil paxil ir paxil cr wellbutrin wellbutrin ir sr wellbutrin xl imigranimitrex lamictal requip antivirals hiv combivir trizivir epivir ziagen agenerase lexiva epzicomkivexa herpes valtrex zovirax zeffix relenza metabolic avandia avandamet avandaryl bonvivaboniva vaccines hepatitis influenza infanrix pediarix boostrix rotarix cervarix cardiovascular urogenital coreg coreg cr coreg ir levitra avodart arixtra fraxiparine vesicare antibacterials augmentin oncology emesis zofran hycamtin tykerb zantac total pharmaceutical turnover includes copromotion incomegsk annual report noitamrofni rotsevni drocer laicnanif financial record continued pharmaceutical turnover international q q q q cer cer cer cer respiratory seretideadvair flixotideflovent serevent flixonaseflonase central nervous system seroxatpaxil paxil ir paxil cr wellbutrin wellbutrin ir sr wellbutrin xl imigranimitrex lamictal requip antivirals hiv combivir trizivir epivir ziagen agenerase lexiva epzicomkivexa herpes valtrex zovirax zeffix relenza metabolic avandia avandamet avandaryl bonvivaboniva vaccines hepatitis influenza infanrix pediarix boostrix rotarix cervarix cardiovascular urogenital coreg coreg cr coreg ir levitra avodart arixtra fraxiparine vesicare antibacterials augmentin oncology emesis zofran hycamtin tykerb zantac total pharmaceutical turnover includes copromotion income gsk annual report noitamrofni rotsevni drocer laicnanif financial record continued five year record record financial performance provided analysed accordance current reporting practice information included five year record prepared accordance ifrs adopted european union also ifrs issued international accounting standards board turnover business segment pharmaceuticals consumer healthcare pharmaceutical turnover therapeutic area respiratory central nervous system antivirals metabolic vaccines cardiovascular urogenital antibacterials oncology emesis pharmaceutical turnover geographic area usa europe international asia pacific japan middle east africa latin america canada international pharmaceutical turnover includes copromotion income consumer healthcare turnover otc medicines oral care nutritional healthcare gsk annual report noitamrofni rotsevni drocer laicnanif financial record continued financial results total turnover operating profit profit taxation profit taxation pence pence pence pence pence basic earnings per share p p p p p diluted earnings per share p p p p p financial results business performance turnover operating profit profit taxation profit taxation pence adjusted earnings per share p adjusted diluted earnings per share p millions millions millions millions millions weighted average number shares issue basic diluted return capital employed return capital employed calculated total profit taxation percentage average capital employed year balance sheet noncurrent assets current assets total assets current liabilities noncurrent liabilities total liabilities net assets shareholders equity minority interests total equity gsk annual report noitamrofni rotsevni drocer laicnanif financial record continued number employees usa europe international asia pacific japan middle east africa latin america canada international manufacturing selling administration research development number employees number permanent employed staff end financial period excludes employees employed managed gsk contract basis exchange rates guide holders adrs following tables set periods indicated information exchange rate us dollars sterling reported federal reserve bank new york noon buying rate average average rate year calculated average noon buying rates last day month year feb jan dec nov oct sept high low noon buying rate nd february usshareholder information share price dividends per ads table sets dividends per ads us dollars last five years translated us dollars applicable exchange rates st january high year year us low year st december decreaseincrease table sets middle market closing prices derived london stock exchange daily official list companys share price decreased price st january st december compares dividend calendar increase ftse index year share fourth quarter price nd february exdividend date th february market capitalisation record date th february market capitalisation based shares issue excluding treasury payable th april shares glaxosmithkline st december billion date gsk fifth largest company market capitalisation first quarter ftse index exdividend date th april smithkline beecham plc floating rate unsecured record date nd may loan stock payable th july loan stock listed exchange holders may require smithkline beecham plc redeem loan stock par ie second quarter every loan stock held first business day march june exdividend date th july september december holders wishing redeem part record date st august loan stock complete notice back loan payable th october stock certificate return registrar arrive least days relevant redemption date third quarter taxation exdividend date th october record date st october general information concerning uk us tax effects share payable th january ownership set taxation information shareholders internet dividends information company including details share price available gsks website wwwgskcom glaxosmithkline pays dividends quarterly continues increase cash returns shareholders dividend policy dividends information made available website constitute part remain essential component total shareholder return gsk annual report committed increasing dividend longterm details dividends declared amount payment dates given investor relations note financial statements dividends investor relations may contacted follows dividends per share uk table sets dividends per share last great west road brentford middlesex tw gs five years tel year pence usa one franklin plaza po box philadelphia pa tel us toll free tel outside us gsk annual report noitamrofni rotsevni noitamrofni redloherahsshareholder information continued analysis shareholdings st december number total total number accounts accounts shares shares holding shares held nominee companies investment trust companies insurance companies individuals corporate bodies bny nominees limited held treasury shares glaxosmithkline bank new york mellons holding held bny nominees limited represents companys adr programme whereby ads represents two ordinary shares p nominal value nd february bny nominees limited held ordinary shares representing issued share capital date nd february number holders shares usa holdings shares number registered holders adrs holdings adrs certain shares adrs held brokers nominees result number holders record registered holders usa representative number beneficial holders residence beneficial holders documents display memorandum articles association company documents referred annual report available inspection registered office company publications late march gsk publish website corporate responsibility report covering performance areas including community investment ethics integrity access medicines rd environment health safety exchange controls limitations affecting security holders currently uk laws decrees regulations restricting import export capital affecting remittance dividends payments holders companys shares nonresidents uk limitations relating nonresidents uk english law companys memorandum articles association right holder vote respect companys shares gsk annual report noitamrofni rotsevni noitamrofni redloherahsshareholder information continued nature trading market annual general meeting ordinary shares company listed london stock queen elizabeth ii conference centre st may exchange th december shares also listed broad sanctuary westminster new york stock exchange nyse form american london swp ee depositary shares adss date annual general meeting companys principal forum following tables set periods indicated high communication private shareholders addition formal low middle market closing quotations pence shares business presentation chief executive officer london stock exchange high low last reported sales performance group future development prices us dollars adss nyse opportunity questions board chairmen boards committees take questions matters relating glaxosmithkline pence per share committees high low investors holding shares company nominee service quarter ended st march arrange nominee service appointed february corporate representative proxy respect shareholding january order attend vote meeting december november adr holders wishing attend meeting must obtain proxy bank new york mellon enable october attend vote business transacted adr holders may september instruct bank new york mellon way quarter ended st december shares represented adrs voted completing quarter ended th september returning voting card provided bank accordance quarter ended th june instructions given quarter ended st march quarter ended st december financial reporting quarter ended th september quarter ended th june financial reporting calendar quarter ended st march announcement st quarter results april year ended st december announcement nd quarter results july year ended st december announcement rd quarter results october year ended st december preliminary announcement annual results february us dollars per ads publication annual reportreview februarymarch high low quarter ended st march results announcements february results announcements issued london stock exchange january available news service shortly afterwards december issued media made available website sent november us securities exchange commission nyse october financial reports september company publishes annual report investor quarter ended st december needing full detail report annual review quarter ended th september available date publication website quarter ended th june annual review sent shareholders shareholders may quarter ended st march also elect receive annual report writing companys quarter ended st december registrars alternatively shareholders may elect receive notification quarter ended th september email publication financial reports registering quarter ended th june wwwshareviewcouk quarter ended st march year ended st december copies previous financial reports available gsks website year ended st december printed copies obtained registrars uk year ended st december gsk response center usa queries relating receipt duplicate copies gsks publications nd february addressed registrars gsk annual report noitamrofni rotsevni noitamrofni redloherahsordinary shares companys shares listed london stock exchange registrar companys registrars equiniti aspect house spencer road lancing west sussex bn da wwwshareviewcouk tel inside uk tel outside uk equiniti also provide following services g laxosmithkline investment plan g laxosmithkline individual savings account g laxosmithkline corporate sponsored nominee hareview service hareview dealing service ividend reinvestment plan shareview dealing service shareholders may buy sell shares internet telephone shareview dealing share dealing service provided equiniti internet purchases sales log wwwshareviewcoukdealing telephone purchases sales call inside uk pm monday friday glaxo wellcome smithkline beecham corporate peps share centre limited oxford house oxford road aylesbury bucks hp sz tel provision details intended invitation inducement engage investment activity advice share dealing obtained stockbroker independent financial adviser american depositary shares companys shares listed nyse form american depositary shares evidenced american depositary receipts adrs one represents two ordinary shares general nyses rules permit company follow uk corporate governance practices instead apply usa provided company explains significant variations explanation provided companys website adr programme administrator adr programme administered bank new york mellon shareholder relations po box church street station new york ny wwwadrbnycom tel us toll free tel outside us administrators also provide global buydirect direct ads purchasesale dividend reinvestment plan adr holders gsk response center tel us toll free gsk annual report noitamrofni rotsevni noitamrofni redloherahs shareholder information continuedtaxation information shareholders gift disposal subject uk inheritance tax summary main tax consequences us estate gift tax estate gift tax convention would holders shares adrs citizens generally provide tax paid usa credited tax residents uk usa set payable uk complete analysis stamp duty possible tax consequences purchase uk stamp duty stamp duty reserve tax sdrt subject certain exemptions payable purchase shares rate ownership securities intended purchase price minimum charge general guide holders advised stamp duty liability arises consult advisers respect us shareholders tax consequences purchase ownership shares adrs following summary certain uk taxation usa federal consequences state local tax income tax considerations may relevant us holder shares adrs summary applies shareholder laws usa implications holds shares adrs capital assets citizen resident current ukus income tax convention usa domestic corporation otherwise subject united states federal income taxation net income basis respect shares adrs resident uk uk tax purposes statement based upon uk us tax laws practices hold shares purposes trade profession date report vocation carried uk branch agency us holders adrs generally treated owners taxation dividends underlying shares purposes current usuk double gross amount dividends received without reduction taxation conventions relating income gains income tax uk withholding tax treated foreign source dividend income convention estate gift taxes estate gift tax convention us tax purposes eligible dividend received deduction purposes us internal revenue code allowed us corporations dividends adrs payable us amended code dollars dividends shares payable sterling dividends paid uk shareholders pounds sterling included income us dollar amount calculated reference exchange rate day dividends taxation dividends received holder subject certain exceptions short th april rate tax credits reduced one ninth term hedged positions individual eligible us holder result compensating reductions rate tax dividend subject us taxation maximum rate respect income increase tax borne uk resident individual qualified dividends received shareholders advised shareholders tax credits however longer repayable consult tax advisers confirm eligibility shareholders tax liability less associated tax credit taxation capital gains taxation capital gains generally us holders subject uk capital gains tax uk shareholders may liable uk tax gains disposal subject us tax capital gains realised sale shares adrs disposals made prior th april disposal shares adrs may also entitled indexation relief taper relief estate gift taxes sales indexation relief calculated market value shares estate gift tax convention us shareholder st march cost subsequent purchases generally subject uk inheritance tax date purchase indexation relief individual shareholders ceased th april taper relief available stamp duty individual shareholders hold deemed hold shares uk stamp duty sdrt subject certain exemptions least three years sold capital gain taxed payable issue transfer shares adr custodian marginal tax rate individual disposals th april depository rate price issued amount proposed indexation taper relief available consideration provided transferred sale value capital gain taxed flat rate rather transferred consideration marginal tax rate individual proposals yet law sdrt would payable transfer adr uk stamp may subject change duty payable transfer adr provided inheritance tax instrument transfer executed remains times outside individual shareholders may liable inheritance tax transfer uk stamp duty transfer adr would payable shares adrs tax may charged amount rate consideration transfer sale value shareholders estate reduced result transfer underlying shares would result liability uk stamp duty way gift disposal less full market value case may sdrt rate minimum charge stamp duty liability arises gsk annual report noitamrofni rotsevni sredloherahs rof noitamrofni noitaxatglossary terms terms used annual report us equivalent brief description accelerated capital allowances tax allowance excess depreciation arising purchase fixed assets delay charging payment tax us equivalent tax depreciation american depositary receipt adr receipt evidencing title ads glaxosmithkline adr represents two ordinary shares american depositary shares adss ordinary shares registered new york stock exchange basic earnings per share basic income per share calledup share capital ordinary shares issued fully paid cer growth growth constant exchange rates combined code guidelines required listing rules financial services authority address principal aspects corporate governance company glaxosmithkline plc currency swap exchange two currencies coupled subsequent reexchange currencies agreed exchange rates dates defined benefit plan pension plan specific employee benefits often called final salary scheme defined contribution plan pension plan specific contributions level pension dependent upon growth pension fund derivative financial instrument financial instrument derives value price rate underlying item diluted earnings per share diluted income per share employee share ownership plan trusts trusts established group satisfy sharebased employee incentive plans finance lease capital lease freehold ownership absolute rights perpetuity gearing ratio net debt percentage total equity group glaxosmithkline plc subsidiary undertakings hedging reduction risk normally relation foreign currency interest rate movements making offsetting commitments intangible fixed assets assets without physical substance computer software brands licences patents knowhow marketing rights purchased outside parties nonequity minority interest preference shares issued subsidiary outside parties preference shares shares issued varying dividend rates treated outside interests profit income profit attributable shareholders net income share capital ordinary shares capital stock common stock issued fully paid shareholders funds shareholders equity share option stock option share premium account additional paidup capital paidin surplus distributable shares issue shares outstanding statement recognised income expense statement comprehensive income subsidiary entity glaxosmithkline holds majority shareholding andor exercises control treasury share treasury stock turnover revenue gsk annual report noitamrofni rotsevni smret fo yrassolgindex performance overview intellectual property accounting policies interest rate risk management acquisitions disposals internal control framework annual general meeting inventories annual remuneration investments associates joint ventures assets held sale investor information associates joint ventures key performance indicators best place best people key accounting judgements estimates best work legal proceedings board movements equity business review net debt cash cash equivalents new accounting requirements chairman ceo summary nonexecutive director terms conditions fees combined code nonexecutive directors remuneration commitments notes financial statements committee reports operating profit consolidated balance sheet optimising performance marketed products consolidated cash flow statement intangible assets consolidated income statement investments consolidated statement recognised income expense noncurrent assets consumer healthcare noncurrent liabilities contact details operating income contingent liabilities provisions corporate executive team outlook risk factors corporate governance pensions postemployment benefits corporate responsibility community investment pharmaceutical turnover critical accounting policies post balance sheet events delivering product pipeline patients presentation financial statements dialogue shareholders principal group companies directors senior management remuneration products competition directors interests property plant equipment directors interests contracts quarterly trend directors statements responsibility reconciliation net cash flow movement net debt dividends reconciliation profit tax operating cash flows earnings per share regulatory environment employee costs related party transactions employee share schemes remuneration policy exchange rates remuneration report executive director terms conditions remuneration report directors finance costs responsibility environment health safety finance income restructuring costs financial instruments related disclosures risk factors financial position resources segment information financial record share capital control financial review share capital share premium account financial review share options financial statements shareholder information financial statements glaxosmithkline plc taxation financial trends ratios taxation information shareholders five questions five answers total equity five year record trade payables foreign exchange management trade receivables global manufacturing supply trademarks glossary terms treasury policies goodwill us law regulation governance policy world economy improving access medicines world market incentive plans wwwgskcom head office registered office glaxosmithkline plc great west road brentford middlesex tw gs united kingdom tel registered number printed uk midas press paper used production document made pulps harvested sustainable forests also using sawmill residues forest thinnings elemental chlorinefree